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EDC 1-ethyl-3-(3-dimethyllaminopropyl) carbodiimide hydrochloride 
EPR Enhanced permeation and retention 
EDTA Ethylene diamino tetra acetic acid 
FLD Fluorescence detector 
FESEM Field emission scanning electron microscopy 
gm gram 
HCL Hydrochloric acid 
HPMA N-(2-Hydroxypropyl) methylacrylamide 
HPLC High performance liquid chromatography 
H2O2 Hydrogen peroxide 
IV intravenous 





LDL Low density lipoprotein receptor 
LOD Limit of Detection 
LOQ Limit of Quantification 
MRM Multiple reaction monitoring 
mL Millilitre  
MillQ Millipore filtered   
µg Microgram 
MRT Mean residence time 





NADP nicotinamide adenine dinucleotide phosphate 
NMR Nuclear magnetic resonance spectroscopy 
NaOH Sodium Hydroxide 
PDA Photo diode array 
PEG Polyethylene Glycol 
PCL Polycaprolactone 
PLA Polylactic acid 
PTX Paclitaxol  
ROS Reactive oxygen species 
RPM Rotations per minute 
RSD Relative Standard Deviation 
SAR Structure activity relationship 
SD Standard Deviation 
TNF Tumour necrosis factor 
TPA 12-O-tetradecanoylphorbol-13-acetate 
TCDD 2, 3, 7, 8,-tetrachlorodibenzo-p-dioxin 
UDPGA Uridine diphosphoglucuronic acid 
UGT UDP-glucuronosyltransferases 






Resveratrol (RSV) is a natural polyphenol with diverse biochemical, physiological 
and pharmacological effects.  Chemically resveratrol is a stilbene molecule with 
three hydroxyl group in the structure. These hydroxyl groups are prone to 
metabolism. Hence resveratrol is known to undergo rapid metabolism in rats as well 
as  in human. Because of rapid metabolism there is a lack of correlation between in 
vitro and in vivo biological activities of resveratrol. Resveratrol often fails to  
produce the desired pharmacological activities in vivo. In order to produce or 
improve biological activities of resveratrol in vivo,  the pharmacokinetic profile of 
resveratrol has to be improved. These findings led to design of this PhD project to 
address poor pharmacokinetic profile of resveratrol. 
 
In this study novel formulation strategies were designed to improve pharmacokinetic 
profile of resveratrol. Polymeric conjugation approach was explored in this regard. 
The hydrolysable ester and non hydrolysable ether based polymeric conjugates of 
resveratrol were prepared. The resveratrol polymer esters such as MeO-PEGN-Succ-
RSV 2 kDa, 20 kDa, MeO-PEGO-Succ-RSV 2 kDa, MeO-PEG-PLAO-Succ-RSV   
2 kDa and 6.5 kDa were prepared and characterized by NMR, HPLC and LC-MS. In 
all the cases the polymer conjugates were mixture of species with 4’-Polymer-RSV 
as major component followed by 3-polymer-RSV and minor amount of disubstituted 
species. The resveratrol polymer esters were subjected to various in vitro tests such 
as stability in buffers, rat plasma and rat liver microsomes. The MeO-PEGN-Succ-
RSV 2 kDa and 20 kDa were stable in pH 4.5 but hydrolyzed slowly to free 
resveratrol at pH 7.4.  MeO-PEGO-Succ-RSV was stable at pH 4.5 and pH 7.4, this 
stability was attributed to self assembly of polymer conjugate into micelles. Similar 
trend was observed for MeO-PEG-PLAO-Succ-RSV conjugates. All resveratrol PEG 
esters were found to hydrolyze rapidly in the rat plasma and were completely 
hydrolyzed to resveratrol within 5 minutes.  However MeO-PEG-PLAO-Succ-RSV 
conjugates were stable in rat plasma and stability was attributed to aggregation of 
conjugates into micelles. The plasma stability of micelle forming conjugates was 
found to be dependent on hydrophobicity of polymer. However this was true to a 
certain extent. Finally multiple parameters such as hydrophobicity, PEG corona 
(PEG chain length and surface density) and aggregation behavior 
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(micelle/nanoparticles) were found to influence plasma stability of polymer 
conjugates. The MeO-PEG-PLAO-Succ-RSV 2 kDa conjugate with a balanced of 
PEG/PLA content and ability to form compact structure was found to be stable in 
plasma with a half life of 3 hr. 
 
In parallel,  the resveratrol-PEG ether conjugates, with a non cleavable ether bond 
were prepared employing potassium carbonate mediated etherfication using MeO-
PEG-Br as starting material. Resveratrol-PEG ethers were evaluated for stability in 
buffer, rat plasma and rat liver microsomes. Resveratrol-PEG ether 2 kDa was stable 
in buffers, plasma and microsomes.  
 
Selected polymer conjugates were evaluated for preliminary pharmacokinetic profile 
in Wistar rats. MeO-PEG-PLAO-RSV 2 kDa although showed significantly better 
pharmacokinetic profile than resveratrol, was still cleared by mononuclear phagocyte 
systems. Resveratrol-PEG ethers 2 and 5 kDa displayed significantly better 
pharmacokinetic profiles than that of resveratrol and MeO-PEG-PLAO-Succ-RSV 2 
kDa with improved peak plasma concentration, area under curve ( AUC) and longer 
plasma residence time. 
 
Solvent mediated fluorescence enhancement and quenching effects were explored to 
develop a highly sensitive HPLC method for analysis of MeO-PEGN-Succ-RSV 2 
kDa. The effect of solvent composition on fluorescence intensity of MeO-PEGN-
Succ-RSV 2 kDa conjugate was evaluated by varying concentration of methanol in 
solvent mixture. The fluorescence intensity of MeO-PEGN-Succ-RSV 2 kDa was 
found to be dependent on the methanol concentration and was maximum at 100% 
methanol. The HPLC assay method with a linear gradient was developed which 
allowed the maximum detection of the MeO-PEGN-Succ-RSV 2 kDa conjugate with 
methanol concentration at 95% in the mobile phase, while separation and analysis of 
resveratrol and its metabolites can still be achieved. The LOQ (Limit of 
Quantification) for resveratrol-PEG was 300 ng/mL (equivalent to 30 ng/mL 
resveratrol), nearly ten times more sensitive than HPLC with UV detection (3 
µg/mL). The peaks detected for resveratrol-PEG, resveratrol and its metabolites in 
HPLC were identified qualitatively by LC/MS and LC-MS/MS (metabolites) and 
found to correlate with their respective molecular masses. The results of this study 
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demonstrate that the developed HPLC assay method can accurately and selectively 
quantify MeO-PEGN-Succ-RSV 2 kDa conjugates and resveratrol. This method was 
used for analysis of all polymer conjugates during in vitro and in vivo analysis. 
A simple LC-MS method was developed to monitor PEGylation of resveratrol. The 
developed LC-MS method can separate and quantify unmodified MeO-PEG-OH 2 
kDa, carboxylic acid terminated PEG, resveratrol and PEG-resveratrol conjugates. 
This methodology was able to monitor and determine the extent of conversion of 
MeO-PEG-OH to MeO-PEG succinylester acid (MeO-PEGO-SuccOH), which was 
found to be 100%. The developed method was also utilised to determine the extent 
of conjugation of resveratrol to carboxylic acid terminated PEG. The conversion of 
carboxylic acid terminated PEG to PEG-resveratrol conjugate was found to be 100% 
and 73%, respectively, for MeO-PEG succinylamide resveratrol (MeO-PEGN-Succ-
RSV) and MeO-PEG succinylester resveratrol (MeO-PEGO-Succ-RSV). The 100% 
conjugation of MeO-PEGN-Succ-RSV is consistent with the result obtained from an 
NMR study. The average molecular weights determined by LC-MS for MeO-PEG-
OH, MeO-PEGO-SuccOH and MeO-PEGO-Succ-RSV were found to be 2108, 2321 
and 2423 respectively. These data correlate well with the theoretical values. This 
methodology proved to be simple and effective in determining the extent of 
fuctionalization of PEG and its conjugation to resveratrol. Overall our LC-MS 
method coupled with NMR permitted extensive characterization of PEGylated 
resveratrol and the reaction precursors. However due to mass limitations of LC-MS 
instruments, this method could not be applied to all polymer conjugates of 
resveratrol.   
 
Overall in this project, effective formulation strategies were designed and 






























There has been increasing public awareness created these days about health benefits 
of consuming fruits and vegetables. There have been many reports about beneficial 
effects of consuming fruits and vegetables 1. Chemoprevention, cardioprotection and 
anti aging are the few of health benefits of fruits and vegetables consumption. In 
Australia, the famous slogan “Go for 2&5” (2 serves of fruits and 5 serves of 
vegetables a day) has been effectively used to convey the message of health benefits 
of fruits and vegetables. Presence of the variety of essential vitamins, minerals and 
antioxidants in fruits and vegetables are said to be responsible for these health 






                  Figure 1.1: Chemical structure of trans-resveratrol 
 
Resveratrol, as a natural polyphenolic compound (Figure 1.1 shows the structure of 
its major natural form- trans isomer), its therapeutic utility dates back to the ancient 
history.  The Hindus ancient medicinal book “Ayurveda” described grape juice as an 
effective cardiotonic and it was referred to as a gift of God and was presumably used 
for cleansing body and soul. In 1940,  resveratrol was first time identified as 




1.2 SOURCES OF RESVERATROL  
Resveratrol is found in many plant sources. It is believed to be produced in response 
to external stress such as water deprivation, exposure to UV irradiation and 
especially fungal infection. Thus the production of resveratrol in plants can be 
considered a defense mechanism. This property classifies it as a phytoalexin, the 
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compounds produced by plants in response to damage1.  The major natural source of 
resveratrol is found in the roots of the plant Polygonum cupsidatum cultivated 
mainly in China and Japan. The skin of whole grapes contains around 50-100 mg of 
resveratrol (per grape), which is believed to be responsible for the cardio protective 
activity of red wine 1. Resveratrol is found in a wide variety of other fruits such as 
mulberry, bilberry, lingonberry, sparkleberry, deerberry, partridgeberry, cranberry, 
blueberry, and jackfruit. Resveratrol is also found in peanuts, and a wide variety of 
flowers and leaves including: gnetum; white hellebore; corn lily; butterfly orchid 
trees; eucalyptus; spruce; poaceae; scots pine and rheum 1
1.3 PHYSICOCHEMICAL PROPERTIES OF RESVERATROL 
. 
Resveratrol is an off white powder with a melting point of 2530C. It is sparingly 
soluble in water, but soluble in organic solvents like DMSO, ethanol, diethyl 
formamide   etc. Resveratrol is a hydrophobic molecule with a logP value of 3.13 2. 
Resveratrol was found to be stable in solid state for 4 years in accelerated conditions 
(400C/75%RH) and in liquid state (standard resveratrol added to grape extract) was 
stable for 2 years under ambient conditions 3. When protected from light, trans-
resveratrol was stable for at least 42 h (CV ≤ 1.0%) and for at least 28 days with a 
CV ≤ 4.7% in buffers pH 1-7. However, resveratrol is found to be unstable at higher 
pH conditions. The initial half-life for trans-resveratrol in pH 10.0 buffer was 1.6 h. 
The stability studies were conducted in hydro alcoholic solution with 50% alcohol 
(Ethanol) in the buffer solution. This was done because of the poor solubility of 
resveratrol in aqueous solutions.3 Yang and colleagues 4 have studied stability of 
resveratrol in various buffer solutions. Their results indicated that resveratrol was 
unstable in base modified eagles medium (BME) containing NaHCO3 and  Milli Q 
water with NaHCO3. There was no significant decrease in resveratrol content when 
incubated with NaH2PO4, other inorganic salts, amino acids, and vitamins of BME 
in water. It was evident from the study that presence of bicarbonate ions contributed 
to in-stability of resveratrol by generating free radical H2O2 which catalyzed 
oxidative decomposition of resveratrol. Trans reveratrol is stable and naturally 
occurring in plants, where as cis resveratrol is unstable and commercially not 
available 5.  The trans and cis resveratrol were found to have different spectral 
properties, UV max for trans resveratrol is 304 nm and for cis resveratrol 286 nm. 
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Both forms can be distinguished and analyzed by the UV spectropphotometer. 5 The 
monitoring of each form can done by HPLC with PDA (Photodiode array) detector. 
Trans resveratrol  was found to undergo photoisomerization after exposing to 
sunlight for 8 h.
 
5 
1.4 BIOLOGICAL ACTIVITIES OF RESVERATROL 
Resveratrol was reported to have diverse biochemical and physiological effects 
including antioxidant, anticancer, cardio protective, antiplatelet, chemopreventive, 
and, anti-inflammatory activities 1, 6. Das et al 1, have summarised the various 
biological activities of resveratrol including chemoprevention, anti-inflammatory, 
cardio protection and outlined the possible mechanism for each activity. The 
cardioprotection and cardiac preconditioning have been extensively deliberated. In 
another report chemopreventive, functions as phytoestrogen, anti-inflammatory, and 
antiprogression activities were reviewed and potential  possible mechanisms were 
proposed6
 
. It is not the intention of this thesis to produce a comprehensive review of 
all biological activities of resveratrol, here the focus was given to those studied or 
reported extensively in the literature.   
1.4.1 Anti-oxidant activity 
Resveratrol is capable of scavenging intracellular reactive oxygen species due to its 
unique molecular structure. Although, resveratrol has shown to exhibit antioxidant 
activity in vitro, it was reported to be a weak antioxidant, when compared to ascorbic 
acid, in terms of its ability to scavenge hydroxyl radicals in vitro 1.  Depending on 
the biological system, resveratrol can also scavenge superoxide anion O2-.  In 
contrast to this, resveratrol was reported to show a strong antioxidant activity in vivo.  
This strong antioxidant activity in vivo could be because of its ability to increase the 
synthesis of nitric oxide (NO) inside the body, which in turn acts as the in vivo 
antioxidant, scavenging superoxide radicals 7, 8. In the ischemic reperfused heart, 
brain, or kidney, resveratrol induces NO synthesis and lowers oxidative stress. Nitric 
oxide having an unpaired electron possesses a strong affinity for free radicals and 
hence is a stronger antioxidant.  These findings indicate, that resveratrol by virtue of 
structure, acts directly as an antioxidant, and by inducing various other enzymes. 
Based on these observations, it is anticipated that resveratrol would produce much 




1.4.2 Cardio-protective activity  
The extracts of grapes and wines found to relax pre-contracted smooth muscles of 
intact rat aortic rings. 9 It was concluded that the observed muscle relation was due to 
the function of resveratrol. Cardio protective activity of resveratrol comes from its 
ability relax blood vessels. The increase in NO synthesis and the amount of 
guanosine 3’,5’–monophosphate (cGMP) was responsible for vasorelxation. 
Resveratrol was believed to bring about these changes. 8The direct evidence of NO 
activity was observed when cultured pulmonary endothelial cells showed increased 
NO synthesis when treated with resveratrol 10
 
. These finding clearly suggest that 
resveratrol protects heart against heart attack by vasorelaxation and scavenging free 
radicals which are harmful to heart. 
1.4.3 Anti inflammatory activities of resveratrol 
The anti-inflammatory activities of resveratrol have been attributed to various 
mechanisms in different reports. In ischemic heart experiments, treatment with 
resveratrol has significantly improved post ischemic ventricular function, and 
reduced myocardial infarct size when compared to the non treated control group. 
This effect was shown to be mediated by increased NO synthesis11. The anti-
inflammatory activity of resveratrol is also attributed to the suppression of aberrant 
expression of tissue factor and cytokines in vascular cells. 12  In contrast to these 
observations, other reports, concluded that resveratrol exhibits its anti-inflammatory 
activity by the inhibition of cylooxygenase enzymes COX-1 and COX-2, and also by 
decreasing NO production 13,14. The NF-kB, mediates inflammation through its 
ability to induce proinflammatory genes 15. Resveratrol is found to suppress the 
activation of NF-kB in MCF-7 breast cell lines 16
 
. 
1.4.4 Resveratrol as a phytoestrogen 
The phyotoestrogenic activity of resveratrol was evidenced by its capacity to bind 
and activate α and β-estrogen receptors 17. The estrogenic activity of resveratrol 
remains ambiguous because of contradicting reports 18. Gehm et al. showed 
resveratrol (3-10 µM) as super agonist when combined with estradiol (E2) in MCF-7 
cells 17. However, Lu et al. reported that resveratrol (5 µM) exerts antagonism in 




1.4.5 Resveratrol and lipoproteins, atherosclerosis  
Resveratrol was found to decrease total cholesterol and total triglycerides in mice. 
There are various cellular mechanisms that would lead to increased low density 
lipoprotein (LDL)-cholestrol leading to atherosclerosis; a disruption in 
apolipoprotein E or low density lipoprotein receptor (LDLR) genes, and an over 
expression of human apolipoprotein B (apoB), contributes to an increase in the level 
of very low density lipoprotein (VLDL)-cholestrol. Resveratrol was reported to 
reduce the apoB content and secretion. Resveratrol was also found to decrease 
intracellular content and the rate of secretion of cholesteryl ester enzymes from 
hepatoblastoma cells 19-22. In addition, resveratrol was found to reduce lipid 
peroxidation via copper chelation and scavenging free radicals 18. This activity 
coupled with vasorelaxation may have contributed to anti atherosclerosis in humans. 
French people are known to consume high levels of cheese, butter, eggs, rich creamy 
sauces and other fatty foods, however they are considered healthy, with a low 
incidence of coronary heart diseases and certain types of cancer. A French diet 
contains 15% more saturated fat than an American diet. However, the rate of heart 
disease in France is 60% lower than that of the American population. Similarly 
France has a lower incidences of certain types of cancer.  This may have been 
attributed to the high consumption of red wine by the French, a phenomenon referred 
to as the French Paradox 23
 
. 
1.4.6 Anti-platelet aggregation property 
An aggregation of platelets contributes to atherosclerosis and chronic heart disease. 
Resveratrol showed a marked reduction in platelet aggregation in human platelet rich 
plasma, after induction by thrombin and adenosine-5’-diphosphate (ADP) 
treatment 24-26. The thrombin down regulates the endothelial ectonucleotidase 
activity, resulting in high levels of ADP and ATP, which activate the platelets, 
leading to platelet aggregation.  Resveratrol, inhibits thrombin induced secretion of 




1.4.7 Chemopreventive activity  
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Biotransformation is the part of our biological defence mechanisms by which body 
fight against any foreign chemical compounds entering  the body. Phase-I 
biotransformation induces oxidation, reduction and hydroxylation of chemical 
compounds. Phase-II biotransformation brings about chemical conjugation such as 
sulfation, glucorinidation etc.  However, phase-I biotransformation of certain 
chemicals, such as poly cyclic aromatic hydrocarbons and poly chlorinated 
biphenyls, may transform them into potential carcinogens 29-31.  Cytochrome p450 
1A1 (CYP 1A1) in particular converts these chemicals into hydroxylated 
compounds, which are carcinogenic/mutagenic metabolites. In addition, poly cyclic 
aromatic hydrocarbons play a role in induction of CYP 1A1, CYP 1A2 and CYP 
1B1. After phase-I transformation, these hydroxylated carcinogens are anticipated to 
undergo chemical conjugation to inactive compounds amenable for excretion. 
However, certain enzymes such as O-acetyl transferases and sulfotransferases, 
collectively called phase-II carcinogen activators, can trigger carcinogen formation, 
for example the induction of tumours by aromatic amines 32. Resveratrol was found 
to inhibit CYP 1A1 33 and also O-acetyl transferases and sulfotransferases, 34-36 
thereby collectively preventing the formation of carcinogens. In addition, resveratrol 
decreases the activity of breast cancer resistance proteins responsible for transferring 
carcinogen into cells 37-38
In another report 
. 
14, the chemopreventive activity of resveratrol was attributed to the 
collective action of various other biological effects, this is because resveratrol acts as 
an antioxidant and an antimutagen, induces phase-II drug-metabolizing enzymes 
(Anti initiation effect), mediates anti-inflammatory activity, inhibits cyclooxygenase 
and hydroperoxidase functions (Antipromotion activity) and induces human 
promyelocytic leukemia cell differentiation (Anti-progression activity) 38. All these 
effects stop initiation, promotion and progression stages of cancer development, 14
 
 
and suggest that  resveratrol has the capacity to be a strong chemopreventive agent. 
 1.5 ANTICANCER/CHEMOPREVENTIVE EFFECTS OF RESVERATROL ON 
VARIOUS CANCER CELL LINES 
1.5.1 Prostate cancer 
Prostate cancer is the third most frequently diagnosed cancer in USA and other 
western countries 22. Studies conducted in cell culture have showed antiproliferative 
effects of resveratrol on prostate carcinoma cells 39.  Hsieh and Hu 40 investigated the 
11 
 
effects of resveratrol on growth, induction of apoptosis, and modulation of prostate 
specific gene expression using DU-145, PC-3 and JCA-1 human carcinoma cells 40
1.5.2 Breast cancer 
. 
The study suggested that, resveratrol reduced cell growth by affecting mitogenesis as 
well as inducing cell apoptosis, leading to anticancer activity. 
Breast cancer is the most common cancer affecting woman in the world. Resveratrol 
showed antiproliferative effects against various breast cancer cells irrespective of 
their estrogen receptor status in vitro  41, 14. Resveratrol inhibited development of 
preneoplastic lesions in carcinogen treated mouse mammary organ cultures 43. 
Resveratrol was also found to inhibit 4T1 breast cancer cells in time and dose 
dependent manner 41. The inhibition of breast cancer cell growth could be attributed 
to resveratrol’s ability to inhibit the induction of CYP 1A1, down modulation of p53, 
induction of apoptosis and various other cellular interventions  42. 
 
  
1.5.3 Skin cancer 
Skin cancer is one of the major cancers affecting Australian population and 
constitutes nearly 80% total diagnosed cases of cancer. Two in three Australians will 
be diagonised with skin cancer by the time they are 70 years old 43. Resveratrol 
demonstrated chemopreventive effect in chemically induced skin carcinogenesis in 
mouse model 34.  In a study conducted by Jang and Pessuto 14, application of phorbol 
12-myristate-13-acetate (TPA) to mouse skin to establish an animal model with 
increased oxidative stress as indicated by generation of H2O2 , enhanced levels of 
methyl peroxidise activity, oxidized glutathione reductase activity and decreases in 
glutathione levels and super oxide dismutase activity.  The TPA treatment showed 
increase in expression of COX-1, COX-2 and TNF-α.  Pre-treatment with resveratrol 
negated several of these activities. The H2O2,
 
 methyl peroxidise activity, oxidized 
glutathione reductase activity, glutathione levels and super oxide dismutase activity 
were restored to the level of control group levels which received no TPA treatment. 
1.5.4 Liver cancer 
The resveratrol was found to inhibit growth of hepatoma cell line H22 in a time and 
dose dependent manner via induction of apoptosis 44. The resveratrol has also been 
shown to decrease the growth of tumour cells (25%) in the rats inoculated with 
Yoshida AH-130 ascites hepatoma cells 45. Ciolino and Yeh  have studied the effect 
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of resveratrol on aryl hydrocarbon receptor (AHR) and CYP 1A1 in human 
hepatoma cells 46
 
. They found that resveratrol inhibited the increase in CYP1A1 
mRNA caused by AHR ligand 2, 3, 7, 8,-tetrachlorodibenzo-p-dioxin (TCDD) in a 
concentration dependent fashion, resulting in chemo preventive activity.   
1.5.5 Colorectal and intestinal cancer 
Various studies have reported anti-proliferative and chemopreventive activity of 
resveratrol against colorectal cancer 47, 48. Schneider et.al 49 studied the effect of 
resveratrol on polyamine metabolism of CaCo-2 human colon cancer cells. The 
treatment with 25 µM of resveratrol showed 75% inhibition in growth of cancer 
cells. This was associated with significant decrease in the ornithine decarboxylase 
activity, a key enzyme in polyamine biosynthesis, which is normally high in cancer 
cells. This indicates polyamines might be one of the targets which resveratrol acted 
upon to produce observed activity. Wolter et.al 50 investigated the effect of 
resveratrol on human colonic adrenocarcinoma Caco-2 cells, and found that, 
resveratrol inhibited growth and proliferation of these cells. They attributed such 
activity to down regulation of cyclin D1 and cyclin dependent kinase. Several other 
studies have linked the observed anticancer effects of resveratrol to its activation of 
p53, a tumour suppressor 
 
51, 52,  53,  54. 
 1.5.6 Blood cancer 
Various studies have reported the anti proliferative and chemo preventive effects of 
resveratrol against leukaemia cells 55-57
  
.  It was reported that resveratrol, reduced the 
viability and DNA synthesis in cultured leukaemia (HL-60) cells (58 pap3). The 
study showed that antiproliferative and chemo preventive effects were due to 
induction of apoptosis. There was a decrease in expression of anti-apoptotic Bcl-2. 
Other study correlated observed effects to involvement of capsages, CD95- CD95L 
pathways in apoptosis . 
From above mentioned studies it is evident that resveratrol is involved in many 
different biological process. The mechanisms of actions for various biological 
activities of resveratrol are summarized in Figure 1.2 and these mechanisms of 




























Figure 1.2: Interventions of resveratrol in various biological pathways responsible 
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1.6. IN VIVO PHARMACOLOGICAL EFFECTS OF RESVERATROL 
Data obtained from these in vitro studies suggest that resveratrol could be a 
promising therapeutic agent for many diseases/disorders. Interestingly, the in vivo 
studies on animal models, sometimes revealed different stories. 
Elamai  et al. have carried out experiments to investigate the effect of resveratrol on 
osteoarthritis, using rabbits with surgically induced osteoarthritis by anterior cruciate 
ligament transection (ACLT), to create degenerative changes in the articular 
cartilage in the knee 58
 Jang et.al 
. Five weeks after this procedure, one group of rabbits 
received 10µmol/kg of resveratrol in DMSO injected directly into the knee; another 
group just received the DMSO as a control once a day for two weeks. The rabbits 
were killed after 7 days of  the last injection, and a histological examination of knee 
cartilage was performed. Results indicated a significant decrease in cartilage 
destruction with a score of 1.7 vs 2.8 for control. A loss of matrix proteoglycan 
content in the cartilage was also much lower in the the treatment group. Authors 
have attributed these effects to the inhibition of prostaglandin synthesis, mediated by 
COX-2 gene expression and COX-2 enzyme activity by resveratrol. The inhibition of 
NF-kB activation by resveratrol was also proposed as being the responsible factor for 
the activity.  
14
 
 investigated the chemopreventive activity of resveratrol using a skin 
cancer mouse model. Tumeourogenesis was evaluated in two stages in mouse skin 
using 7, 12-dimethylbenzanthracene (DMBA) as an initiator, and 12-O-
tetradecanoylphorbol-13-acetate (TPA) as a promoter. An application of resveratrol 
along with TPA, twice a week to the skin at a dose of 1,5,10 and 25 µmol showed a 
reduction of tumour per mouse by 68, 81, 76, and 98%,, suggesting resveratrol could 
be an effective chemopreventive agent for skin cancer. Researchers speculated that 
the chemopreventive activity of resveratrol is a result of reduced oxidative stress, 
induced by the combined antioxidant effects of resveratrol and antioxidant enzymes 
induced by it. Similar results were reported by Soleas et.al on resveratrol’s 
chemopreventive activity with a 2 stage CD-1 mouse skin model produced by 
DMBA and TPA. 
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The chemopreventive effects of resveratrol on azoxymethane induced colon 
carcinogenesis have been investigated by Tessitore et.al 59
Li et.al 
. In the study, rats were 
given orally a solution of resveratrol (200 µg/kg body weight) in drinking water 
(with 0.3mL of alcohol /liter) for 100 days. The resveratrol dosing began 10 days 
before a carcinogen injection and ceased 3 months after. Carcinogen, azoxy methane 
was injected twice subcutaneously one week apart, at the dose of 15 mg/kg.  The 
growth of aberrant crypt foci (ACF) was measured at the end of the study. The 
results showed less numbers of ACF/colon (25.7) for the resveratrol treated group as 
against 39 for the control group.  
60
Gao et.al 
 studied the suppression of N-nitrosomethylbenzylamine (NMBA) induced 
tumerogenesis in F344 rats by resveratrol. Resveratrol was dosed at 2 mg/kg orally 
for 16 weeks, two groups were dosed at 1 mg/kg and 2 mg/kg for 16 weeks 
intraperitonially; another group received resveratrol 1mg/kg intraperitonially for 20 
weeks. At the same time all the groups received 1mg/kg of NMBA subcutaneously. 
The resveratrol group revealed a reduction in the development of oesophageal 
tumours to 78, 62, 54, and 48% respectively at these doses, as against the control 
group. 
57, have compared in vitro and iv vivo antileukemic effects of resveratrol in 
C3H mice. Treatment of 32Dp210 leukaemia cells with resveratrol at concentration 
of 25-50 µmol/L showed significant and irreversible inhibition of growth  in-vitro. 
The in vivo antileukemic studies with resveratrol dosed orally at 8 and 40mg/kg 
daily, five times per week did not show any effects on improving survival of mice 
injected with leukaemia cells. Allthe mice died. Only at the 80mg/kg dose, a very 
weak antileukemic effect was seen with 2 mice surviving out of 14 mice treated.  
However when mice injected with leukaemia cells pre-treated with resveratrol in 
vitro before injection, did not produce leukaemia and 92% mice  survived, this effect 
could be due to strong chemopreventive effects of resveratrol in vitro.  Resveratrol 
pretreatment could have affected proliferation ability of leukaemia cells and hence 
no development of leukaemia. This clearly shows that resveratrol is active in vitro 
but failed to show its effectiveness in vivo, possibly its pharmacokinetics 
(absorption, distribution, metabolism and excretion) may have affected its activity in 
vivo.  In a similar study conducted by Ziegler et.al 61, the researchers  reported a lack 
of in vivo effects on tumerogenesis in Apcmin/+mice following the treatment of 
resveratrol. The resveratrol when given orally in feed to mice at the dose of 0-
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90mg/kg did not show any reduction in number of tumours per mice against control. 
Moreover, analysis of mice plasma by HPLC showed only resveratrol-glucoronide 
but not the native resveratrol present. Researchers concluded that resveratrol did not 
produce chemopreventive effects because of its rapid metabolism to resveratrol-
glucuronide. 
Wenzel et.al 62
The review of the above studies indicates that resveratrol is more active when 
applied directly to the site of action such as the knee joints and skin; this showed 
remarkable activity when compared to those studies, where resveratrol was given 
orally or by other routes where the drug has to undergo absorption and distribution 
before it reaches target tissue. Hence there is an obvious need to understand the 
correlation between phamacodynamics and pharmacokinetics of resveratrol. The 
absorption, distribution, metabolism and excretion profile of resveratrol needs to be 
reviewed. 
 evaluated the bioactivity and metabolism of resveratrol when given 
orally with food to wistar rats. The resveratrol at the dose of 50 and 300 mg/kg per 
day was fed to the rats for 8 weeks. The chemopreventive parameter such as phase I 
and phase II metabolizing enzymes, total antioxidant activity, and vitamine E status 
were evaluated. The plasma, urine, kidney and liver samples were analyzed for 
quantification of resveratrol and its metabolites. Various metabolites of resveratrol 
were synthesized to correlate with metabolites detected in various samples.  The 
study revealed that resveratrol had no effect on the biochemical parameters 
responsible for chemopreventive action, except for antioxidant activity which was 
just up by 19%. The lack of a significant effect on chemopreventive parameters, was 
attributed to rapid metabolism of resveratrol in the body to various sulfated and 
glucuronide metabolites. 
 
1.7 PHARMACOKINETIC PROFILE OF RESVERATROL IN RODENTS AND 
HUMAN 
`There are numerous studies reported in the literature, concerning in vitro 
metabolism and pharmacokinetic study of resveratrol on various animal species such 
as rats and mice. The pharmacokinetics of resveratrol in human beings has also been 
reported.  
 Yu et al. 63 investigated the metabolism of resveratrol in humans, rats and mice. The 
resveratrol was incubated with human liver microsomes, rat and human hepatocytes 
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in vitro. In the same study, resveratrol solution in neobee oil (with 6.5 % v/v  of 
alcohol in oil) was dosed intraperitoneally to rats at 20mg/kg body weight. Similarly 
the solution of resveratrol in corn oil ( with 5.4% v/v of alcohol in oil) was dosed 
respectively to mice at 20mg/kg, and 60mg/kg intraperitoneally and orally. The urine 
from rat and serum from mice were processed and along with samples collected from 
in vitro incubations, were analyzed by HPLC coupled with LC-MS.  The results 
showed that, resveratrol did not undergo any phase-I metabolism like oxidation, 
reduction or hydroxylation; however, resveratrol underwent extensive metabolism 
when incubated with rat and human hepatocytes. Resveratrol-3-O-glucuronide, 
Resveratrol-4’O-glucuronide were major metabolites detected with human 
hepatocytes. The resveratrol-3-O-sulfate was a major metabolite, with traces of 
resveratrol-3-O-glucuronide with rat hepatocytes. Only resveratrol-3-O-glucuronide 
was detected in rat urine samples tested 2 hours post dose. The mice serum samples 
did not show any native resveratrol but abundant resveratrol-3-O-glucuronide and 
resveratrol-3-O-sulfate metabolites were detected in serum samples, from initial time 
point of 5 minutes to 1 hour post dose.  
 
In another study oral and an intravenous pharmacokinetic profile of resveratrol was 
investigated in Sprague-Dawley rats 64. The rats were dosed at 15 mg/kg , 50 mg/kg 
using oral and intravenous routes respectively. The plasma profile after IV dosing, 
was characterized by low and rapidly decreasing levels of resveratrol with high 
amounts of resveratrol glucuronide. The plasma half life (t½) of resveratrol after 
intravenous dosing was found to be 0.13 hrs. The plasma profile after oral dosing 
was slightly different, with lower levels of resveratrol detected than those samples 
employing IV dosing. The plasma concentration of resveratrol was found to be 
depleting at a slower rate. In comparison, the t1/2
Absorption and metabolism of resveratrol in the jejunum of an isolated rat’s small 
intestine has been reported 
 after oral administration was found 
to be 0.29 hrs. Although, the plasma levels were seen reaching base line in around 
two hours, there were slight increases in levels of resveratrol concentration after 4 
hours; this was attributed to the enterohepatic recirculation of resveratrol, and was 
confirmed by analysing  bile samples taken from the rats.  
65. The resveratrol solution (200 µM) when perfused 
through the isolated intestinal segment, showed only trace amounts of resveratrol 
crossing the membrane unmodified and 95% of detected compound on serosal side 
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of jejunum was resveratrol glucuronide. The presence of resveratrol glucuronide was 
confirmed by HPLC-PDA and nano ES-MS/MS. The authors concluded, that 
resveratrol is most likely to be in the form of glucuronide conjugate after passing 
through the intestine and reaching blood circulation. They pointed out that, the lack 
of native resveratrol entering blood circulation would impact on the in vivo 




 studied the bioactivity and metabolism of resveratrol in Wistar rats 
after oral administration. The rats were dosed with resveratrol in their feed at two 
dose levels of 50mg and 300mg/kg body weight for 8 weeks. The resveratrol and 
metabolites concentrations were analyzed in plasma, urine, feces, liver and kidney by 
HPLC. The metabolite standards were also synthesized and analysed by HPLC. The 
biological activity such as phase-I and Phase-II biotransformation activities, were 
determined by the analysis of NADPH-cytochrome-c reductase (CCR) and 
glutathione-S-transferase in the liver and kidneys respectively. The antioxidant 
activity of plasma samples were determined by inhibitory effects on linoleic acid 
peroxidation. The study revealed that neither resveratrol nor metabolites, could be 
detected in plasma, liver and kidneys at 50mg/kg dose, and was only detected in 
pooled urine and feces collected during 3rd and 8th week.  The absence of 
resveratrol and its metabolites in plasma, liver and kidneys, could be because 
samples were collected after 24 hours of fasting (no resveratrol dosed) at the end of 
the 8th week.  At 300 mg/kg dose, half of the animals showed only metabolites in 
plasma, liver and kidneys, but not free resveratrol. Based on the dose and biological 
samples analysed, 6 different metabolites of resveratrol such as 3,4’5-trisulfate, 3,4’-
disulfate, 3,5-disulfate, 3-sulfate, 4’-sulfate, and 3-glucuronide were detected. The 
antioxidant and chemopreventive activity of the resveratrol fed rats did not differ 
from the control group. The authors concluded, that a lack of in vivo activity was 
probably due to the formation of conjugate metabolites, and similar findings were 
reported for resveratrol from other rat, mice and human pharmacokinetic studies.  
In addition to animal studies, there are reports on pharmacokinetic profile of 
resveratrol in healthy human volunteers 66,67. Walle et al examined absorption, 
bioavailability and metabolism of 14C-resveratrol after IV and oral administration in 
6 healthy volunters 66. The 25 mg of 14C resveratrol  in alcoholic simple syrup 
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solution with 50 mg of ascorbic acid was dosed orally. The 0.2 mg of 14C-resveratrol  
in alcohol/ saline mixture was dosed intravenously as infusion for 10 minutes. The 
plasma samples collected immediately after IV dosing showed unchanged resvertrol 
at concentrations of 3.7 to 16.4 ng/mL. There was a significant metabolite peak with 
an estimated concentration of 9 to 13.5 ng/mL, which was investigated and found to 
be sulphated metabolite of resveratrol. However, only trace amounts of unchanged 
resveratrol (<5 ng/ml) could be detected in plasma after oral dosing as against total 
radioactive compound with peak plasma levels of resveratrol and metabolites of 491 
± 90 ng/ml. The oral bioavailability of resveratrol calculated based on total 
radioactivity was 70%. However there was not much unchanged resveratrol in blood. 
Hence authors termed the pharmacokinetics of resveratrol as “high absorption but 
very low bioavailability. In the study five metabolites were identified by LC-MS, 
M1,M2, two monoglucorindes, M3 dihydromonoglucorinide, M4 monosulfate and 
M5 dihydromonosulfate. Detection of dihydro glucorinide and sulphate metabolites 
indicates possible phase I metabolism resulting in hydrogenation of double bond. 
The group reported the detection of sulfate conjugate M4/M5 in plasma samples 
within 2 hrs post iv or oral dose and suggested that the sulfation of resveratrol may 
be the major limiting factor to its bioavailability. Authors also speculated that, 
although the systemic bioavailability of resveratrol is very low, rapid uptake and 
accumulation of resveratrol in epithelial cells along the aerodigestive tract, together 
with the formation, in the colon, of dihydroresveratrol metabolites, which were 
shown potency slightly less than resveratrol in cell line,  may contribute to the 
chemopreventive action of resveratrol against colon cancer 67
  
. They pointed out that, 
because of the rapid metabolism, the chemopreventive action of resveratrol at other 
target sites such as breast and prostate, would need to reply on the activation or 

































                                                                                          












   




Figure 1.3: Structure of trans-resveratrol’smetabolic products A:Resveratrol, B:Resveratrol-3-O-sulfate, C:4’-O-sulfate, D:3,4’-O-disufate, E:3, 




Boocock et.al have 67
 
 also studied the pharmacokinetics of resveratrol after oral 
administration at various doses to healthy human volunteers. The doses selected for 
the study were 0.5, 1, 2.5 and 5 g.  Consumption of resveratrol did not cause serious 
adverse events. Resveratrol and six metabolites were detected in plasma and urine 
samples. Peak plasma concentration of resveratrol at the highest dose was  539 ±384 
ng/mL (2.4 µmol/L), which was observed 1.5 h post dosing. Peak levels of two 
monoglucuronides and resveratrol-3-sulfate were 3- to 8-fold higher than resveratrol. 
The area under the concentration curve (AUC) values for resveratrol-3-sulfate and 
resveratrol monoglucuronides were up to 23 times greater than those of resveratrol. 
Resveratrol and its metabolites were excreted rapidly in the urine. Authors have 
concluded that the levels of resveratrol observed with highest dose could be 
insufficient to elicit chemopreventive activity as 5 µmol/L is required for the 
chemopreventive activity in vitro conditions. However this could only be true if 
resveratrol metabolites lack chemopreventive activities. Researchers suggested 
investigation of chemopreventive activity of metabolites such as resveratrol-
glucuronide and resveratrol-sulfate.   
To study safety, tolerability and pharmacokinetic profile of resveratrol, a study with 
various doses of resveratrol administered six time a days until 13th dose was 
conducted in healthy volunteers 68.     The 25, 50, 100 and 150 mg of resveratrol 
were given orally as capsule formulation and all the doses were well tolerated 
without any major clinically significant adverse effects. The resveratrol produced 
very low plasma levels. Following the 13th dose of trans-resveratrol 25, 50,100 and 
150 mg, mean peak plasma concentrations were at 3.89, 7.39, 23.1 and 63.8 ng/mL 
and mean area under the plasma concentration–time curves (AUC0 -t) were 3.1, 11.2, 
33.0 and 78.9 ng.h/mL respectively. There was no significant difference in AUC 
between 1st and 13th dosing. The Cmax also did not vary between repeated dosing. 
Only in higher dose 150 mg, the Cmax was doubled after 13th dose. Trough (Cmin
 
) 
concentrations were ≤1 ng/mL following 25 and 50 mg, 3 ng/mL following 100 mg 
and <10 ng/mL following 150 mg. It was concluded that the results of this study 
indicate metabolism of resveratrol is very fast. Repeated dosing of resveratrol at a 
high frequency can not compensate for its fast metabolism. 
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The various studies which were conducted to understand in vitro metabolism and 
pharmacokinetic profile of resverarol indicated that resveratrol undergoes rapid 
metabolim. Pharmacokinetic profile is similar across different animal species and 
human.  The levels of resveratrol in plasma were below the anticipated 
concentrations required for biological activity. In most of the studies, the metabolites 
concentrations were higher than native resveratrol even at the initial sampling points. 
The researchers from different groups have concluded that resveratrol would not 
produce substantial  biological effects in vivo because of its rapid metabolism. 
However some researchers speculated that there can be significant in vivo biological 
effects if metabolites are biologically active. In order to validate these 
speculations, Miksits et.al 69 have conducted in vitro experiments to evaluate anti 
tumour activity  resveratrol sulfated metabolites and compared with activity of 
resveratrol. Three major sulfated metabolites of resveratrol, Resveratrol-3-O-sulfate, 
resveratrol-4’-O-sulfate and resveratrol-3,4’-O-disulfate metabolites were 
synthesized. The anti-tumour activity was evaluated against three breast cancer cell 
lines (two hormone-dependent: MCF-7 and ZR-75-1; one hormone-independent: 
MDA‐MB‐231) and one immortalized breast epithelial cell line (MCF-10A). It was 
found that, in comparison to resveratrol, all three sulfated metabolites were less 
potent against MCF-7, MDA‐MB‐231 and ZR-75-1 cells (trans-resveratrol 3-O-
sulfate < trans-resveratrol 4′ -O-sulfate < trans-resveratrol 3-O-4′-O-disulfate) 
indicating that any conjugation of the phenolic groups with sulfuric acid strongly 
affecting the cytotoxicity. Interestingly, all sulfated metabolites displayed  about 10-
fold decrease in anti-tumour activity, but showed nearly equal cytotoxicity towards 
nonmalignant MCF-10A breast cells (IC50  202-228 µM). Despite these findings, 
authors have concluded that observed low activity of metabolites may not actually 
reflect their in vivo performance, because ubiquitously existing human sulfatases 
could convert the metabolites back to resveratrol in humans 69
In summary, the metabolism and pharmacokinetic studies revealed that resveratrol 
undergoes rapid metabolism to produce resveratrol glucuronides and sulfate 
conjugates. In rodents, mice showed little unchanged resveratrol after IV dosing and 
only metabolites after oral
. 
63. Similarly, in rats, there was very little unchanged 
resveratrol but metabolites after oral dosing and although resveratrol level was 
slightly higher after IV dosing but still very low. The half life for IV and oral were 
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0.13 and 0.29 hrs respectively 63. In human, after oral dosing very low levels of 
resveratrol was seen in plasma 66, 67. The repeat dosing did not improve the 
resveratrol levels in plasma. In all the pharmacokinetic studies , it was concluded 
that resveratrol levels were not high enough to elicit pharmacological activities and 
warranted the study on activity of metabolites 66-68. Few studies were conducted on 
the activity of metabolites, it was observed that metabolites were less active than 
resveratrol 69 
 
. Although it was suggested that under in-vivo conditions the sulfate 
metabolites may convert back to resveratrol but that was not seen in any 
pharmacokinetic studies yet. The sulfation process seems to be faster than 
desulfation resulting in more metabolites. Hence resveratrol belongs to a class of 
compounds where poor bioavailability is a cause for attrition in drug development 
process as shown in Figure 3.  It is clear from the above review that administering 
resveratrol in a conventional way would not result in desired pharmacological 
effects. Hence there is need to develop formulation strategies to deliver the 
resveratrol in the native form and sustain its level in vivo for an adequate period of 


























Figure 1.4: Attrition of new drugs during drug development stages for various 
reasons 70
 















1.8 STRUCTURE ACTIVITY RELATIONSHIP (SAR) 
The pharmacokinetic and metabolism studies of resveratrol revealed that resveratrol 
is very short lived in the body, with a half life of 0.13 hours. The reason for the rapid 
clearance of resveratrol from the body is due to its rapid metabolism to sulfate and 
glucuronide metabolites. These findings suggest a need for changes in the structure 
of resveratrol, in order to improve its pharmacokinetic profile. However, before 
making attempts to modify structural properties of resveratrol, the structure-activity 
relationship of resveratrol needs to be carefully reviewed. 
Ovesna et.al 71 reported their work on the structure activity relationship of 
resveratrol. They found the chemopreventive activity of resveratrol is dependent on 
the number and position of the hydroxyl group, stereochemistry, double bond and 
intramolecular hydrogen bonding. They reported that the stilbene structure with 
intact 4’ hydroxyl group, double bond and bearing orthodiphenoxyl or 
paradiphenoxyl functionalities possesses a greater antichemopreventive 
activity.Another group reported  the structure activity relationship of resveratrol, as a 
COX-2 inhibitor. 72  The study revealed that, the introduction of hydroxyl groups, in 
addition to existing ones, has resulted in an increased COX-2 inhibitory effect of 
resveratrol. The 3, 3’;4, 4, 5, 5’ hexa- hydroxyl- trans-stilbene was a potent COX-2 
inhibitor, with a IC50 value of 0.00104 µM, against 0.034 µM for celecoxib. The 
compound was more selective for COX-2 than COX-1, with a selectivity index of 
719 compared to 546 for celecoxib. Replacement of the OH group with the methoxyl 
group at 3,4’ and 5 positions, resulted in decreased activity, activity was lesser than 
resveratrol itself. However 3,3’,4,4’,5,5’ hexamethoxyl-trans-stilbene slightly 
bettered the COX-2 inhibitory effect. The IC50 value for this hexa methoxy 
derivative was 0.35 µM. as against 0.99 µM for resveratrol. One factor that has 
become evident from this study is that for better COX-2 activity, existing hydroxyl 
functional groups are essential. Replacing only hydroxyl groups, without changing 
the rest of the structure leads to decreased activity. However there is no information 




In another study, the same group reported 73 
 Lee et.al 
that hydroxylated resveratrol had 
exhibited better antioxidant and cytotoxic effects compared to unmodified resveatrol. 
The 3, 3’, 4’, 5 tetrahydroxystilbene was found to have 6600 fold higher antiradical 
activity than resveratrol. The cytotoxicity studies with HL-60 cell lines, showed that 
stilbenes with the orthohydroxy group exhibited 3 fold increase in antistatic activity.  
74
1.9 USE OF RESVERATROL DERIVATIVES AND DRUG DELIVERY 
SYSTEMS TO IMPROVE PHARMACOKINETIC PROFILE AND 
BIOLOGICAL ACTIVITY. .  
 have studied the free radical scavenging activity of resveratrol 
derivatives. They found that, having bromo, fluromethyl and iodo groups, while 
preserving existing hydroxyl groups, increases the free radical scavenging activity of 
resveratrol. Replacing all hydroxyl groups with methoxyl groups, results in a 
complete loss of activity. However, substituting only one hydroxyl group with 
glycoside moiety, results in just doubling IC-50 value, and not a complete loss of 
activity. 
To overcome rapid metabolism of reseratrol many efforts have been made. Pujic and 
his coworkers 75 proposed the use of various conjugates of resveratrol for delivery of 
resveratrol into skin. They prepared the various ester and conjugates of resveratrol 
and studied their hydrolysis in-vitro in presence of stratum corneum and cholesterol 
esterase enzymes.  The resveratrol was initially  reacted with acetic anhydride in 
pyridine to get triacetate ester followed by selective enzymatic deacetylation to yield 
3,5-resveratrol diacetate. The diacetate resveratrol was conjugated to lipoic acid and 
vitamin E succinate to yield 3,5-diacetyl-resveratrol-4’-O-lipoate and 3,5-diacetyl-
resveratrol-4’-O-succinate-vitamin E respectively. The lipoate and vitamin E 
conjugates of resveratrol were tested for stability at pH 5.5 and 7.4 at 370 C. Both 
conjugates were stable in pH 5.5 and were less stable underwent slow hydrolysis to 
yield mono and diacetate esters. The lipoate conjugate hydrolysed to resveratrol and 
lipoic acid with stratum corneum enzymes over period of 3 days by a slow release of 
resveratrol thus enabling antioxidant activity. The resveratrol-vitamin E conjugate 
did not undergo hydrolysis in presence of stratrum corneum enzymes, instead 
hydrolysed in presence of esterase, cholesterol esterase. Although this paper 
describes the scope for sustained delivery of resveratrol across the skin but did not 
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provide information of stability of conjugates while passing through actual skin. 
Further studies such as actual permeation these compounds across the skin and their 
stability in skin are needed. After passing through skin, these conjugates will be 
taken up into systemic circulation and stability of these compounds in presence of 
plasma estereases need to be studied. Moreover resveratrol itself is lipophilic,  
solubility after conjugating with lipophilic compounds was not given. Further 
increase in lipophilicty would make i.v delivery difficult. Hence further investigation 
such as solubility, stability in plasma and pharmacokinetic profile after i.v., oral and 
dermal administration is required in order to know whether these conjugates are 
better than resveratrol and are really viable options as  a delivery system. 
Lucia Biasutto et.al 76 
Same group in another study 
 have synthesized mitochondria targeted resveratrol derivatives 
and evaluated their in vitro anti cancer activity. The 3,5’ diacetylresveratrol-4’-O-(4-
triphenylphosphoniumbutyl) iodide was synthesized. The compound showed good 
activity against the murine colon cancer cell line, fast growing mouse embryonic 
fibroblast (MEF) but not against slow growing MEF. The activity was better than 
native resveratrol. Although authors claimed that product had transient stability 
against metabolic conjugation but no elaborate studies on metabolism was reported. 
The detailed pharmacokinetic and pharmacodynamic studies are essential to assess 
the metabolic stability and activities in vivo. Further biological evaluation of these 
compounds in animal models is required. In addition safety and toxicity of 
compounds are also essential. As there was new group added onto resveratrol as 
ether, no hydrolysis can be expected in the body to release parent compound. If 
proven safe and active than resveratrol, these compounds would be candidates for 
clinical studies. 
77 have prepared and evaluated pharmacokinetic 
properties of 3,4’,5-tri(a-D-glucose-3-O-succinyl)-resveratrol. They found that ester 
bond in the compound did undergo rapid hydrolysis in the blood, all was converted 
back to resveratrol within an hour. After oral administration this glucose ester of 
resveratrol, only delayed absorption with Cmax achieved after 4 hours compared to 60 
minutes for resveratrol. However there was no change in the amount of native 
resveratrol reaching systemic circulation. AUC of resveratrol was found to be 53,4 
µg*h/mL and for 3,4’,5-tri(a-D-glucose-3-O-succinyl)-resveratrol  it was found to be 
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51,8 ± 37,2 µg*h/mL. Both resveratrol and glucose ester did undergo metabolism to 
the same extent.  
Biasutto and co workers 78
Li et.al 
 have also evaluated various carboxy esters of resveratrol 
and evaluated their stability in blood and permeability across isolated rat jejunum. 
The resveratrol triacetate and resveratrol-tri-mPEG hydrolysed completely in blood 
within an hour. But resveratrol-trimethane sulfonate was stable. The resveratrol and 
triacetate form appeared in basolateral side as phase-II metabolites. Resveratrol-
triPEG although underwent hydrolysis but metabolism of resveratrol was prevented 
by adjacent PEG molecules. The resveratrol triamethane sulfonate neither underwent 
hydrolysis nor metabolism during the permeation studies. There was no information 
on biological activity of these molecules. Though resveratrol trimethane sulfonate 
was stable, but again it is a new molecule altogether, further preclinical biological 
evaluation is required for  advancing this molecule into clinical trials. 
79
Jiang and his colleagues reported 
 have reported synthesis, in vitro mineralization and in vivo work focusing 
on bone regeneration activity of resveratrol-polycaprolactone conjugates. There was 
no report on the conjugates other biological activities, their stability in plasma and 
metabolism. Since these conjugates were used as implants in this study, solubility of 
conjugates was not an issue. However for IV dosing this conjugate had to be 
formulated in nanoparticles. Which may lead to their clearance by reticulo 
endothelial system.  The drug release and other activity studies need to be 
performed. On other hand soluble conjugates may have advantages over this 
compound as they can be formulated as intravenous solution.   
80 design and synthesis of resveratrol with aliphatic 
acid ligands to assess their impact on biological activity of resveratrol. Research also 
studies the solubility of various resveratrol-4’-O-aliphatic acids and their binding to 
human serum albumin. The author reported that reseveratrol aliphatic acid 
derivatives had stronger affinity towards human serum albumin. There are no details 
about the activity and metabolic stability of acid ligands.  Although 4’ hydroxyl 
group was modified into aliphatic ligand, there two more hydroxyl groups at position 
3 and 5 of resveratrol which can undergo metabolic conjugation to glucuronide and 
sulfate metabolites. The detailed studies to ascertain the activity and stability of 
resveratrol ligands in vivo are needed. Since the derivatives were made through non 
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cleavable ether linkage with aliphatic substitution, they constitute relatively new 
compounds which would not undergo hydrolysis. Further animal studiesare required. 
Feng et.al 81
 
 prepared resveratrol biotin conjugate for studying protein binding 
pattern of resveratrol in order to understand molecular mechanism of bioactivity. The 
conjugate was synthesized via ester linkage between resveratrol and biotin. 
Biotinylated resveratrol was synthesized in the presence of 1,3-
dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine as catalyst. The 
biotinylated resveratrol and un-modified resveratrol were tested for anticancer 
activity. The growth inhibitory activity was tested in MCF-7 and Hep G2 cell lines. 
At 300 µM, the resveratrol-biotin showed growth inhibition of 30% against 40% for 
resveratrol and similar pattern of inhibition was observed for both cell lines. The 
authors have concluded that biotinylation did not affect biological activity of 
resveratrol. There was a small decrease in solubility of resveratrol reported after 
conjugation to biotin. The biotinylated resveratrol was used as substrate instead of 
native resveratrol in order to facilitate easy assay with enzyme linked immnosorbent 
assay (Elisa).  The information on plasma stability and metabolism of resveratrol is 
not mentioned in the paper. Detailed structure elucidation of conjugate was not 
performed, although MS spectrum indicates mono biotinylated resveratrol but exact 
position of substitution was not derived. The positive outcome of the study was that 
mono substitution of resveratrol with bulky biotin does not impair its biological 
activity; however fate of  conjugated molecule in vivo needs to be investigated.  
In addition to resveratrol derivatives and conjugates, drug delivery systems have also 
been investigated for resveratrol. Guo et.al have investigated the antitumor effects 
and functional mechanism of resveratrol-bovine serum albumin nanoparticles on 
human primary ovarian carcinoma cells in nude mice 82. The tumour was developed 
in the mice by injecting carcinoma cells subcutaneously. The tumour bearing mice 
were given intraperitoneally resveratrol nanoparticles, normal saline and albumin. 
The in vivo antitumor efficacy was evaluated by measurement of tumor volume, 
whereas morphological alterations were observed by transmission electron 
microscope (atomic force microscopy); TUNEL assays and immunoblotting for 
apoptotic and cell proliferation proteins were carried out to elucidate the possible 
mechanism. The administration of resveratrol nanoparticles significantly retarded the 
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growth of carcinomas in nude mice from the third week onwards, and the inhibition 
rate was markedly higher than in mice treated with resveratrol (52.43% vs. 46.34%, 
p < 0.05), without causing weight loss (p > 0.05). The nanoparticle formulation 
approach proved to be effective in enhancing biological activity of resveratrol in 
animal model, however formulation needs to be worked out to release all entrapped 
resveratrol in a reasonable period of time to maximize its activity. 
 
Shao et.al have studied the cytotoxic effects of resveratrol loaded mPEG-PCL 
nanoparticles in comparison to free resveratrol in glioma cells 83. The results 
revealed better uptake of resveratrol loaded naoparticles by glioma cells than free 
resveratrol. The resveratrol loaded nanoparticles showed significantly higher cell 
death compared to resveratrol. Furthermore free resveratrol was less cytotoxic than 
resveratrol loaded nanoparticles. The authors attributed such difference in this 
activity between free resveratrol and its nanoparticles to improved uptake of 
resveratrol into cells when it is in nanoparticles. Increased intracellular reactive 
oxygen species (ROS) levels was thought to be the reason for the anticancer activity. 
In contrast to the ability of resveratrol to scavenge ROS 1, in malignant cells it 
induced the ROS there by exerting cyctotoxic activity 83
 
. Although this formulation 
technology has improved the in vitro anticancer activity of resveratrol, authors did 
point out need of confirmation from in-vivo studies. It is envisaged that problems 
such as limited drug loading, incomplete drug release, stability of system and fast 
clearance by RES inside the body are likely going to be the barriers. 
 
1.10 EFFECT OF POLYMER CONJUGATION ON METABOLISM OF DRUGS 
There are many reports on possible effects of polymer conjugation on metabolism 
and pharmacokinetic profile of peptide and non peptide drugs. Many factors are 
involved in the removal of substances from the circulation. Proteins and peptides are 
rapidly eliminated by proteolytic degradation, renal filtration, and/or immunogenic 
and antigenic reactions. For small molecules such as resveratrol, its clearance from 
blood circulation involves biotransformation to various metabolites followed by 
excretion.  Monfardini  et.al 84 in their review,  summarized various research 
outcomes of polymer conjugation on circulation time of peptides and proteins. Based 
on their survey, it can beconcluded that elimination of peptides/proteins by 
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proteolytic degradation, immunogenic and antigenic responses were significantly 
reduced and circulation times were prolonged by conjugation with polymers.  They 
also concluded that polymer conjugation of non protein drugs leads to the long-
lasting activity due to the increased half-life in the circulation, which is a result of 
protection against metabolism and/or reduced kidney ultrafiltration because of the 
increased size of the drug-polymer conjugate. They also stated that polymer 
modification could also impart decreased toxicity due to polymer shielding of 
“toxic” moieties, and the possibility of targeting to specific organs and tissues by 
introduction of a active targeting ligand along the polymer backbone. 
 
Polymer conjugation approach has been successfully applied for improving safety, 
efficacy and pharmacokinetic profile of small molecule drug such as doxorubicin 
(DOX), norfloxacine (NOR), campothecine (CAMP) and paclitaxol (PTX). 
Numerous reports have been published on polymer conjugation of doxorubicin. 
Dororubicin-dextran polymer conjugates were extensively investigated.  
Doxorubicin was coupled to oxidized dextran 70 chain via Schiff’s base formation.  
Conjugate was found to have higher plasma level, persisting for long time, thus 
provided very effective passive targeting 85. However phase I clinical studies of the 
conjugate showed that conjugate was slightly more toxic than DOX itself. WHO 
grade IV hepatotoxicity,  grade III cardiotoxicity, grade III thrombocytopenia were 
some of the major clinical signs noticed. However polymer conjugate had prolonged 
circulation time with dose dependent elimination half life of  t1/2β of 2.69 to 11.58 
hours and t1/2γ of 41.44 to 136.58 hours (doses 12.5mg/m2 to. 40mg/m2). Based on 
these studies, dose of 12.5mg/m2 
 
was recommended for phase II clinical studies. 
Doxorubicin conjugates with polyethylene glycol (PEG) were also investigated in 
preclinical studies. Various DOX-PEG conjugates were prepared with different 
tetrapeptide spacers and PEGs of varying molecular weight 86. The purpose of 
research work was to achieve longer circulation and greater tumour targeting. 
Among the various spacers tested Glycine-phenyl alanin-leucine-glycine(GFLG), 
Glycine-leuci-glycine (GLG), Glycine-Glycine-arginine-arginine (GGRR), and 
Arginine-Glycine-Leuci-Glycine (RGLG) were found to provide porolonged release 
in presence of lysosomal enzymes in vitro (16% release in 5 hours). Thus providing 
slow and targeted release of DOX in cytoplasm of  the cells by action of lysosomes.  
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The circulation time of DOX-Peptide-PEG in the body was dependent on the Mw of 
PEG, the longer Mw PEGs provided prolonged circulation time, however there was 
no exact coorelation between Mw of polymer and circulation time. This was because 
some of DOX-peptide-PEG with smaller PEG chain formed micelles, which 
eventually had longer circulation times. The conjugates were found to be 10 fold less 
cytotoxic than DOX (IC 50 > 2µg/mL vs 0.24µg/mL for DOX).  DOX-peptide-PEG 
conjugates had improved tumour taragetting with releatively less DOX levels in the 
heart. Antitumor activity of DOX-Peptide-PEG in the sc B16F10 and ip L1210 
models in black male mice shown that conjugates had superior activity compared to 
DOX (T/C value 146 against 120 for DOX).  
 
Doxorubicin was successfully conjugagted to D-α-tocopheryl polyethylene glycol 
1000 succinate (TPGS) 87
 
. The TPGS was initially derivitized to acid functional 
succcinyl end group, later connected to DOX via ester link.  DOX-TPGS exihibited 
better in vitro activity than DOX itself against MCF-7 cell lines, with IC50   of 0.03 
µM against 0.117 µM for DOX. This was attributed to improved uptake of 
conjugates by cells. The pharmacokinetic studies of conjugate revealed 4.5 fold 
increase in half life and 24 fold increase in area under the curve (AUC). Drug levels 
in heart, gastric and intestine were reduced, indicating passive targeting and 
decreased side effects. 
Paclitaxol has been conjugated to soluble polymers such as polyethylene glycol 88,   
micelle forming diblock polymer polyethylene glycol-polylactide (PEG-PLA) 89 and 
triblock polymer PLA-PEG-PLA 90. The paclitaxol-PEG conjugated made via ester 
link was found to undergo rapid hydrolysis in plasma with t1/2 of 30 minutes. The 
PTX-PEG ester conjugates were considered ideal for prodrugs for parenteral 
formulation to overcome solubility issues. However PTX-PEG prodrugs were found 
unsuitable for the use as long circulating drug delivery systems. The paclitaxol was 
conjugated to PLA-PEG with an ester bond, the conjugate was found to be active 
against H7402 liver cancer cell line 89. Authors concluded that paclitaxol was 
released in the cells and polymer conjugation did not affect the activity of paclitaxol. 
However there are no data on pharmacokinetic and in vivo activity was reported. 
Similarly PTX-PLA-PEG-PLA was also prepared, and micelle properties and in 
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Although polymer conjugates were reported to slow down metabolism of 
drugs/peptides and enhance the circulation time, the mechanism by which the 
polymer stabilize the drugs against metabolism needs to be reviewed. 
Veronese et.al 91
 
 conducted review on the possible mechanism for reduced 
metabolism and increased circulation time of drugs after conjugation to polymers. 
They hypothesized that shielding effect of polymer provides protection against 
chemical and enzymatic degradation and masks the antigenic sites of drugs which 
can trigger immunogenic response from the body. In the case of PEG, high 
molecular mobility, conformational flexibility and water binding ability of polymer 
chain prevent, mainly by thermodynamic effects, approach of degrading enzymes 
towards drugs. The large size of macromolecular conjugates reduces the renal 
excretion of drugs. This happens when threshold volume of molecule reaches the 
volume of serum albumin. Due to large molecular size, it makes possible for tumour 
targeting of drugs via enhanced permeation and retention (EPR) phenomenon.  
In addition to shielding effects, some PEG derivatives such as Vitamin E-succinate-
PEG (TPGS) has shown to have inhibitory effects on drug metaboliszing enzymes 
such as cytochrome P450 3A (CYP3A) thereby exerting chemical inhibition of drug 
metabolism 92
Inhibitory effects of various formulation vehicles on Cytochorme P450 using human  
liver microsomes, monkey intestinal microsomes with 7-benzyloxy-4-
(trifluoromethyl)-coumarin (BFC) as substrate has been reported 
.  
93. The PEG 400 
was found to inhibit metabolism of BFC. It was suggested that inhibition of CYP 3A 
was responsible for reduction in the metabolism of BFC. Gonzalez et.al 94 have 
investigated effect of surfactants such as solutol HS, Cremophore EL and Tween-80 
on metabolism of midazolam with liver microsomes and hepatocytes. There was up 
to 51% reduction in the midazolam clearance observed with all surfactants. The 
surfactants did not show cytotoxic effects on cells. The direct enzyme inhibition and 
molecular interactions between surfactant and microsomes were attributed to 
reduction in metabolism. In case of Tween-80 and Cremophore EL, reduction in 
metabolism of midazolam with hepatocytes was only significant above the critical 
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micelle concentrations. This indicates release of midazolam from micelles or 
shielding effects micelles would also contribute to reduction metabolism. Hence it 
was suggested that physical entrapment of drugs by micelles can also be an fficient 
tool for stabilizing drugs against metabolism. 
 
Biasutto et.al also have reported the inhibitory effect of PEG on intestinal 
metabolism of resveratrol. The resveratrol-PEG conjugates although hydrolysed 
while passing through intestinal membrane but adjacent PEG molecules prevented 
the metabolism of resveratrol 78
 
. 
Overall the polymer conjugation can be considered as an effective option for 
improving pharmacokinetic profile of resveratrol. By using appropriate  polymers, 
the prodrugs /conjugates may also form polymeric micelles which  could also 
provide opportunity to improve the stability and biological activity of resveratrol. 
The resveratrol can either be entrapped into the micelles or it can be conjugated to 
polymers which can self assemble into micelles. These formulations can be used for 
prolonged release of resveratrol in the body. It is believed that micelle structures can 
also provide additional stability of conjugates against hydrolysis by plasma esterases.  
The entrapment of resvertrol in mPEG-PCL micelles has shown to improve in vitro 
anticancer activity and such an effect was attributed to improved uptake of micelles 
by cancer cells 83.  In light of these observations  exploration of micelle formulations 
either by physical entrapment or by chemical conjugation of the resveratrol to 
polymers appears to be a feasible approach to improve pharmacokinetic profile of 
resveratrol. Despite of these, there is very limited research conducted with 
resveratrol polymer conjugates ( Table 1.1), further development and evaluation of 
resveratrol polymer conjugates will bring the benefit to not only to the therapeutic 
application of resveratrol but also to the research  field addressing the issues of how 
to overcome the rapid metabolism of some therapeutic molecules.
35 
 









Formulation Studies conducted/Outcomes Reference  
PEG Not mentioned 1900 Da solution Blood stability, intestinal stability and 
metabolism. The conjugate hydrolysed 
completely in an hour in the blood. Permeation 
studies showed that polymer hydrolyzed to 





Not given 80000 Da Polymer 
porousscaffold 
Bone remineralization in rats. Resveratrol-PCL 
increases bone remineralization. 
79 
PEG Not given 2000-20000 
Da 
Not mentioned RGD binding and other biological studies. 
Improved biological activity. No details are 




Not given 2000-20000 
Da 
Not mentioned Same patent, not much of information given 95 
PLA-Polylysine/ 
Hyaluronic acid 
Not given 2000-20000 
Da 





1.11. OBJECTIVES OF THIS STUDY  
This PhD research project aimed to develop resveratrol-polymer conjugates which 
could provide the prolonged circulation of resveratrol in the body and protect the 
resveratrol against metabolism. Various polymers with diverse chemical structure 
were explored for this purpose. Below are detailed in vitro and in vivo studies which 
were performed to achieve the overall objective and to test the effectiveness of 
polymeric conjugation strategies for formulation of resveratrol delivery systems. 
1. Synthesized resveratrol-PEG conjugates via ester linkage and studied the 
effect of polymer molecular weight and linker on plasma stability. 
2. Synthesized resveratrol-PLA-PEG conjugates via ester linkage. 
3. Synthesized resveratrol-PEG conjugates with non hydrolysable ether linkage. 
4. Characterized the polymer conjugates by NMR, IR and LC-MS for structural 
elucidation. 
5. Studied the physicochemical properties of conjugates in terms of particles 
size and critical micellar concentrations.  
6. Developed and validated suitable HPLC method to separate and quantify the 
resveratrol, its polymer conjugates and analysis of plasma samples of 
selected polymer conjugates and resveratrol. 
7. Evaluated stability of conjugates in various buffers and rat plasma. 
8. Developed  LC-MS/MS method closely matching LC conditions of HPLC to 
identify the metabolites.  
9. Conducted preliminary metabolism studies of resveratrol and its polymer 
conjugates in rat liver microsomes in presence of uridine diphsopho 
glucuronic acid ( UDPGA). 
10. Conducted preliminary single dose pharmacokinetic studies of resveratrol 







1.12 SIGNIFICANCE OF PROPOSED WORK  
Although resveratrol has shown diverse bioactivities in vitro, its in vivo activities 
have not been proven unequivocally. The reason for lack of in vivo effectiveness was 
due to  its rapid metabolism in the body. It was proposed that the formulation 
approaches which could protect resveratrol against its metabolism in vivo  could 
eventually enhance its pharmacological activities.  This research work tested the 
strategy of using polymeric conjugates to protect resveratrol against metabolism in 
vivo, thereby prolong the its biological half life and improve pharmacokinetic 
profile.. The success of the project would improve possibilities of therapeutic 
success of resveratrol, thus provides new therapeutic opportunities for resveratrol. 
Furthermore this study wouldalso provide an opportunity to gain knowledge in 
optimization of the design of resveratrol-polymer conjugates.   
 
1.13 THESIS OVERVIEW 
The research work of the project has been compiled in four chapters, each consisting 
of an introduction, experimental, results and discussion section. These chapters are 
followed by a general discussion and conclusions chapter. The four main chapters of 
thesis explain four varied parts of my research work as explained below, 
 Synthesis, characterization, biological and preliminary pharmacokinetic 
evaluation of resveratrol-polymer ester conjugates. This chapter describes 
synthesis and characterization of resveratrol-polymer conjugates formed via  
ester bonds. It explains how polymer conjugates of resveratrol were assessed  
in vitro for  buffer stability, plasma stability, in vitro antioxidant function and 
metabolism in presence of rat liver microsomes. This chapter also reports  the 
preliminary intravenous pharmacokinetic studies conducted for selected 
polymer conjugates in Wistar rats. Due to the time constrain, only single dose 
i.v. bioavailabilities of resveratrol and selected polymer conjugates were 
studied.   
 Synthesis, characterization, biological and preliminary pharmacokinetic 
evaluation of resveratrol-PEG ethers: This chapter focuses on synthesis 
and characterization of resveratrol-PEG ethers. This chapter elaborates how 
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reaction conditions were optimized to achieve maximum PEG conjugation to 
resveratrol. It also describes  in vitro and in vivo biological studies conducted 
to evaluate the effectiveness of polymer ether conjugates in improving 
pharmacokinetic profile of resveratrol.  
 Development of HPLC method for simultaneous analysis of resveratrol, 
resvertrol-polymer conjugates and  detection of resveratrol metabolites:  
This chapter describes the development of a sensitive HPLC method for 
detection and quantification of resveratrol, its polymer conjugates and 
detection of metabolites. This chapter also explains how method was 
optimized to get maximum sensitivity with fluroscence detection. Various 
validation parameters for resveratrol and some of selected conjugates were 
reported and discussed. 
 Developments of a LC-MS methodology to separate, detect, characterize 
and quantify resveratrol-PEG conjugates and the conjugation reaction 
precursors and intermediates: This chapater emphasizes on how an LC-MS  
method was developed and applied for characterization of resveratrol-PEG 
conjugates. Italso explains  how method was utilized to monitor PEGylation 
process and determine extent of PEG functionalization and conjugation to 
resveratrol. 
All investigations in this project were carried out using a commercially 
available isomeric form of resveratrol, ie trans-resveratrol,which is a stable 
form of  naturally occurring polyphenol.  . 
 
The research objectives/activities associated with  this  PhD project are 




























Figure 1.5: Summary of objectives of this PhD project. 
  
Design strategies to improve 
pharmacokinetic profile of resveratrol  
Synthesize releasable resveratrol-polymer ester 
conjugates such as MeO-PEGN-Succ-RSV 2 kDa 
and 20 kDa, MeO-PEGO-Succ-RSV 2kDa, MeO-
PEG-PLAO-Succ-RSV 2 KDa,  and 6.5 kDa 
 
Develop HPLC and LC-MS 
method for analysis of RSV 
and its conjugates. 
Synthesize stable non 
releasable RSV-PEG ether 
conjugates, 2kDa, 5 kDa 
Characterize polymer 
conjugates by NMR, 
HPLC and LC-MS Conduct buffer, plasma 
and microsomal 
stability studies  
Carry out free radical 
scavenging activity for 
selected polymers 
Carry out buffer, 
plasma, microsomal 
stability and free radical 
scavenging activity 
 
Select polymer conjugates for in vivo studies based on outcome of  in vitro tests. Carry out single dose preliminary pharmacokinetic studies 
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2.1 INTRODUCTION  
Due to natural abundance and diverse biological activities, resveratrol has attracted 
much of research.1-4 Resveratrol being polyphenolic in nature has tendency to 
undergo phase II metabolism  to form metabolites via glucuronidation and sulfation. 
5-9 Despite showing good biological activity under in vitro conditions, resveratrol 
failed to produce the desired pharmacological activity in animal models. 10-12 
However, the presence of hydroxyl groups in resveratrol provides an opportunity for 
chemical modification to produce ester or ether prodrug derivatives. This could be 
explored to design polymeric prodrugs/conjugates for masking molecules against 
metabolism. Although the structure of resveratrol is favourable for modification to 
form  polymeric conjugates, the structure activity relationship of resveratrol should 
be taken into consideration in developing polymer conjugates. Studies of resveratrol 
revealed that the hydroxyl group in resveratrol is essential for the biological activity. 
The structural modifications with bromo, iodo and fluromethyl groups on aromatic 
rings have shown better activity than resveratrol; however replacement of hydroxyl 
groups with any other functional moieties has resulted in reduced activity. 13, 14 This 
indicates that hydroxyl groups in structure contribute to its bioactivity.  In order to 
sustain resveratrol activity in the body, simple but reversible chemical modification 
of resveratrol, which can mask the molecule against metabolism, as well as being 
able to release native resveratrol in the body would be desirable. In this regard, 
developing polymeric conjugates would be an effective formulation strategy for 
overcoming the rapid metabolism and prolonging resveratrol residence time in vivo.  
As reviewed in chapter one, the polymer conjugation strategy has been successfully 
applied to small molecules such as paclitaxol, campothecin, docetaxol, doxorubicin, 
norfloxacin. The polymer conjugation proved effective in improving solubility, 
circulation time, enhanced cellular uptake and tumour targeting.
 
 15 
2.1.1 Review of synthetic procedures for the synthesis of drug-polymer ester 
conjugates. 
The release of drugs from the polymer conjugates depends on the nature of polymer, 
the type of linker and the drug. 16, 17 The hydrolysis of polymer conjugates (esters) in 
plasma is a rate limiting process. Not all chemical modification or polymer 
conjugation will enhance the activity of drug molecules. For instance, PEGylation of 
paclitaxol using carbamate bonding reduced the drug activity. 18 The reduced activity 
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was attributed to two reasons, the large bulky PEG substitution blocked the activity 
at the target cell and the possibility that paclitaxol failed to reach the target site. 18 
The half life of polymeric conjugates can depend on the nature of the drug and the 
position of the functional group to which the polymer is attached; for example, 
paclitaxol when PEGylated via ester linkage at 2’ hydroxyl group had a very short 
plasma half life (hydrolysis) of 0.4h. In contrast to this, the paclitaxol-7-PEG with 
the same linker had t1/2 of >400 h.
The prolonged release of drugs from a polymer conjugate can be achieved by 
varying the type of linker. The plasma hydrolysis of campothecin-PEG ester was 
strongly dependent on the structure of the linker. The PEG esters with glycine linker 
hydrolysed  more slowly in rat plasma than the plain PEG ester.
 19 
 20 The plasma 
stability further varied as the electronegativity of the α amido group changed. The 
highest plasma stability of ester was observed with the most electronegative 
substitution on the α amido group of  the linker 20. The alkylations of nitrogen also 
lead to a significant increase in plasma stability. Although the glycine PEG ester was 
more stable than carboxy PEG ester in plasma, it was less stable compared to the 
other N-substituted glycine linker, attributed to anchimeric participation of a basic 
NH group in a-lactam intermediate formation in the campothecin-glycine-PEG 
molecule. 20 Tripartate PEG conjugates have been extensively investigated for drug 
delivery. Essentially, the system consists of two prodrug moieties; one actually 
cleaves by enzymatic hydrolysis and another by chemical decomposition. Tripartate 
PEG drugs were not only soluble, but also had extended plasma half life. This 
technology has been successfully applied to anticancer drugs containing amine 
group.  Benzyl elimination systems were explored for this purpose, the amine 
containing anticancer drug daunorubicin was coupled to the benzyl linker via the 
carbamate bond, and the benzyl linker was conjugated to the PEG with different 
bonding chemistry such as ester, carbonate, and carbamate. The PEG was removed 
in plasma by hydrolysis which was followed by a classical 1, 4- or 1, 6- benzyl 
elimination reaction to produce the free amine drug. 21-23 The stability of polymer 
conjugate can be varied by changing the bonding chemistry between the PEG and 
the benzyl linker, and also by increasing the stearic hindrance on the benzyl group. 17 
However, detachment of PEG from the benzyl group was found to be a rate limiting 
step in the overall stability of conjugate in plasma. The benzyl conjugation and 
elimination technology was also successfully applied for antifungal agent 
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amphotericin B. 24, 25 The permanently linked PEG-urethane-amphotercin B, showed 
similar activity to that of native amphotericin B; however, the PEG prodrugs with 
benzyl elimination technology with a plasma stability of 1-3 h, were found to be 
safe, with approximately six times less toxicity than the native drug. The maleamide 
spacer was reported to be a versatile linker for the polymer conjugation of 
anthracyclines with simple conjugation chemistry and prolonged circulation times of 
anthracyclines. 26
Apart from the effect of the linker on plasma stability of polymer conjugate, the 
physical and chemical properties of the polymer linked to the drug also play a 
significant role in the stability of the polymer conjugate. N-(2-Hydroxypropyl) 
methylacrylamide (HPMA) copolymer has been used to conjugate drugs. Several 
factors, such as the inter and intra-molecular association of side chains, have been 
shown to affect the enzyme catalysed release of drugs from the conjugate.
  
 27 The 
polymers that have the ability to form micelles have advantages over other polymers 
in their application in drug delivery. Possible aggregation of polymer chains in 
micelles could have impeded hydrolysis. The micelles can provide additional 
benefits such as the long circulation, internalization into the tumour, and the better 
plasma stability of the drug-polymer conjugate. 27 In case of water soluble polymers 
such as PEG, the polymer with Mw < 30 kDa would be excreted via the kidney, 
because threshold of kidney filtration is not reached. 15-17 However, the micelle 
forming polymer can overcome this limitation as the size of micelles prevents kidney 
filtration. The paclitaxol conjugates PLA-PEG diblock and triblock PLA-PEG-PLA 
polymers have been developed for this pupose and unfortunately not much 
information on plasma stability of conjugates has been reported. 
 
28-29 
There are several approaches reported to produce polymer conjugates which are 
stable in plasma but undergo hydrolysis at specific sites. The controlled and site 
specific release of drugs can only be achieved by proper selection of spacers. 30 The 
pH controlled drug release was successfully developed by using acid sensitive but 
serum peptide resistant spacers. When macromolecular polymeric drugs are taken 
into cells by endocytosis, the conjugate is anticipated to be expose to the acidic 
environment of lysosome. Moreover,  the pH in and around the tumour cells was 
reported to be a little lower than the healthy tissues. 30 This can be exploited to 
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The acid labile spacers were first developed by Shen and Ryser.31 They synthesized 
the daunorubicin-linked aminoethyl polyacrylamide beads and poly(d-lysine) using a 
N-cis-aconityl spacer. The pH-controlled hydrolysis of the cis-aconityl was 
demonstrated by measuring the half lives at pH 5 ranging from 1 to 4 h, depending 
on the conjugate and the type of buffer used. The cis-aconityl spacer was readily 
hydrolysed at pH 4 but negligible at pH 6. 31 Such results were also reported for 
adriamycine 32. Similarly, the example involving streptomycin coupled to dextran 
and to poly-(N-(2-hydroxyethyl)-l-glutamine) via a carboxylic hydrazon linkage 
were reported 33. The conjugate showed pH dependent release of streptomycine at 
lysosomal pH (4.5). After internalization of conjugates into cells by endocytosis, the 
drug-polymer conjugate was not only exposed to acidic pH but also to lysosomes 
and any spacer which can be selectively cleaved by the lysosomes and would 
provide a excellent opportunity for controlled and targeted release of polymer 
conjugates in the body 34-39. The lysosomes are often over expressed in tumours 34-39.  
Several lysosomal proteases such as cathepsins B, D and metalloproteinases promote 
tumour growth and formation of metastases 34-39.  This provides a rationale for 
polymer conjugate based anticancer drug delivery. If the spacer is oligopeptide, a 
substrate of lysosome enzymes, cyctotoxic drugs can be delivered to the tumour and 
subsequently released. The rate of drug release would be dependent on the amino 
acid sequence of oligopeptide.   A series of hydroxyl poly methacrylic acid (HPMA)-
Doxorubicin conjugates have been prepared and evaluated for lysosomal sensitive 
drug delivery. In vitro release  study of doxorubicin in media with lysosomal 
enzymes  suggested that drug release can be tailored by length and composition of 
amino acids 40
However, the possibility of using various spacers would be limited for resveratrol as 
hydroxyl groups are the only sites for conjugation. Any efforts to conjugate polymer 
to resveratrol should be based on the chemistry of the hydroxyl group. The peptide 
spacers used in the polymer conjugation of doxorubicin provide resistance to 
hydrolysis of the amide bond between the drug and peptide in the conjugate by the 
carboxy peptidases of plasma, but they can be hydrolysed by lysosomes. Similar 




structure; peptide spacer even if used in the polymer conjugation, would contain an 
ester link with resveratrol. The role of the peptide spacer in stabilizing ester bond 
against plasma esterases has not been documented. However, for resveratrol 
exploring different polymers with varying physiochemical properties and using a 
suitable ester linker would be good option for resveratrol, in order to achieve 
reasonable stability of polymer conjugate in the plasma. 
 
As mentioned early, synthesis of polymer conjugates of resveratrol can be achieved 
by exploiting hydroxyl groups of resveratrol. The phodophyllotoxin, having the 
hydroxyl group in the structure, has been coupled to PEG with various bonding 
chemistry such as ester using PEG with acid end group 
and  Diisopropylcarbodiimide, 4-Dimethylaminopyridine (DIPC-DMAP), carbonate 
using PEG paranitrophenol carbonate (and DMAP) and as carbamate using PEG 
isocynate (and DMAP) 43. These approaches have been demonstrated in polymer 
conjugation of other drugs. For instance, paclitaxol has been conjugated to PEG acid, 
PEG-PLA acid and PLA-PEG-PLA di-acid. In all of these couplings, the 
carbodiimide coupling reactions were employed 19, 28, 29. The carbodiimide coupling 
agents are also referred as zero length cross linkers as they are the smallest linking 
agents 30. These coupling agents mediate the formation of bond between two 
molecules without any additional spacer atom. The carbodiimides activate the 
COOH group by forming an O-acylisourea active intermediate which upon reaction 
with amine or hydroxyl groups forms amide or ester bonds and the by-product a urea 
derivative is formed, which in many cases is insoluble in organic solvents and can be 
separated by filtration. Since the carbodiimide mediated esterification needs 
hydroxyl and a COOH group, either the drug or the polymer must bear a COOH 
group. In the case of resveratrol, only hydroxyl functionality is present in the 
structure, which can be converted into acid ester (Example using succinic anhydride) 
or directly coupled to acid fuctinalized polymer. There are a few PEG acids available 
commercially or the polymers can be easily derivitized to have an acid end group. 
PEG  chain was converted to a PEG acid for paclitaxol conjugation by reacting with 
PEG-OH with ethylbromoacetate in the presence of tert-butoxide to form ethyl ester. 
The ethyl ester was treated with NaOH and the HCl to produce PEG-acid. 19 In 
another approach, the MeO-PEG-PLA-OH was converted to carboxyl terminated 
polymer by treating with succinic anhydride in the presence of DMAP. 19  In 
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addition, PEG can also be succinylated by treating with succinic anhydride in 
presence of pyridine in 1,4-dioxane 44 . The simple procedure for succinylating PEG 
was reported by Kuang  et.al, where PEG was refluxed with excess succinic 
anhydride in toluene 45
 
. 
The polymer conjugation approaches have been reported for resveratrol; however, 
most of approaches offered limited or no protection against metabolism due to the 
rapid hydrolysis of polymer conjugates in plasma. Biasutto et al.  prepared and 
evaluated various esters, such as PEG caboxyester, methanesulfonate and acetate 
ester of resveratrol. 46 The PEG conjugation to resveratrol was achieved by reacting 
PEG acid (PEG-glycine) with resveratrol in dimethyl formamide (DMF), in the 
presence of DMAP and N,N’-dicyclohexylcarbodiimide (DCC). The PEG esters of 
resveratrol underwent rapid hydrolysis in blood (hydrolyzed completely in an hour), 
so was acetate ester; whereas the methane sulfonate ester was stable in blood. 
Intestinal permeation studies revealed that for resveratrol-PEG ester, although 
hydrolyzed while passing through the intestine, adjacent PEG molecules prevented 
metabolism of resveratrol. In contrast, acetate ester was also hydrolyzed while 
passing through the membrane, but did not offer any protection against metabolism.  
Methanesulfonate ester was found to be stable and permeated as is, across the 
intestine membrane. In a patent covering polymer conjugation of various 
polyphenols 47, resveratrol was conjugated with different polymers such as PEG, 
PLA, polylysine-PLA, hyaluronic acid etc. But no details on the hydrolysis of 
polymer conjugates in plasma, metabolism and the pharmacokinetic profile of 
conjugates were given in the patent. Resveratrol was also coupled to biotin using 
DCC and DMAP in DMF 48
 
. The conjugate was used in biological assays to deduce 
the mechanism of actions responsible for various activities of resveratrol. The 
plasma stability, metabolism and pharmacokinetic profile of conjugate have not been 
reported. 
2.1.2 Objectives of the study  
The objectives of the work described in this chapter were to design and synthesize 
ester based polymer conjugates of resveratrol, and to characterise and evaluate them 
in comparison with resveratrol. Various acid linkers and polymers with different Mw 
and physicochemical properties were synthesized and characterized to gain the 
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knowledge on how to obtain stable but slowly hydrolysable polymer conjugates. The 
polymer conjugates were studied by NMR, HPLC and LC-MS for structural 
characterization and were investigated for stability in buffers and plasma. The 
micelle forming polymer conjugates were evaluated for critical micellar 
concentration (CMC), micelle size and morphology by microscopy. The polymers 
conjugates with reasonable stability in rat plasma were then selected and evaluated 
for single dose preliminary pharmacokinetic studies in vivo in comparison to 
resveratrol.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                               
2.2. MATERIALS AND METHODS 
2.2.1 Materials 
Trans-Resveratrol  was purchased from DND Pharma-Tech Co., Inc, Shanghai, 
China, with 99% purity. Polyethylene glycol carboxylic acid monomethyl ether 
(MeO-PEGN-SuccOH) of molecular weight Mw 2 kDa and 20 kDa were obtained 
from IRISH biotech GMBH, Germany. Monomethoxy polyethylene glycol (MeO-
PEG-OH, Mw 2 kDa), monomethyl polyethylene glycol-co-polylactide (MeO-PEG-
PLA-OH, Mw 2 kDa) and succinic anhydride were procured from Sigma Aldrich, 
Australia. MeO-PEG-PLA-OH, Mw, 3.7 kDa, 6.5 KDa was purchased from Akina 
Inc, Indiana, USA. N, N’-Diisopropylcarbodiimide (DIC) and 1-ethyl-3-(3-
dimethyllaminopropyl) carbodiimide hydrochloride (EDC.HCl) were obtained from 
GL Biochem, Shanghai, China. Rat liver microsomes (20mg/mL protein) were 
obtained from Invitrogen, Australia.  UDP-glucuronosyltransferases (UGT A) and 
UGT B solutions were purchased from BD Bioscience, Australia.Dimethyl yellow 
was obtained from Sigma, Australia. Wistar rat plasma was obtained from Animal 
resource centre, Perth.  0.1M acetate buffer pH 4.5 and 0.1M phosphate buffer pH 
7.4 were prepared in house.  All remaining chemicals such as pyridine, toluene,  and 
diethyl ether were of analytical grade and used without any further purification. 
 
2.2.2 Synthesis of MeO-PEGO-SuccOH 
MeO-PEG-OH (Mw 2 kDa,  5 g , ca 2.5 mmol)) was dissolved in  toluene (50 mL) 
and succinic anhydride (1.2g, 12 mmol) was added to the mixture. The reaction 
mixture was refluxed at 900C for 4 h in a round bottom flask fitted with a condenser. 
At the end of the reaction, the solution was concentrated to 10 mL in vacuo at 1100C. 
The solution was cooled to room temperature and diethyl ether (150 mL) was added 
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to precipitate the MeO-PEGO-SuccOH.  The precipitate was collected by filtration, 
air driedand was characterized by NMR and LC-MS..  The development and details 
of LC-MS method described in the chapter 5. 
 
2.2.3 Synthesis of MeO-PEG-PLAO-SuccOH 
 MeO-PEG-PLA-OH, (Mw 6.5 kDa, 1 g, ca 0.15 mmol) was dissolved in toluene (10 
mL) and an excess of succinic anhydride (0.2 g, 2 mmol) was added to mixture. The 
reaction mixture was refluxed at 900C for 4 hours in a round bottom flask fitted with 
a condenser. At the end of the reaction, the mixture was cooled to room temperature 
and diethyl ether (100 mL) was added to precipitate  the MeO-PEG-PLAO-SuccOH. 
The precipiate was isolated by filtration and was characterized by NMR. 
 
A similar 
process was used to prepare MeO-PEG-PLAO-SuccOH Mw 2 kDa. 
2.2.4 Synthesis of Resveratrol-PEG conjugates 
DIC (0.1 g, 0.79 mmol) was added to a solution of MeO-PEGN-SuccOH (Mw 2 
kDa, 1 g, ca. 0.5 mmol) and excess resveratrol (0.25 g, 1.09 mmol) in pyridine (2 
mL) and the resulting solution was stirred in darkness, at room temperature for 24 h. 
The solution was filtered (0.44 μm filter) and the filtrate was diluted with diethyl 
ether (150 mL). The resulting precipitate was then washed with a solution of ethyl 
acetate/diethyl ether (20 mL/80 mL), a solution of ethyl acetate/diethyl ether (50 
mL/50 mL), and then dried in vacuo to afford an off white material (300 mg, 30% 
yield). A similar procedure was followed for preparation of resveratrol conjugates 
with MeO-PEGN-SuccOH 20 kDa and MeO-PEGO-SuccOH 2 kDa. 
 
2.2.5 Synthesis of Resveratrol-PLA-PEG conjugates 
MeO-PEG-PLAO-SuccOH, (Mw 6.5 kDa, 1g, ca 0.15 mmol) was dissolved in  
pyridine (5.0 mL). The excess of resveratrol (0.15g, 0.65 mmol) and EDC.HCl (0.15 
g , 0.78 mmol) were added to the mixture. The reaction mixture was stirred at room 
temperature for 48 hours under dark conditions. At the end of the reaction, the 
mixture was added to diethyl ether (150mL) and the product was isolated by 
filtration.  The product was dissolved in dichloromethane (50 mL) and was extracted 
with 0.1M HCl (50 mL) twice to remove any unreacted EDC.HCl and its urea by-
product. Finally DCM layer was evaporated in vaccum to get off white powder 
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(500mg, 50% yield). The MeO-PEG-PLAO-Succ-Resveratrol, Mw 2 kDa was also 
prepared with the same procedure. 
 
2.2.6 Characterization of resveratrol-polymer conjugates 
2.2.6.1 Analysis of polymer conjugates and their precursors by 1
Dried powder samples of reaction products obtained from section 2.2.2 to 2.2.5 were  
analysed by 
H NMR 
1H NMR to elucidate the chemical structures of compounds/mixtures. 
All 1H NMR analyses were performed on a Bruker AVN400 spectrometer (400.1 
MHz for 1
 
H, Bruker, USA, country) with spectra referenced to solvent signals.   
2.2.6.2 Analysis of Polymer conjugates by LC-MS 
Qualitative and quantitive LC-MS methodology was developed to characterize 
resveratrol-PEG conjugates and intermediates. Details about methods and results of 
analysis are described in Chapter 5.  
 
2.2.6.3. Micelles preparation and characterization  
A solution of 10-40 mg of MeO-PEG-PLAO-Succ-RSV conjugates in acetonitrile (2 
mL) was prepared and the solution was added to water (4 mL). The acetonitrile was 
removed by bubbling inert nitrogen gas at room temperature in the dark. The final 
volume of micellar/nanoparticle dispersion was adjusted to the required volume with 
water. The micelles of MeO-PEGO-Succ-RSV were formed spontaneously after 
dispersing in water. 
 
2.2.6.3.1 Measurement of micelles size 
Particle size and size distribution of the resveratrol polymer conjugate micelles were 
measured by a Zetasizer (3000HS, Malvern Instruments, UK), using a quartz cell 
with the automatic mode at 250C and a detection angle of 900
 
. Mean diameters (Z-
average) were obtained after 10 repeated measurements. 
2.2.6.3.2 Determination of critical micellar concentration values (CMC) for 
resveratrol polymer conjugates.  
The critical micellar concentrations for some micelle forming resveratrol polymer 
conjugates were determined by a UV spectrophotometery employing dimethyl 
yellow as a probe. The extent of dye solubilisation and absorption maximum (λmax)  
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shifts were monitored as a function of the concentration of polymer conjugates. A 
concentrated solution of dimethyl yellow (10mg/mL) was prepared in acetone. 
Aliquots of 25 µl were dispensed into different vials and dried in a fume hood at 
ambient temperature to remove the solvent. Stock solutions of MeO-PEG-PLAO-
Succ-RSV (20 mg/mL) conjugates were prepared in acetone ( for 2 kDa) and 
acetonitrile ( for 6.5 kDa).  The initial concentrated micelle solutions were prepared 
by diluting 125 µL of polymer conjugate stock solution to 100 mL with millQ water. 
The solution was spurged with nitrogen gas for an hour to remove solvent, and 
finally made up to 100 mL with water. This solution was further diluted serially with 
water to get solutions with various concentrations of polymer conjugates (1-50 
mg/L). The MeO-PEGO-Succ-RSV solutions were prepared by dissolving 40 mg of 
conjugate in 10 mL of MillQ water, further serial dilution to get solutions of 
concentrations 0.005 to 0.4% (50 to 4000 mg/L). These polymer conjugate solutions 
were added separately to vials containing dimethyl yellow and sonicated for 10 
minutes. The solutions were stored in the dark for 3 hours to equilibrate. These 
solutions were scanned for λ max using a UV-Visible spectrophotometer between 
300 and 510 nm.  The change in wavelength of maximum absorption and absorbance 
at fixed wavelengths 441 and 423 were noted as a function of polymer conjugate 
concentration. The CMC values were calculated from a plot of the log of 
concentration (log C) of polymer conjugates versus λ max (or absorbance at 441 
nm).  
 
2.2.6.3.3 Micelle morphology by atomic force microscopy (AFM) and field emission 
scanning electron microscopy (FESEM) 
Atomic Force Microscopy was used to visualise the samples. All measurements were 
taken in Tapping Mode operation with a Digital Instruments Dimension 3000 SPM 
system (Veeco, Santa Barbara, USA). Standard silicon Tapping Mode probes type 
NCH (NanoWorld, Switzerland) with resonant frequency 330 kHz, spring constant 
42 N/m and tip radius < 8 nm.The samples were prepared by drop casting the micelle 
solution onto a freshly cleaved mica substrate. The sample was placed in a desiccator 
attached to a vacuum pump to remove excess solvent 
Morphological evaluation of micelles was also performed using FESEM, Zeiss Neon 
40 ESB,(Oberkocken, Germany). For FESEM, one drop of micelle solution was 
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mounted on a carbon coated stub. Excess sample was removed carefully. A Polaron 
E5100 sputter-coater was used to sputter coat the samples with chromium. Samples 
were then examined under the FESEM with an accelerating voltage of 1 kV.  
 
2.2.6.4 Stability of resveratrol-polymer conjugates in physiological relevant buffers 
The stability of resveratrol polymer conjugate was evaluated at different pH buffers 
4.5 (acetate buffer 0.1M) and 7.4 (phosphate buffer 0.1M) to mimic lysozomal and 
blood pH. The resveratrol polymer conjugates of different Mw and linkers were 
incubated in the two buffers at a concentration of 10 mg/mL at 370C, the samples 
were withdrawn at 0, 1, 2, 4, 6 and 24 hours and were diluted with water/acetonitrile 
(50:50) and were analysed by HPLC. A similar procedure was used to study the 
stability of MeO-PEG-PLAO-Succ-RSV in buffers, micelles were prepared as per 
section 2.2.6.2 and diluted 1:5 with buffer solutions and incubated at 370
 
C. All 
samples were protected against light during the experiments, 
2.2.6.5 Stability of resveratrol-polymer conjugates in rat plasma 
The stability of various resveratrol polymer conjugates in rat plasma was tested in 
order to assess the stability of the ester linkages towards plasma esterases. The MeO-
PEGN-Succ-RSV, 2 kDa, 20 kDa and MeO-PEGO-Succ-RSV 2 kDa  at the 10 
mg/mL were incubated in plasma at 370C. The micelles of MEO-PEG-PLAO-Succ-
RSV 2kDa and 6.5 kDa were prepared and, finally the micelles were mixed with 
plasma and incubated at 370
 
C. Aliquots of plasma (0.1 mL) were withdrawn at 
regular intervals and mixed with acetonitrile (0.9 mL). The mixtures were 
centrifuged at 10000 rpm for 5 minutes. The supernatant (0.25 mL) was diluted with  
water (0.25 mL) and analysed by HPLC. All samples were protected against light 
during the experiments, 
2.2.6.6 In vitro preliminary metabolism studies of resveratrol and its polymer 
conjugates in rat liver microsomes. 
To evaluate the effect of polymer conjugation on metabolism of resveratrol, 
metabolism studies of resveratrol and its polymer conjugates were conducted in rat 
liver microsomes following the protocol provided by BD bioscience ( Appendix xx). 
Since resveratrol reportedly to undergoes only phase II metabolism, such as 
glucuronidation and sulfation6, the metabolism studies were conducted in the 
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presence of uridine diphosphoglucuronic acid (UDPA). The stock solutions of 
resveratrol (0.13 mM) and polymer conjugates (0.13 mM resveratrol eqvivalents) 
were prepared in 10% DMSO in water. The rat liver microsomes, UGT (UDP-
glucuronosyltransferases) solution A (contains UDPA) and UGT solution B were 
thawed at 370C. The 200 µl of UGT solution B, 80 µl of UGT solution A and 660 µl 
of water were mixed, and 10 µl of the test substance stock solution (resveratrol or 
conjugates) was added to the mixture. The mixture was kept at 370
 
C. The reaction 
was initiated by adding 50 µl of microsomes ( 1mg protein ). Samples from reaction 
mixtures were withdrawn at 0, 10, 20, 30, 40 and 60 minutes and mixed with equal 
volumes of cold acetonitrile. The mixtures were centrifuged at 10000 RPM for 10 
minutes and supernatans were collected and analyzed by HPLC. Similary, control 
incubations of test substances were performed in reaction mixtures without 
microsomes. All samples were protected against light during the experiments, 
2.2.6.7 In vitro antioxidant assay of resveratrol and its polymer conjugates 
The free radical scavenging effects of resveratrol and its polymer conjugates were 
evaluated using 1,1-dipehnyl-2-picrylhydrazyl (DPPH) inhibition assay.  Initially 
series of solutions of resveratrol and resveratrol-PEG ester conjugates were prepared 
in methanol. The solution of DPPH (2 X 10-4M) was prepared in methanol. The  
DPPH solution of 1mL was mixed with 1 mL of resveratrol solution. Final 
concentration of DPPH was maintained at 1 X 10-4
 
M. The procedure was repeated 
for other resveratrol solutions of various concentrations and also for resveratrol-PEG 
ester solutions. Finally the concentration of resveratrol in testing solutions was 
ranged from 21-877 µMol/L and 210 to 8770 µMol/L for polymer conjugates.  After 
30 minutes of incubation at room temperature, absorbances of these solutions were 
read at 518 nm using a Hewelett Packard 8452A, UV-VIS spectrophotometer 
(Waldbrann, Germany).  Remaining DPPH concentration in solution was calculated 
by comparing with the control, a standard solution of DPPH without any resveratrol 
or conjugate. The IC 50 values were obtained from plot of concentration of RSV vs 
% DPPH remaining. 
2.2.6.8 Preliminary pharmacokinetic  study of resveratrol and its polymer conjugates 
in Wistar rats with iv injection  
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The pharmacokinetic studies were conducted in male Wistar rats (170-210g) and rats 
were housed in the animal facility for at least 3 days prior to experiments. All dosing 
and bleeding procedures were conducted under anaesthesia. The volatile anaesthetic 
agent isoflurane at 5% for the induction and 2% for the maintenance was used along 
with 1.5% oxygen. A resveratrol solution (6 mg/mL) was prepared in 20% hydroxyl-
propyl-β-cyclodextrin. The solution was dosed to Wistar rats at 10 mg/kg body 
weight via the tail vein. Similarly the MeO-PEG-PLA-Succ-RSV 2 kDa and 6.5 kDa 
micelles were prepared as per section 2.5.2  (10 mg/mL) and dosed to rats at a dose 
of 2mg/kg of resveratrol equivalent.  The blood was collected at 0.083, 0.5, 1, 2, 4 
and 8 hours into EDTA coated tubes. The blood samples were immediately kept on 
ice. The blood samples were then immediately placed into a centrifuge maintained at 
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C. The plasma was separated by centrifuging at 12000 RPM. The plasma was then 
mixed with an equal volume of acetonitrile and centrifuged again for 12 minutes. 
The supernatant was collected and analysed by HPLC. All samples were protected 
against light during the experiments, Due to the time constraints, only plasma 
concentration profiles of resveratrol and resveratrol equivalent (polymer conjugates) 
were determined. Metabolites were identified using LC-MS/MS (chapter 4). Non 
compartmental analysis of plasma vs time profile was performed using Kinetica™ 
Version 4.4 (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Area under the curve 
total (AUC total) , Mean residence time (MRT) and other parameters were obtained from 
software. (Table 7.1, Appedex). All animal experiments were approved by the Animal 






2.3. RESULTS AND DISCUSSION 
2.3.1 Synthesis of succinic acid terminated polymers for resveratrol conjugation 
The addition of an acid end group in the polymer by esterification with succinic 
anhydride is essential for conjugation with the polymer which did not bear any acid 
group in their chain. The esterification of polymers in this study was achieved by a 
ring opening reaction mediated by heat in toluene. This was performed using 
modified procedure adopted from Kuang et.al (Figure 2.1). 45
 
 The reaction worked 
well for both MeO-PEG-OH and MeO-PEG-PLA-OH irrespective of their polymer 
chain length and composition with approximate 80% yield. The esterification of 
polymer was confirmed by the presence of ethylene protons of succinic acid end 
group at 2.3 and 2.4 ppm in NMR analysis and 7.1 in Appendix), which are 
characteristic triplet peaks of ethylene protons. The formation of succinic acid 
terminated MeO-PEG-OH was also supported by qualitative and quantitative LC-MS 
analysis.  The new peak at 2.8 minutes for succinylated PEG was observed in LC-
MS chromatogram in contrast to unmodified MeO-PEG-OH at 4.5 minutes. The 
quantitative analysis revealed that the conversion of MeO-PEG-OH to MeO-PEGO-
SuccOH was 100% as there was no peak observed at 4.5 minutes, the retention of 
native MeO-PEG-OH, in the final MeO-PEGO-SuccOH solution. Figure 2.1 shows 





























Figure 2.1:  A: Reaction scheme for the synthesis of MeO-PEGO-SuccOH; B: 
Reaction scheme for the synthesis of MeO-PEG-PLAO-SuccOH 
 
2.3.2 Synthesis of resveratrol-PEG ester conjugates 
The conjugation of various molecular weight  PEGs to resveratrol was achieved by 
carbodiimide coupling, using  modification of a procedure reported by Greenwald et 
al for the PEGylation of 6-hydroxyquinoline 49  as shown in Figure 2.2. Detailed 
NMR analysis of MeO-PEGN-Succ-RSV 2 kDa was performed to understand the 
chemistry of the conjugation. The mixture (MeO-PEGN-Succ-RSV 2 kDa)  included 
two mono-PEGylated resveratol conjugates 4'-MeO-PEGN-Succ-RSV (ca. 50%) and 
3-MeO-PEGN-Succ-RSV (ca. 35%) as the major products, and is presumably 
disubstituted derivative 3,4'-di(MeO-PEGN-Succ)-RSV as a minor product. The 
identification of the mixture, and the substitution pattern, was based on the 1H NMR 
spectra for the resveratrol-PEG conjugate mixture (see Figure 2.3,Figures 2.4 and 
2.5). The 1H NMR spectra revealed that the conjugate mixture contained no free 
resveratrol, as indicated by the absence of a signal at ca. 6.1 ppm in Figure 2.4(a). 
This signal, observed in Figure 2.4(b), is due to H-4 of free resveratrol (see Figure 
2.5 for assigned spectra). As a control, a solution of resveratrol and MeO-PEG-
CO2H in d6-DMSO was analysed by 1H NMR spectroscopy. The chemical shifts of 
the signals for resveratrol in the mixture were identical to that shown in Figure 2.4(b) 





mixture also indicated that no free MeO-PEGN-SuccOH remained in the material.  
Signals corresponding to the succinyl moiety in MeO-PEGN-SuccOH were absent in 
the spectra for the resveratrol-PEG conjugate mixture (see Figure 2.4). The 
assignment of signals corresponding to 3-MeO-PEGN-Succ-RSV and 4'-MeO-
PEGN-Succ-RSV in Figure 2.5 was based on a comparison with the spectra for 
resveratrol and 2D NMR spectra (COSY). Additional minor signals remain 
unassigned in Figure 2.5.  These signals presumably are due a third product, 3,4'-
di(MeO-PEGN-Succ)-RSV which was formed as a minor component. To confirm 
this assumption a sample of the resveratrol-PEG conjugate mixture in d6-DMSO was 
treated with water and then heated at 90°C for ca. 1 week, to hydrolyse the phenolic 
ester linkages. The 1H NMR spectrum for the sample, shown in Figure 2.3(c) (and 
Figure 2.4), revealed the majority of the material had hydrolysed to afford free 
resveratrol. The remaining signals shown in Figure 2.4(c) can be attributed to 
residual 3-MeO-PEGN-Succ-RSV and 4'-MeO-PEGN-Succ-RSV. Interestingly, the 
hydrolysis of the resveratrol-PEG conjugate did not afford MeO-PEGN-SuccOH as 
the other hydrolysis product, though this may have formed as an intermediate. 
The 1H NMR spectra for the solution after the hydrolysis reaction are consistent with 
the formation of a succinimide-terminated PEG chain (Figure 2.6). Figure 2.4(d) 
displays a singlet at ca. 2.5 ppm consistent with the succinimidyl ring methylene 
protons, and the absence of the succinyl amide acid protons observed for MeO-
PEGN-SuccOH (c.f. Figures 2.4(a) and 2.4(d)). The formation of a succinimide ring 
is consistent with literature observations for the hydrolysis of succinyl ester amide 
moity. 50-52 Integration of the signals for resveratrol and the succinimide-terminated 
PEG in Figure 2.4(d) indicated that there was more succinimide-terminated PEG 
than free resveratrol, which supports the assumption that the minor component of the 
resveratrol-PEG conjugate was the disubstituted product 3,4'-di(MeO-PEGN-Succ)-
RSV. The NMR spectra (full drawn) of MeO-PEGN-Succ-RSV, MeO-PEGN-
SuccOH and MeO-PEGN-Succ-RSV after hydrolysis are shown Figures 2.7, 2.8 and 
2.9. The 1H NMR spectra for other PEG ester conjugates of resveratrol showed that 
the conjugation pattern was the similar to that of MeO-PEGN-Succ-RSV 2 kDa. 
However the extent of PEG conjugation to resveratrol varied between PEGs of 
different Mw and acid functional groups.  The conjugation was almost ca 100% for 
MeO-PEGN-SuccOH 2 kDa, ca 70% and 50% respectively for MeO-PEGO-
SuccOH, 2 kDa and MeO-PEGN-SuccOH 20 kDa, This was based on the amount of 
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free PEG acid/acyl urea peaks in NMR.   However MeO-PEGO-Succ-RSV 2 kDa 
and MeO-PEGN-Succ-RSV 20 kDa contained significant amount of an N-acyl urea 
as a by-product. In the reaction of a carboxylic acid with a carbodiimide the reactive 
O-acylisourea is formed, which would normally react to form the desired product. 
However, O-acylisourea, can decompose to the non-reactive N-acylurea (Figure 2.6 
B) 53, 54. The presence of N-acyl urea indicates the reaction is slow and incomplete 
with MeO-PEGO-SuccOH and MeO-PEGN-SuccOH, 20 kDa. These results clearly 
indicate that, in given reaction conditions, the extent of PEG conjugation to 
resveratrol depends on the structure of the acid end group and the PEG chain length.  
Different reaction conditions, such as prolonged reaction time, the increased amounts 
of base pyridine and the DIC did not improve extent of conjugation. The reactions 
involving MeO-PEGO-SuccOH were also carried out with a different base 4-
Dimethylamino pyridine (DMAP);  however,  there was no significant improvement 
in the extent of PEG conjugation. The presence of unreacted PEG in the form of N-
acylurea is not uncommon.Similar results were reported for PEGylation of 
paclitaxol, significant amount of N-acylurea was observed in the reactions involving 
PEG acetic acid and paclitaxol 19
 
. Authors reported that product was used as is, 
without any purification since the PEG-N-Acyl urea was found to be biologically 
inert. 
The formation of MeO-PEGN-Succ-RSV was also confirmed by LC-MS and HPLC. 
The new peak believed to be of MeO-PEGN-Succ-RSV 2 kDa was observed at 21.5 
minutes in HPLC and 6.5 minutes in LC-MS.  The new peak in HPLC showed a UV 
spectrum similar to that of resveratrol. The peak at 6.5 minutes in LC-MS showed a 
mass spectrum with a range of intense peaks between a mass range of 600-1000, 
which are reported to be fragmented peaks of PEG. Simultaneous monitoring of the 
same peak in PDA showed a UV spectrum similar to resveratrol. This clearly 
confirms the formation of a new structure, resveratrol-PEG conjugate. Results of 

















Figure 2.3: The down field region of 1H NMR spectra (400 MHz) for: (a) a solution 
of the MeO-PEGN-Succ-RSV  2 kDa mixture in d6-DMSO; (b) a solution of 
resveratrol in d6
 
-DMSO; and (c) the solution from (a) after treatment with water and 
heat (90 °C) for ca. 1 week. In (c) the signals for free resveratrol are highlighted in 
































Figure 2.4. 1H NMR spectra (400 MHz) for: (a) MeO-PEGN-SuccOH 2 kDa; (b) 
MeO-PEGN-Succ-RSV 2 kDa mixture; (c) resveratrol; and (d) the solution from (b) 
after treatment with water and heat (90 °C) for ca. 1 week). All solutions are in d6-
DMSO. Key: † = d5-DMSO, ‡ = H2
 
O. To identify the low intensity down-field 












Figure 2.5: The down field region of the 1H NMR spectra (400 MHz) for: (a) a 
solution of the resveratrol-PEG conjugate mixture in d6-DMSO showing the 
assigned signals for the two major products 4'-MeO-PEGN-Succ-RSV 2 kDa and 3- 





















Figure 2.6: A &B Structures of Resveratrol-PEG conjugates and intermediates. C 
Structures of O and N-acylurea. D: The succinimide-terminated PEG chain that 







Figure 2.7. 1H NMR spectra for the MeO-PEGN-Succ-RSV 2 kDa conjugate mixture 









Figure 2.8. 1H NMR spectra for MeO-PEGN-SuccOH 2 kDa in d6-DMSO, recorded 






Figure 2.9 1H NMR spectra of the MeO-PEGN-Succ-RSV 2 kDa conjugate mixture 
after treatment with water and heat (90 °C) for ca. 1 week, in d6-DMSO, recorded at 






2.3.3 Synthesis of resveratrol-PLA-PEG conjugates 
The synthesis of MeO-PEG-PLAO-Succ-RSV was achieved by, again, using the 
carbodiimide coupling  method modified from that reported by Zhang for the 
conjugation of paclitaxel to PLA-PEG 28
 
. The successful conjugation chemistry was 
optimized by using EDC.HCl as the coupling agent and pyridine as the base (Figure 
2.10). The obtained product was purified by precipitation with diethyl ether and 
extraction with 0.1 M HCl. The NMR analysis of MeO-PEG-PLAO-Succ-RSV, 2 
kDa (Figure 7.2 of Appendix) indicated that the product is a mixture of conjugates 
4'- MeO-PEG-PLAO-Succ-RSV (ca. 50%) and 3- MeO-PEG-PLAO-Succ-RSV (ca. 
35%) as the major products, and disubstituted derivative 3,4'-di(MeO-PEG-PLAO-
Succ)-RSV  as a minor product (Figure 2.10). The HPLC analysis of MeO-PEG-
PLAO-SUCC-RSV showed a new peak appearing at 21.5 minutes, similar to the one 
observed for MeO-PEGN-Succ-RSV, 2 kDa. The photo diode array (PDA) spectrum 
of the peak revealed the presence of a UV spectrum similar to resveratrol. Again it 
unequivocally proved conjugate formation and corroborated NMR observations. The 
NMR observations for the substitution pattern remained the same for MeO-PEG-
PLAO-Succ-RSV 6.5 kDa but there was a considerable amount of un-conjugated 
resveratrol. The exact pattern of the conjugation could not be determined because of 
the interference from the un-conjugated resveratrol. Since the HPLC was able to 
separate and quantify free resveratrol and the polymer conjugate, all the in vitro 
studies were unaffected. Moreover MeO-PEG-PLAO-Succ-RSV, 6.5 kDa did not 
show significant stability in rat plasma and was not the suitable candidate for 


















2.3.4 Characterization of micelles of resveratrol-polymer conjugates 
The PLA-PEG is a copolymer of hydrophilic polyethylene glycol and hydrophobic 
polylactic acid. Since this polymer is insoluble in water, they were converted into 
polymeric micelles/nanoparticles for all in vitro/in vivo studies. Interestingly the 
MeO-PEGO-Succ-RSV was found to self aggregate into micelles in water. This was 
observed during in vitro stability studies in buffers. The solutions at higher 
concentration turned slightly cloudy after some time, initially it was speculated that, 
this was because of the hydrolysis of conjugate to free resveratrol, which is insoluble 
in water. However, HPLC analysis did not indicate significant hydrolysis. The MeO-
PEGO-Succ-RSV, made with a PEG of molecular weight 2000 Daltons, only had  
resveratrol as a hydrophobic moiety, but the succinic acid linker would also impart 
some hydrophobicity to the structure. Succinic anhydride, which has a closed ring 
structure, is more hydrophobic and water insoluble and only becomes soluble in 
water after hydrolysis. It is hypothesized that combined structure of resveratrol and 
succinic acid linker would provide sufficient hydrophobicity to counter the 
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solubilising effects of PEG with the shorter molecular weight of 2000 Da, and hence 
the micelle structure was formed in the solution at high concentrations. In stark 
contrast to this, MeO-PEGN-Succ-RSV 2 kDa was soluble and formed a clear 
solution with no cloudiness, even at a higher concentration (10 mg/mL). This 
improved solubility and lack of aggregation could be due to the presence of nitrogen 
in linker, which imparts additional polarity to molecules, promotes hydrogen 
bonding with water, and prevents hydrophobic intermolecular interaction. Veronese 
et al. have reported similar findings with doxorubicin (DOX)-PEG conjugates with 
the tetra peptide linker GFLG. They found that the tendency of polymer conjugate to 
aggregate into micelles was dependent on the molecular architecture and Mw of 
polymer. 40
 
 The DOX-GFLG-PEG with PEG5000 aggregated more readily than with 
PEG10000.  
The critical micelle concentration for MeO-PEG-PLA-Succ-RSV, 2 kDa, 6.5 kDa, 
and MeO-PEGO-Succ-RSV 2 kDa  were found to be 4 mg/L, 8 mg/L and 500 mg/L 
respectively (Figure 2.11-2.13 and Table 2.1). This clearly indicates that CMC is 
strongly dependent on the hydrophobic content in the chain and the Mw of polymer. 
The CMC values reduced as the hydrophobic chain length increased in the polymer. 
However, this observation was true to a certain extent of hydrophobic chain length. 
There are other molecular mechanics that drive the assembly of molecules into 
micelles, and are discussed in detail in the section 2.3.6, plasma stability of 
polymer conjugates. The CMC values were determined by using a UV probe as 
opposed to familiar fluorescent probes such as pyrene. This was because of the 
interference of resveratrol in the fluorescent measurements involving pyrene. The 
resveratrol has a very broad excitation (290-350 nm) and emission (380-420 nm) 
ranges. Although excitation and emission maxima were 320 and 400 nm 
respectively, the broad peak overlapped with those of the fluorescent probe, such as 
pyrene. The dimethyl yellow employed in this study has poor aqueous solubility 
(13mg/L), this property of molecule facilitated monitoring parameter, absorption as a 
function of surfactant concentration in addition to change in wavelength 55
 
. The 
CMC values obtained by both dye solubilisation and wavelength shift have 
correlated well. This indicates the efficiency of dimethyl yellow as an alternative UV 
probe in CMC determination. 
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The micelles size and polydispersibility index of resveratrol polymer conjugates are 
given Table 2.1.  There was no exact correlation between micelle size and polymer 
architecture, such as chain length and hydrophobic content of polymers. In general, 
polymer conjugates with lesser hydrophobic content have formed micelles with 
smaller diameter. The micelles diameter was found to increase as the polymer 
concentration was increased. This could be due to  the formation of large aggregates 
at higher polymer concentration. 
 
Morphology studies with FESEM were not completely successful and only images 
of MeO-PEG-PLAO-Succ-RSV, 2 kDa and MeO-PEGO-Succ-RSV 2 kDa micelles 
could be captured. The images of the other micelles of resveratrol conjugates with 
PLA-PEG could not be detected in FESEM. Generation of heat during imaging, 
from electron beam, may have destroyed the polymer matrix. The images of MeO-
PEG-PLAO-Succ-resveratrol 2 kDa micelles showed that micelles were rather solid 
nanoparticles once dried (Appendix, Figure 7.16). The hollow micelle-like structures 
could not be seen. The micelles would have been fused to form a solid structure 
during drying at room temperature or polymer itself would have aggregated into 
nanoparticles. The formation of nanoparticles could be the result of the inherent 
physicochemical properties of the polymer. Since the polymer has a short chain 
length with more than 60% PLA, at higher concentrations, the close and compact of 
assembly of the polymer chains leading to formation of solid nanoparticles cannot be 
ruled out. This close and compact structure with reasonably good PEG corona on the 
surface may also contribute to the improved plasma stability of the drug-polymer 
ester bond in the plasma (section 2.3.6). The FESEM image of MeO-PEGO-Succ-
Resveratrol showed a melted wax-like material (Appendix, Figure 7.16). This could 
be due to a rupture of the micellar structure and a melting of the polymer due to the 
heat generated by the electron beam. The slides of MeO-PEG-PLAO-Succ-RSV 6.5 
kDa did not show any particulate matter, that could be again due to melting. Because 
of these limitations of FESEM analysis, morphology studies were later performed 
with AFM. The images of micelles of all polymer conjugates of resveratrol were 
recorded. This was possible because AFM allows to capturing of images without 
generation of heat. AFM images of MeO-PEG-PLAO-Succ-RSV 2 kDa and 6.6 kDa 
showed a solid nanocrystalline structure. The images of MeO-PEGO-Succ-RSV 
showed a few distinct micelles with more of the collapsed PEG mass. All FESEM 
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images are presented in Figure 7.16 (Appendix) and AFM images in the Figures 






Figure 2.11: Determination of CMC for MeO-PEG-PLAO-Succ-RSV 2kDa A: plot 
of log (Concentration mg/L) vs Absorbance for dimethyl yellow at 441. B: plot of 







































































Figure 2.12: Determination of CMC value for MeO-PEGO-Succ-RSV A: plot of log 
(Concentration mg/L) vs Absorbance for dimethyl yellow at 441. B: plot of log 





















































Figure 2.13: Plot of absorbance vs wavelength for dimethyl yellow in various 
concentration of A: MeO-PEG-PLAO-Succ-RSV, 2 kDa (1-25 mg/L). B:MeO-





















Meo-PEG- PLAO- Succ RSV 2kDa   Meo-PEG-PLAO-Succ RSV 6.6K 
 
 
0.05 170(0.63) 0.21(0.051) 147(3) 0.25(0.079) 
0.1 249(10.44) 0.59(0.03) 147(6.11) 0.342(0.070) 
0.2 255(3.0) 0.489(0.079) 165(14.42) 0.75(0.15) 
 
MeO-PEGO-Succ-RSV 2 kDa 
0.1 116(1.52) 0.121(0.024) 
  0.25 136(1.15) 0.076(0.05) 
  0.5 181(2.51) 0.19(0.03) 
   
2.3.5 Stability of polymer conjugates in buffers at different pH 
The stability of polymer conjugates was studied in buffers of pH 4.5 and 7.4 at 370C,  
physiologically relevant to the pH of the lysosomes and the blood. The concentration 
of polymer conjugates in buffers was monitored by HPLC. All the polymer 
conjugates of resveratrol were found to be stable in pH 4.5, with nearly 90% of 
polymer conjugates remaining intact after 24 hours (Figure 2.14). The MeO-PEGN-
Succ-RSV, 2 K and 20 K were found to be unstable at pH 7.4, with only about 9% of 
polymer conjugates remaining intact after 24 hours, which indicates that the ester 
link is unstable in slightly alkaline conditions. Similar results were reported for PEG-
scutellarin conjugates and PEG-Taxol conjugates 19, 56. MeO-PEGO-Succ-RSV was 
found to be relatively stable in pH 7.4 with nearly 65% of polymer conjugate found 
intact after 24 hours. This could be attributed to the self assembly of polymer 
conjugates to micelles. The micelles could form a barrier for ion catalysing 
hydrolysis (H+/OH-). The fact was further confirmed from the results of MeO-PEG-
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PLAO-Succ-RSV conjugates of different Mw, which were found to be stable in pH 
4.5 and 7.4 with >80% polymer conjugates found intact after 24 hours. 
 
 
Figure 2.14: Stability of resveratrol polymer conjugates in buffers, A: MeO-PEG-
PLAO-Succ-RSV, 2 kDa pH 4.5 ; B: MeO-PEG-PLAO-Succ-RSV, 2 kDa pH 7.4; 
C: MeO-PEG-PLAO-Succ-RSV, 6.5 kDa pH 4.5 ; D:MeO-PEG-PLAO-Succ-RSV, 
6.5  kDa pH  7.4 ;E: MeO-PEGO-Succ-RSV, 2 kDa pH 4.5;  F: MeO-PEGO-Succ-
RSV, 2 kDa pH 7.4;  G: MeO-PEGN-Succ-RSV, 2 kDa pH 4.5;  H: MeO-PEGN-
Succ-RSV, 2 kDa pH 7.4;  I: MeO-PEGN-Succ-RSV, 20 kDa pH 4.5 ; J: MeO-
PEGN-Succ-RSV, 20 kDa pH 7.4 All the data are presented as mean ± SD (n = 3) 
 
2.3.6 Stability of resveratrol-polymer conjugates in rat plasma  
The effectiveness of drug-polymer conjugates with an ester link intended for the 
sustained release of drugs would depend on the stability of ester bonds in plasma, as 
plasma esterase would catalyse the hydrolysis. All PEG conjugates of resveratrol, 
irrespective of the linker and polymer chain length, hydrolysed rapidly to free 

































almost no intact polymer conjugate was detected in HPLC at the initial time point of 
0 hr.  The rate of hydrolysis was more rapid than that observed for campothecin-20-
PEG and taxol-2’-PEG with plasma T1/2 of 2 and 0.4 hours respectively 19, 20. The 
reason for this rapid hydrolysis could be because of the phenolic OH being more 
acidic than the aliphatic OH group, and electron delocalization and resonance 
stabilization of phenoxide ions would contribute to ester bond cleavage. However, 
phenols would not be ionized at a physiological pH of 7.4, since the pKa of phenols 
is >10. Hence electron delocalization contributes significantly to the instability of the 
ester link catalysed by plasma esterases.  Although there are a few reports suggesting 
the application of more electronegative acid linkers, such as glycine for 
campothecine and peptides in the case of doxorubicin for greater plasma stability, for 
resveratrol, pegylating via a glycine linker did not provide any improvement in 
stability 46. The PEG-peptide attached to doxorubicin through an amide linker has 
provided better stability against carboxy peptidases in plasma. Introducing a peptide 
linker between PEG and resveratrol demands an ester link between resveratrol and 
peptide, for there is no amine group in resveratrol. So the role of peptide in slowing 
down ester hydrolysis would be minimal. Hence the possibility of micelle forming 
polymeric conjugates to slow the ester hydrolysis was explored in this study. 
Accordingly the MeO-PEG-PLAO-Succ-RSV of different Mw and with a PLA/PEG 
ratio, were prepared and evaluated for plasma stability. The plasma t1/2 , Mw of 
conjugate, Mw of PLA/PEG segments are tabulated in Table 2.2 and the stability 
profile is shown in Figure 2.15.  The results indicate that MeO-PEG-PLAO-Succ-
RSV, 2 kDa was found to be more stable than other MeO-PEG-PLAO-Succ-RSV, 
6.5 kDa conjugate. The other micelle forming conjugate MeO-PEGO-Succ-RSV 2 
kDa was no different from MeO-PEGN-Succ-RSV, 2 and 20 kDa in terms of plasma 
stability (Figure 2.15). It had hydrolysed rapidly with no intact conjugate being 
detected at the initial time point.  The trend indicates that the plasma stability 
depends on hydrophobic chain length in polymer conjugates. Stability increased as 
hydrophobicity increased. However the contrasting trend between MeO-PEG-PLAO-
Succ-RSV, 6.5 kDa and 2 kDa, where the plasma stability decreased as the PLA 
chain length increased, indicates there are other parameters affecting the plasma 
stability. The plasma stability of the polymeric drug conjugate is a complex 
phenomenon, Pan et al. reported in their work on plasma a stability of various 
HPMA polymer-PGE1 conjugates 27. The authors attributed the difference in plasma 
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hydrolysis of conjugates of various species of poly HPMA to physicochemical 
properties such as conformation, inter and intra molecular forces, and the 
hydrophobicity. The authors have also reported that adsorption of plasma proteins, 
such as albumin onto polymer conjugates may favour enzyme substrate formation 
and activate enzyme-substrate, thereby leading to rapid hydrolysis.  In another 
report, the higher amount of the hydrophobic drug bound to the polymer increased 
the plasma stability 57. Association between heptapeptide side chains of HPMA 
copolymer have been shown to decrease the enzymatically catalysed release of 
doxorubicin from conjugate 58. Riley et al. 59  studied the effect of PEG corona (PEG 
chain length and suface density) on the colloidal stability of  PEG-PLA 
nanoparticles. With a fixed PEG chain length of 5 KDa, the colloidal stability was 
higher when the PLA chain varied between 3-5 kDa. A further increase in the PLA 
chain length resulted in reduced colloidal stability and the authors attributed this to 
the presence of naked PLA patches on nanopartilces. In another study, Gref et.al 60 
reported the influence of PEG corona on plasma protein adsorption and the 
phagocytic clearance of PLA-PEG nanoparticles. They concluded the protein 
adsorption and phagocytic uptake was high when the PLA content in the 
nanoparticles is high, and they attributed this to the unprotected PLA surface. Jay 
Prakash Jain and Neeraj Kumar 61  reported the effect of PEG content on the 
formation of the polymersomes (micelles) of  PEG-PLA structure. They concluded 
that the formation of self assembled polymersomes was dependent on the PEG chain 
length and assembly was favoured when the PEG content is high. They reported 
trisubstituted PLA (with 3 PEG chains and one PLA chain using a citrate linker) has 
the tendency to form a vesicle even at 10% PEG content because of the complete 
coverage of PLA by a branched PEG structure around the PLA chain. Considering 
these observations and reports, for a better plasma stability of the conjugate, it is  
concluded that there has to be optimum hydrophobicity, micelle forming ability and 
colloidal stability, with adequate surface protection by the PEG. In this regard, MeO-
PEG-PLAO-Succ-RSV 2 kDa would form compact, colloidally stable micelles, with 
a strong PEG corona, thereby providing maximum stability against ester hydrolysis.  
MeO-PEG-PLAO-Succ-RSV 6.5 kDa, with a longer PLA chain length would lead to 
the formation of colloidally unstable micelles, with significantly higher naked PLA 
surfaces providing little protection against ester hydrolysis. In addition, solid 
nanoparticle-like structures were observed in AFM for air dried samples of MeO-
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PEG-PLAO-Succ-RSV 2 kDa micelles. Formation of this solid nanoparticle-like 
structure would impart more resistance to hydrolysis. 
 
 
Figure 2.15: Plasma hydrolysis profile of resveratrol polymer conjugagtes A: MeO-
PEG-PLAO-Succ-RSV, 2 kDa   B: MeO-PEG-PLAO-Succ-RSV, 6.5 kDa  C,D,E:  
merged profiles represents MeO-PEGN -Succ-RSV, 2 kDa, MeO-PEGN-Succ-RSV, 
20 kDa and MeO-PEGO-Succ-RSV, 2 kDa respectively.  All the data are presented 









































Table 2.2: Various RSV-PLA-PEG conjugates with CMC values and Plasma 
stability 






1000 750 3 hours 4 0.002 
MeO-PEG-PLAO-Succ-RSV  
6.5 kDa 
4600 2000 5 minutes 8 0.0012 
MeO-PEGO-Succ-RSV 
 2 kDa 
Not 
applicable 
2000 <5 minutes 500 0.25 
 
 
2.3.7 In vitro metabolism studies of resveratrol and its polymer conjugates in rat 
liver microsomes 
Since resveratrol undergoes phase II metabolism, such as glucuronidation and 
sulfation and minimum phase I metabolism, such as oxidation, reduction, and 
hydroxylation. The microsomal incubations were supplemented with a UGT reaction 
mixture A ( contains uridine diphospho glucuronic acid, UDPA)  and  mixture B 
(buffer system), in order to bring about glucuronidation of resveratrol.  Results of 
microsomal studies are shown in Figure 2.16 and 2.17. This study showed that 
resveratrol readily underwent metabolism to produce two monoglucuronide 
metabolites (Figure 2.18). The similar metabolites were also observed in the plasma 
samples of rats from the pharmacokinetic studies and were characterized by LC-MS 
(chapter 4). The metabolism of resveratrol was rapid and almost all of the resveratrol 
was metabolized within 10 minutes. The incubations of MeO-PEG-PLAO-Succ-
RSV, 2 kDa with microsomes over 60 minutes did not result in any detectable level 
of  metabolites in HPLC and presumably  there was no metabolism occurring. 
However there was a fluctuation in the concentration of  MeO-PEG-PLAO-Succ-
RSV, 2 kDa  in the microsomal incubations over the same period of time,  errors in 
the analysis could not be excluded as there was only single incubation due to a 
shortage of microsomes and time constrain in getting supply. The control 
incubations without microsomes did not show any appreciable decrease   In contrast,  
the incubation samples of MeO-PEGN-Succ-RSV 2 kDa, showed formation of 
moderate amount of glucuronide metabolites. However the control incubations of 
MeO-PEGN-Succ-RSV showed some degree of conjugate hydrolysis to free 
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resveratrol and which was subsequently metabolized. Hence metabolites were 
observed in microsomal incubations. These observations clearly demonstrated that, 
to provide protection against the metabolism of resveratrol, the polymer conjugates 
need to be intact and with micelle forming ability;  the physical mixture of polymer 
conjugates with resveratrol would not be helpful in reducing metabolism. These 
observations are in contrast to those observed with metabolism studies of resveratrol-
PEG conjugates carried out with intestinal membrane46
 
. In that study, despite the 
hydrolysis of resveratrol polymer conjugates, resveratrol did not undergo metabolism 
and was attributed to the inhibitory effects of adjacent polymer molecules. This 
could be because of the weak enzymatic activity in intestinal membrane compared to 
isolated and concentrated liver microsomal preparation. 
 
 
Figure 2.16 : The degradation profile of A: Resveratrol and B: MeO-PEG-PLAO-









Figure 2.17 Degradation profile of A:MeO-PEGN-Succ-RSV 2 kDa in micosomal 
incubation with UDPA. B: :MeO-PEGN-Succ-RSV 2 kDa in control incubations in 














Figure 2.18: Chromatogram of resveratrol in microsomal incubations at 10 minutes. 









In vitro antioxidant activities of resveratrol and its polymer conjugates were assessed 
based on their ability to scavenge the free radical DPPH. The results of antioxidant 
assay revealed that the free radical scavenging ability of polymer conjugates ( MeO-
PEGN-Succ-RSV 2kDa and MeO-PEG-PLAO-Succ-RSV 2 kDa) was decreased (IC 
50 values 219 µM vs 60 µM for RSV) as shown in Figure 2.19.  This decrease in the 
activity may not really affect in vivo activity profile of the polymer conjugates, as 
these ester conjugates would hydrolyze in the body to produce native resveratrol. 


















Figure 2.19 DPPH inhibition profile of A: Resveratrol; B: MeO-PEGN-Succ-RSV, 




2.3.9 Single dose preliminary pharmacokinetic study   
The plasma concentration  profile of resveratrol, MeO-PEG-PLAO-Succ-RSV 2 kDa 
is shown in Figure 2.20 and the HPLC chromatogram of RSV plasma sample with 
























plasma concentration profile showed rapid elimination of resveratrol from the 
plasma. The plasma levels dropped to almost no detectable levels within an hour. 
There were four major metabolites detected in HPLC and characterized by LC-
MS/MS. The four metabolites could be assigned to 3- and 4’- monoglucuronides, 3-, 
4’- mono sulphates. The area under the curve (AUC total) for resveratrol was found 
to be 0.63 µg*h/L with T ½ of 2.3 h and mean residence time (MRT) of  1.7 h. The T 
1/2 was overestimated; because software calculations were based on plasma 
concentration at few terminal time points, where the concentrations are low and were 
approaching base line.   When MEO-PEG-PLAO-Succ-RSV 2 KDa was dosed to 
rats at 2 mg/kg equivalent to resveratrol. There was a comparatively higher plasma 
concentration observed at the initial time point of 5 minutes, however there was a 
rapid decline in the plasma concentration thereafter. This can be attributed to 
clearance by mononuclear phagocyte systems (MPS)  62. There was no appreciable 
amount of conjugate in plasma after 2 hours, as the level was approaching the 
detection limits. The AUC total, t 1/2
 
 and MRT ( 5.54 µg*h/L, 2.3 h and 2.5 h)   were 
significantly higher compared to resveratrol. Interestingly, some of the free drug 
released after hydrolysis of polymer conjugates was not completely metabolized as 
was in the case of free resveratrol. The intensity of the resveratrol peak with polymer 
conjugates was greater than that of metabolites. This was in stark contrast to free 
resveratrol profile, wherein, metabolite concentration was more from the initial time 
point of 5 minutes. This clearly demonstrates that the majority of resveratrol 
produced from hydrolysis was still in micelles, which prevented the metabolism of 
resveratrol.  
The plasma profile of MeO-PEG-PLAO-Succ-RSV 6.6 kDa was very different from 
that of MeO-PEG-PLAO-Succ-RSV 2 kDa. There was no appreciable amount of 
polymer conjugate detected in the plasma, even at initial time point of 5 minutes. 
The rapid decline or non-availability of polymer conjugate could be due to the 
combined effect of hydrolysis and MPS clearance. Unlike the MeO-PEG-PLAO-
Succ-RSV 2 kDa , MeO-PEG-PLAO-Succ-RSV 6.6 kDa displayed  higher level of 
metabolites,  possibly due to  a naked PLA surface bearing resveratrol, which in turn 
released resveratrol upon hydrolysis, and the latter was subsequently metabolized. 







Figure 2.20: Single dose IV plasma concentration–time profile of resveratrol (RSV) 
and MeO-PEG-PLAO-Succ-RSV2 kDa conjugate. All the data are presented as 











































Figure 2.21: Chromatogram of plasma samples of rats at 5 minutes A: MeO-PEG-
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SYNTHESIS, CHARACTERIZATION, BIOLOGICAL 
AND PRELIMINARY PHARMACOKINETIC 


















Resveratrol has shown remarkable activities in vitro 1, 2, which have not been able to 
be translated into the activities in vivo. The very low availability of native resveratrol 
in the circulation was attributed to this effect 3, 4. The metabolic conjugation was 
responsible for rapid clearance of resveratrol from systemic circulation, and the 
metabolites are reported to be either less active or inactive 5, 6, 7.  Poor 
pharmacokinetic properties would impede clinical efficacy 8.  Polymeric conjugates 
(prodrugs) have been reported for providing a masking effect against the metabolism 
of conjugated drugs 9. The polymeric conjugate  strategy involves covalent 
attachment of a polymer to drugs mainly via amide or ester bonding. After 
administration into the body, these polymeric systems release the drug by action of 
plasma esterases/carboxy peptidases in the blood 9, 10. The rate of release depends on 
the type of spacer used for the ester/amide link, and the physicochemical properties 
of the polymer and the drug. Peptide spacers have reported to produce stable and 
long circulating polymer conjugates 10 However to introduce a peptide spacer 
between the drug and polymer, there has to be specific functional groups, for 
example, NH2and SH and would not always result in enhanced circulation times of 
polymeric drugs 10, 11. Peptide spacers may provide protection against carboxy 
peptidases of the plasma, but cannot be anticipated for esterases if the  spacer is 
connected to the drug via an ester link. The polymeric ester conjugates have been 
reported to undergo rapid hydrolysis in the plasma. Similarly, resveratrol PEG 
conjugates have been reported to hydrolyse very rapidly in the plasma 13.  The efforts 
described in the chapater 2 to design ester based PEGylated resveratrol with 
reasonable stability were partially successful and desired goal have not be achieved. 
So far, only micelles forming PEG-PLA block polymer conjugates have shown a 
certain degree of resistance against plasma esterases but improvement in the 
pharmacokinetic profile was not up to expectation. In this regard, permanent 
PEGylation of resveratrol would be the best option to protect resveratrol against 
metabolic conjugation. Although permanent PEGylation via linker stronger than 
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esters, has been reported to slightly reduce the biological activity of some of  the 
small molecule nonpeptide drugs, the increased plasma concentration and long 
circulation time may compensate for  this effect and even provide overall advantage.  
  
 
3.1.1 Review of procedure for synthesis of permanently PEGylated drug conjugates 
Various approaches have been tested reported for permanent PEGylation of small 
molecules. The paclitaxol was conjugated by a carbamate bond 14. Drugs with thiol 
groups have been modified into stable PEG conjugates by a carbon-sulphur bond or 
a thiocabamate link 12. The possible chemistry for permanent PEGylation of 
resveratrol is either through a carbamate or  an ether bond. However , PEGylation 
via a carbamate link needs modification of one of the hydroxyl groups of resveratrol. 
On the other hand, linking PEG via an ether bond appears to be less complicated, 
given commercial availability of PEGs with an end group bearing halides. Careful 
review of the literature of structural activity relationship studies of resveratrol leads 
to the conclusion  that converting one hydroxyl group into ether or any other small 
chain substituent would not completely destroy the bioactivity of resveratrol; in fact 
some derivatives showed better anticancer activity than native resveratrol 15-19
 
. 
It has been reported that small chain alkyl substitution on the 4’-OH of resveratrol 
could  be accomplished by use of an alkyl bromide in the presence of K2CO3 15, 16. 
The K2CO3 was reported to abstract proton selectively at 4’ OH group, thus enabling 
the formation of monosubstituted resveratrol ether derivatives, but yields of reactions 
were oftern low (10-20%) after purification . Such reactions can be explored to 
synthesize resveratrol-PEG conjugates with ether links. A similar approach for 
PEGylation of butylated hydroxyl toluene has been reported, where in the methyl 
group of BHT has been  modified into a benzyl halide and reacted with HO-PEG-OH 
in the presence of NaH/DMF 21
 
.  
3.1.2 Objectives of the study  
The objectives of the study described in this chapter were to: design and optimize 
synthetic schemes for the preparation PEGylated resveratrol via an ether link; 
characterize resveratrol-PEG ethers by NMR for structural confirmation; evaluate 
the selected PEG ether conjugates for stability in physiologically relevant buffers 
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and plasma; assess the effect of PEGylation on the bioactivity of resveratrol through 
in vitro antioxidant assay; and, finally to evaluate the pharmacokinetic profile of 




3.2. MATERIALS AND METHODS 
3.2.1 Materials 
Trans-Resveratrol was purchased from DND Pharma-Tech Co., Inc, 
Shanghai.P.R.China, with 99% purity. Monomethoxy polyethylene glycol bromide 
(MeO-PEG-CH2-CH2-Br) of different molecular weights were obtained from, 
IRISH biotech GMBH, Germany(>99% purity). N, N-Dimethyl formamide (DMF, 
99.8%) was purchased from Sigma Aldrich, Australia. Potassium carbonate (K2CO3
3.2.2 Methodologies for  synthesis of resveratrol-PEG ethers  
) 
was obtained from BDH chemicals, Poole, England. Other chemicals, such as 
Diethyl ether, and Dicloromethane (DCM), were of labarotary grade and were used 
without any further purification.  
3.2.2.1 Potassium carbonate mediated etherification in acetone  
MeO-PEG-CH2-CH2-Br, (2 kDa, 1 g ca 0.5 mmol) and resveratrol (0.25 g, 1.09 
mmol) were dissolved in acetone (20 mL). K2CO3 (0.8g, 5.79 mmol) was added to 
the solution and the mixture was heated at 600 
 
C for 24 hours in the dark. At the end 
of the reaction, mixture was analysed by HPLC. 
3.2.2.2 Potassium carbonate mediated etherification in DMF 
The reaction conditions were optimized to achieve maximum PEG conjugation by 
varying the amount of K2CO3 
 A) MeO-PEG-CH
and solvent DMF. The reactions that were attempted 
are described as below. 
2-CH2-Br, (Mw 2 kDa, 0.2 g, ca 0.2 mmol) and resveratrol 
(0.05g, 0.219 mmol) were dissolved in  DMF (2 mL). K2CO3 
B) MeO-PEG-CH
(0.04 g, 0.289 mmol) 
was added to solution and mixture was stirred at room temperature for 24 hours in 
dark. At the end of the reaction, mixture was analysed by HPLC. 
2-CH2-Br, (Mw 2 kDa, 1 g, 0.5 mmol) and resveratrol (0.15g, 
0.657 Mmol) were dissolved in DMF (5 mL). K2CO3 (0.15g, 1.08 Mmol) was added 
to solution and mixture was stirred at room temperature for 24 hours in dark. At the 
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end of the reaction, the mixture was added to DCM (50 mL), solution was filtered to 
remove potassium bromide produced in the reaction and also unreacted K2CO3. 
Filtrate was extracted with 0.1M HCl (50 mL) solution to remove traces of KBr and 
K2CO3
C) MeO-PEG-CH
. The extraction process was repeated 2 more times and DCM layer was 
evaporated in vacuo to yield off white to slightly brown product (500 mg, 50%). 
2-CH2-Br, (Mw 2 kDa, 1g, 0.5 mmol) and resveratrol (0.15g, 
0.657 mmol) were dissolved in of DMF (5 mL). K2CO3 (0.25 g, 1.81 mmol) was 
added to solution and mixture was stirred at room temperature for 24 hours in dark. 
At the end of the reaction, the mixture was added to DCM (50 mL), solution was 
filtered to remove potassium bromide produced in the reaction and also unreacted 
K2CO3. Filtrate was extracted with of 0.1M HCl solution (50 mL) to remove traces 
of KBr and K2CO3
 
. The extraction process was repeated 2 more times and DCM 
layer was evaporated in vacuo to yield off white to slightly brown product (500 mg, 
50%). The resveratrol-PEG ether with MeO-PEG-Br Mw 5 kDa was also prepared 
with the same procedure. 
3.2.3 1H NMR analysis of polymer conjugates 
1H NMR analysis was performed on a Bruker AVN400 spectrometer (400.1 MHz 
for 1
 
H, Bruker, Australia) with spectra referenced to solvent signals. The HPLC 
analysis was performed to qualitatively characterize the extent of conjugation.  
3.2.4 HPLC monitoring of conjugate synthesis 
  HPLC method described in chapter 4, was used to qualitatively analyse or 
monitoring the completion of the reaction. The same method was also used for  
quantitative analysis of conjugate samples in buffer and plasma stability studies, and 
also for the analysis of plasma samples in preliminary pharmacokinetic studies. 
Briefly, the method employed a gradient elution with solvent A, buffer pH-7.0 with 
triethyl amine-formic acid (0.05 and 0.2% v/v in water) and solvent B, methanol. A 
30 minute linear gradient was programmed as follows: 0 min 5% B, 4 min 20% B, 7 
min 20% B, 16 min 55% B, 18 min 55% B, 18.5 min 95% B, 23 min 95% B,and 24 
min 5% B. The flow rate was maintained at 1mL/min. The injection volume was 
fixed at 50 µL. An analysis was performed using an Agilent HPLC-1100 series 
(Agilent Technologies, , USA). The fluorescence detection with excitation at 320 nm 




3.2.5 Stability of resveratrol-PEG ether conjugates in physiological relevant buffers  
The stability of the resveratrol polymer conjugate was evaluated at different pH 
buffers, 4.5 (0.1 M acetate buffer) and 7.4 (0.1M phosphate buffer), to mimic the 
lysozomal and the blood pH. The resveratrol -PEG ether conjugate was incubated in 
two buffers at concentration of 10 mg/mL at 370
 
C; the samples were withdrawn at 0, 
1, 2, 4, 6 and 24 hours and were diluted with water/acetonitrile (50:50) and  analysed 
by HPLC.   
3.2.6 Stability of RSV-polymer conjugates in Rat plasma 
 The resveratrol -PEG ether, 10 mg/mL was incubated in Wistar rat plasma at 370
 
C. 
The aliquots of plasma (0.1 mL) were withdrawn at regular intervals and mixed with 
acetointirle (0.9 mL). The mixture was centrifuged at 10000 RPM for 5 minutes. The 
0.1 mL of supernatant was diluted to 10 mL with an acetonitrile/water mixture and 
analysed by HPLC. 
3.2.7 In vitro antioxidant activity of resveratrol and its polymer conjugates 
Antioxidant activity of resveratrol and PEG ether conjugates was assessed based on 
their ability to scavenge free radical DPPH. Details of procedure are mentioned in 
chapter 2, section 2.2.6.7. 
 
3.2.8 In vitro metabolism studies of resveratrol and its polymer conjugates 
The metabolism of resveratrol and its polymer conjugates was carried out with rat 
liver microsomes in presence of UDPA. Details of study given chapter 2, section 
2.2.6.6. In addition, metabolism studies were also conducted with microsomes in 
presence nicotinamide adenine dinucleotide phosphate (NDPH) regenerating system 
to check the possibility of polymer detachment from resveratrol by demethylation. 
 
 
3.2.9 Preliminary pharmacokinetic study of resveratrol- PEG ether polymer 
conjugates in Wistar rats following intravenous administration 
Prelminary pharmacokinetic studies were conducted as per the procedure described 
in chapter 2. Briefly, 26 mg/mL of resveratrol-PEG solutions were prepared in water 
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and a dose of 2 mg/Kg body weight given to rats intravenously.  The blood was 
collected at 0.083, 0.5, 1, 2, 4 and 8 hours into EDTA coated tubes. The blood 
samples were immediately placed on ice. The blood samples were then immediately 
transferred into a centrifuge maintained at 40
 
C. The plasma was separated by 
centrifuging at 12000 rpm for 12 minutes. The plasma was then mixed with an equal 
volume of acetonitrile and centrifuged again for 12 minutes. The supernatant was 
collected and analysed by HPLC. The standard calibration curve for each resveratrol-
PEG tested for pharmacokinetic studies was constructed in plasma, by spiking stock 
solution of conjugate (in acetonitrile) into plasma. Subsequents dilutions were 
performed with plasma to get series of solutions. The plasma samples were then 
mixed with equal volme of acetonitrile to precipitate proteins. Supernatant collected 
after centrifugation were analyzed by HPLC. This standard calibration curve was 
utilized for calculating the resveratrol-PEG content in the plasma samples from rats 
dosed with  resveratrol -PEG ether. The resveratrol plasma concentration-time 
profiling  was performed  as per descriptions  in chapter 2. All animal experiments 
were approved by the Animal Ethics Committee of Curtin University. 
3.3. RESULTS AND DISCUSSION  
3.3.1 Synthesis of Resveratrol-PEG ether conjugates 
The synthesis of   resveratrol -PEG ether conjugates were achieved by the 
modification of the procedure used for the synthesis of small chain alkyl ethers of 
resveratrol using alkyl halides in the presence of mild base K2CO3 with different 
solvents 15, 16.   Initially  synthesis of resveratrol-PEG ether was attempted using 
PEG-Br by adopting a procedure reported by Jiang for the synthesis of resveratrol 
aliphatic ligand, in which reactions were carried out in acetone at 600C with K2CO3 
16. The reaction did not yield any desired product as indicated by the HPLC analysis. 
This could be due to the slow reaction rate, and similar results with low yield of 14% 
were reported for etherification of resveratrol with small chain alkyl halide. As 
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expected,  the reactions would progress much slower with long chian alkyl halides. 
After adopting and modifying the procedure reported for synthesis of 4’-(4-O-
chlorobutyl)resveratrol15 ,  a favourable conjugation was achieved with improved 
yield.. Our experiment results  demonstrated that the amount alkali K2CO3 in the 
reaction mixture played an important role in etherification. The extent of conjugation 
was increased as the concentration of alkali K2CO3 was increased in the reaction 
mixture. This was based on a comparison of the normalised HPLC area of the new 
peak corresponding to   resveratrol -PEG ether appearing at 21.5 minutes. The area 
of peak was low when 0.2 mM of K2CO3 was used, and it gradually increased, and 
reached the  highest when K2CO3 was at 1.81 mM and DMF was used as the 
solvent.. In addition to concentration of alkali K2CO3, solvent type was identified as 
critical. For instance, when  very high concentration  of K2CO3 (5.79 mM) was 
employed in the  reaction with acetone as the solvent, there was no significant 
conjugation. This could be due to the solvent effect as K2CO3 is more soluble in 
DMF. It can be concluded that DMF provides a favourable environment for the 
abstraction of protons from  resveratrol  by K2CO3
 
. The reaction schemes are shown 
in Figure 3.1 and HPLC data  in Tabl-3.1.  
The NMR analysis of the final product showed that the product is a mixture of 
different PEGylated resveratrol species, i.e resveratrol PEGylated at different 
positions. The 4’-PEG-RSV was a major product (ca 60%) with 3-PEG-RSV(ca 
30%) and a minor 3,4’-di(PEG)-RSV (ca 10-15%). Although the extent of di-
substituted resveratrol was slightly more than that observed for resveratrol-PEG 
esters, 4’-PEG-RSV is still a major product. The substitution pattern observed here 
was slightly different from that reported for 4’-(4-O-chlorobutyl) resveratrol and 4’-
aliphatic lingands 10, 12, where substitution at 4’ of the position of resveratrol was 
reported. However the procedures included column separation and minor products 
could have been separated. The modest substitution at 3 positions could be due to an 
excess of K2CO3 in the reaction mixture. Although K2CO3 
 
was a mild base, it was 
reported to abstract protons at the 4’ position of resveratrol. Its high concentration in 
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Figure-3.2 NMR spectrum of RSV-PEG 2K, insert expanded version of 

















Table 3.1: Monitoring of reaction completion in synthesis of PEG-RSV ether 
conjugates based on the area of conjugate peak in HPLC 
 
Reaction conditions 
( Amount of  K2CO3 
Area of peak at 21.5 minutes 
and solvent used) ( 100 µg/mL of conjugate 
product in acetonitrile) 
5.79 mM- Acetone Peak not detected 
 0.289 mM- DMF 188 
1.08 mM- DMF 829 
 1.81 mM- DMF 1735 
 
 
3.3.2 Stability of resveatrol-PEG ether conjugates in buffers and plasma 
Stability profiles of resveratrol-PEG conjugate in buffers and plasma are shown in 
Figure 3.3.  The results indicate that resveratrol-PEG ether conjugate was stable in 
both buffers pH 4.5 and 7.4 and plasma. There was no hydrolysis detected in the 
plasma. These results were expected, as the ether bond is very stable and does not 
undergo hydrolysis either in the buffer or plasma. The conjugates were freely soluble 



























































Figure 3.3: Stability of resveratrol-PEG ether 2K in A: in buffers.Data 
presented as mean±SD (n=3) ; red curve is at  pH 4.5; blue curve at pH 7.4 . 




3.3.3 In vitro antioxidant assay of resveratrol-PEG ether conjugates 
The in vitro antioxidant profile is shown in Figure3.4. The IC-50 value of resveratrol 
was found to be 65 µM, which is in close agreement with the value reported by 
Fauconneau et al17. The IC 50 value for resveratrol-PEG was 2190 µM (equal to 219 
µM of resveratrol). The profile also shows that PEGylated resveratrol is  less active. 
There was an almost 3.5 fold increase in IC 50 values compared to resveratrol. The 
decrease in antioxidant activity indicates that all the hydroxyl groups of resveratrol 
are involved in reaction with free radicals. Hence, blocking one or more hydroxyl 
groups would lead to a decrease in activity. However, the activity was not 
completely abolished as reported for 3, 4’, 5-triemethoxy stilbene wherein all the OH 
groups of resveratrol were modified to methoxyl groups18.  The activity indicated by 
this assay method actually was based on direct neutralization of free radicals and 
may not reflect actual in vivo activity, as resveratrol exerts in vivo antioxidant 
activity by many other mechanisms. The literature reported that resveratrol could 
mediate the release or production of nitric oxide, which has stronger affinity for O2-.1 
Resveratrol is believed to induce enzymes dismutase and NAD(P)H:quinine 
oxidoreductase, both of which scavenge the reactive oxygen species. 1, 2 Modifying 
of one hydroxyl group of resveratrol would not lead to a drastic decrease in these 
activities. Although cyclooxygenase (COX-2) inhibition of 3,3’, 4,4’, 5,5’-
hexahydroxystilbene was much higher than resveratrol 15, the introduction of 
additional OH groups  made the structure more susceptible to metabolic 
conjugation 19. In the same report, methoxylated analogues of resveratrol did not lose 
COX-2 inhibitory activity, in fact, it was slightly better than the resveratrol. These 
observations suggest that selectively modifying one of the OH groups of resveratrol 
may not jeopardize the pharmacological effectiveness in vivo.  However, blocking 
more than one OH of resveratrol would lead to the complete loss of certain activities, 
such as antioxidants18. To produce a successful clinical candidate, there has to be a 
balance of all biological properties such as activity, toxicity and metabolism. The 
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molecule which is best, in terms of biological activity would not necessary  make it 
to clinical studies or the market due to other issues such as metabolism 21
 
. Similarly,  
having an unmodified resveratrol with higher activity but prone to metabolism would 
not be useful for clinical studies. Modified resveratrol, such as PEGylated resveratrol 
as discussed here with the better plasma profile would be a better choice for clinical 
















Figure 3.4: DPPH inhibition profile for antioxidant assay of A: Resveratrol B: 
Resveratrol-PEG ether 2 kDa. The data presented as mean±SD (n=3) 
 
3.3.4 In vitro metabolism studies of resveratrol and its polymer conjugates 
 
Resveratrol underwent rapid metabolism with microsomes in presence of UDPA. 
Resveratrol PEG ethers did not undergo metabolism with microsomes in presence of 
either UGT enzymes or NADPH regenerating system.(Data in appendix Figure-7.13) 
 
 































The plasma concentration-time profile of resveratrol-PEG ether and resveratrol are 
presented in Figure 3.5 and the corresponding representative HPLC chromatograms 
in Figure 3.6. The profile indicates that resveratrol undergoes rapid elimination, and 
mainly by metabolism. The initial plasma concentration of resveratrol at 5 minutes 
was very low (1.74±0.67 µg/mL) with high intense peaks of metabolites. The plasma 
concentration of resveratrol declined rapidly and fell almost below the detection 
limits within two hours. On the contrary, the resveratrol-PEG ether 2 kDa displayed 
a better profile with a higher initial plasma concentration (7.24 µg/mL) and depleting 
more slowly than the resveratrol. The AUC total for resveratrol--PEG ether 2 kDa 
was 15.660 µg*h/L  compared to 0.63 µg*h/L for resveratrol. The MRT for 
resveratrol-PEG ether 2 kDa was also higher 6.2h (1.7 h for resveratrol).  Although 
the resveratrol-PEG displayed a significantly better profile than resveratrol, the trend 
still showed a rapid decline followed by stagnation after 1hour. The rapid clearance 
of resveratrol--PEG could be attributed to increased solubility after the PEG 
conjugation, which facilitates kidney filtration. The steady levels after 1 hour were 
initially thought to be because of 3, 4’-di(PEG) resveratrol, which has a larger Mw 
(4200 KDa). The resveratrol--PEG ether 5 kDa was prepared and the 
pharmacokinetic profile was evaluated. Surprisingly there was no difference between 
the elimination patterns of resveratrol-PEG 2 and 5 kDa. Only plasma concentration 
at 5 minutes post dose was higher with the PEG ether 5 kDa. This suggests that an 
increase in Mw from 2 kDa to 5 kDa has a marginal effect on kidney filtration and a 
rise of Mw was not sufficient to reach the threshold limit of filtration (Serum 
albumin volume) 17.  Pharmacokinetic studies with radio labelled PEGs of various 
Mw reported by Reza Mehvar 22 clearly showed that a significant effect of Mw on 
clearance of PEG can be observed only after Mw of 20 kDa.  The low but steady 
plasma levels of RSV-PEG after 1 hour could be due to the intrinsic distribution and 
elimination properties of PEG. It was possible that the special conformational 
arrangements of 3, 4’-di (PEG) may give a more hydrodynamic volume, in turn lead 
to slow kidney filtration  9. Fee et al. have studied the size comparison between 
proteins PEGylated with linear and branched chain PEGs 23. They concluded that 
branched PEG would have a higher viscosity and larger radius than proteins 
PEGylated with linear PEGs of same molecular weight. Based on the same 
reasoning,  disubstituted  resveratrol with a PEG of 2 kDa would appear like 
branched PEG and with a butterfly like shape. This would eventually give rise to 
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more hydrodynamic volume than monosubstituted  resveratrol- with PEG of 5 kDa. 






























Figure 3.5: Pharmacokinetic profile of resveratrol and Resveratrol-PEG 
ether.Data presented as mean±SD (n=6 RSV-PEG 5 kDa, 5 for RSV-PEG 2 































RSV-PEG ether  5 kDA,  Dose 2 mg/kg 
equivalent of  resveratrol 
RSV-PEG ether  2 kDA,  Dose 2 mg/kg 
equivalent of  resveratrol 




















Figure 3.6: HPLC chromatogram of A: resveratrol-PEG ( RSV-PEG) ether sample 
from rat at 5 minutes post dose (2mg/kg resveratrol- equivalent), B: resveratrol-
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DEVELOPMENT OF HPLC METHOD FOR 
SIMULTANEOUS ANALYSIS OF RESVERATROL, 
RESVERTROL-POLYMER CONJUGATES AND  




4.1. INTRODUCTION  
One of the most effective approaches to reduce or even prevent drug metabolism and 
improve therapeutic efficacy is to use a polymeric prodrug or conjugate strategy.  
This involves protecting the drug’s reactive sites with cleavable groups to mask the 
native drug. This approach has been utilised previously to reduce the rate of 
resveratrol metabolism 1. Using the same principle, various resveratrol polymeric 
ester conjugates have also been  synthesized in this project for the same purpose 
(chapter 2). In order to evaluate these systems and to conduct pharmacokinetic 
profiling of these products, a simple but highly sensitive HPLC method is essential 
for detection and quantification of native resveratrol, polymeric conjugates as well as 
metabolites. There are a few reports on resveratrol quantitification by HPLC using 
UV, fluorescence and electrochemical detection 2-5. The sensitive LC-MS methods 
reported for resveratrol 6 bear some limitations for analysis of resveratrol-polymer 
conjugates, for instance, there are mass detection  limits for polymer conjugates with 
higher molecular weights and lack of specificity. Since there would be narrow 
molecular weight differences between drug-polymer conjugates and polymers, the 
specific detection and quantification would not possible unless there is adequate 
separation between them. Moreover the polymers are composed of a mixture of 
polymer  with various molecular weights, narrow difference would not be noticed. 
Hence the simple and sensitive HPLC method is essential of resveratrol-polymer 
conjugates.  So far,  there is no reported method that author is  aware of  which can 
detect both resveratrol and its polymeric conjugate simultaneously in a sensitive 
manner. Developing a single HPLC method which can be applied for separation and 




4.1.1 Objectives of study 
 Objectives of the study described in this chapter were to develop a highly sensitive 
HPLC method for separation and quantification of resveratrol and its polymer 
conjugates and also to detect the metabolites. In the current investigation, a 
systematic approach was used to develop a highly sensitive HPLC assay with 
fluorescence detection to simultaneously analyse resveratrol and its polymer 
conjugates, and also to allow the detection of metabolites. Efforts were also made to 
increase the fluorescence intensity of compounds of interest and to study the effect 
of solvent modulation on the sensitivity of the HPLC method. All the analytes such a 
resveratrol, resveratrol-polymer conjugates and metabolites, which were detected in 
HPLC, were also qualitatively analyzed by LC-MS or LC-MS/MS. The LC-MS 
method was developed as such that compounds of interest were separated and eluted 
with retention times matching closely with the HPLC assay using the same column. 
This HPLC method was initially developed and validated for MeO-PEGN-Succ-
RSV 2 kDa conjugate, later it was applied for quantification of other resveratrol-
polymer conjugates. Hence, this chapter focuses on the methodology and 
mechanistic studies that lead to development a highly sensitive HPLC method for 
MeO-PEGN-Succ-RSV 2 kDa, as well as the  extensive validation of the method. 
The same method was applied for analysis of other polymer conjugates and some of 




4.2.1 Materials and Reagents 
Trans-Resveratrol was purchased from Shanghai DND Pharm-Technology Co., Inc., 
Shanghai, China, with 99% purity. Resveratrol-polymer conjugates: MeO-PEGN-
Succ-RSV, 2 kDa, 20 kDA, MeO-PEGO-Succ-RSV, 2 kDA, MeO-PEG-PLAO-
Succ-RSV, 2 kDa and 6.5 kDa, Resveratrol-PEG ether 2 kDa and 5 kDa were 
synthesized and characterised in house (Chapter 2 section 2.2.4 and 2.2.5 and 
Chapter 3, section 3.2.2.2). Acetonitrile, triethylamine and formic acid were 
analytical grade and purchased from Sigma (Sydney, Australia). They are used 
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without any further purification. The HPLC column, ODS C-18 150 x 4.6 mm, 5 µm 
was purchased from Altech (Sydney, Australia)   
 
4.2.2 Fluorescence and UV Scanning.  
 Excitation and emission wavelengths for resveratrol were determined using a Varian 
Carry Eclipse spectroflurometer (Varian Australia, Australia). A resveratrol standard 
solution of 1 μg/mL was prepared in methanol and scanned for excitation and 
emission. UV absorption maxima were determined using a Hewlett Packard 8452A, 
UV-VIS spectrophotometer (Hewlett Packard, Germany). Based on these results, 
excitation and emission were set at 320 nm and 400 nm respectively for HPLC and 
independent fluorescence analyses.  Solutions of 1 μg/mL of resveratrol and its 
equivalent of MeO-PEGN-Succ-RSV were prepared separately in buffer pH 7.4, and 
buffer-methanol mixtures. The fluorescence intensity of these solutions was recorded 
at 400 nm with an excitation wavelength of 320 nm. The results obtained from these 
experiments were then used to develop solvent gradient parameters for HPLC.   
 
4.2.3 Reverse-phase HPLC Chromatography 
The HPLC analyses were performed using an Agilent Technologies chromatographic 
system (Santa Clara, CA, USA) HPLC-1100 series with dual detection (G1321A 
Fluorescence and G1315B UV-DAD), G1311A pump, G1316A column oven, 
G1329A autosampler and Chemstation B.04.02 software. An Altech Apollo C18 
(150 x 4.6 mm, 5 µm) column was employed. 
 
The HPLC gradient system consisted of solvent A, buffer pH 7.0 with triethyl 
amine-formic acid (0.05 and 0.2% v/v in water) and solvent B, methanol. The 30 
minute linear gradient was programmed as follows: 0 min 5% B, 4 min 20% B, 7 
min 20% B, 16 min 55% B, 18 min 55% B, 18.5 min 95% B, 23 min 95% B, 24 min 
5% B. The flow rate was maintained at 1mL/min and the injection volume was 50 
µL. 
4.2.3.1 Linearity  
A series of standard solutions of resveratrol in methanol/solvent A mixture (50:50) 
were prepared with concentrations ranging from 5 ng/mL to 1000 ng/mL. Similarly 
MeO-PEGN-Succ-RSV standard solutions were prepared using acetonitrile/water 




4.2.3.2 System and method precision  
Standard solutions of resveratrol and MeO-PEGN-Succ-RSV at one concentration 
were injected six times and standard deviation and %RSD were calculated. Similarly 




Standard solutions of resveratrol and MeO-PEGN-Succ-RSV at three different 
concentrations (2, 4, and 6 µg/mL eqvivalent to 200, 400 and 600 ng/mL of RSV) 
were analyzed in triplicate. The accuracy was calculated by comparing the 
concentration determined  against that of prepared. 
 
4.2.3.4 Intra-day and inter-day repeatability 
Standard solutions of resveratrol and MeO-PEGN-Succ-RSV 2 kDa at three different 
concentrations (2, 4, and 6 µg/mL eqvivalent to 200, 400 and 600 ng/mL of RSV) 
were injected two times a day. Standard solutions prepared separately on day 2 were 
also analysed. The concentrations were determined from calibration curve and 
standard deviation and %RSD were calculated. 
 
4.2.3.5 Stability at room temperature  
Resveratrol solutions at three different concentrations were stored in HPLC vials at 
room temperature under dark. Samples were analyzed after 3 days. 
 
4.2.3.6 Stability at refrigeration 
 Resveratrol and MeO-PEGN-Succ-RSV standard solutions at three different 
concentrations were stored at 2-8ºC and analyzed by HPLC. 
 
4.2.3.7 Recovery of resveratrol and MeO-PEGN-Succ-RSV from a mixture 
 The solutions containing a mixture of resveratrol and MeO-PEGN-Succ-RSV at 
three different concentrations were prepared in water/acetonitrile mixtue (50:50). 
They were analysed by HPLC and their recovery was calculated based on 




4.2.3.8 Recovery of resveratrol from plasma 
The recovery of resveratrol from rat plasma was determined by spiking blank plasma 
with the resveratrol standard to obtain the final concentration of 50, 100, 500 and 
1000 ng/mL in duplicates. Plasma samples were then mixed with an equal volume of 
acetonitrile to precipitate proteins, and the supernatants obtained after centrifugation 
were analysed by HPLC. Recoveries were calculated by comparing the measured 
concentration to the spiked concentration of resveratrol.    
 
4.2.4 LC-MS Analysis 
To confirm the detection and quantification of the MeO-PEGN-Succ-RSV 
conjugates performed using HPLC-fluorescence/UV detection, an LC-MS method 
was developed to analyze qualitatively the MeO-PEGN-Succ-RSV conjugates. LC-
MS analysis was performed using a Shimadzu LC-MS system LC-MS 2020 (Kyoto, 
Japan). The System consisted of a binary pump 20AD, auto injector SIL 20 AC HT, 
column oven CTO 20A, PDA detector SPD M 20A, mass analyser MS2020 and 




The LC gradient system consisted of solvent A, water and solvent B, methanol. The 
30 minute linear gradient was programmed as follows: 0 min 5% B, 4 min 20% B, 7 
min 50% B, 12 min 50% B 16 min 55% B, 18 min 95% B, 23 min 95% B, 24 min 
5% B. The flow rate was maintained at 0.4 mL/min. The same column used for 
HPLC analysis was used in LC-MS. Samples were analysed with injection volume 
of 40 µL. The optimised ESI conditions employed included a DL temperature at 
3000C, interface temperature at 3500C.  The heat block temperature  was maintained 
at 2200C. The drying gas, nitrogen flow, was maintained at 10L/minute. Other mass 
parameters were set as per auto-tuning results. The scan mode was used to record the 
abundance of ions corresponding to resveratrol in negative mode and PEG in 
positive mode. The scan was performed with a mass range of 200-2000 Daltons. 
Similar LC parameters were used to detect metabolites using LC-MS/MS system 
(Applied Biosystems, USA) with multiple reaction monitoring (MRM) at 307/227 






4.2.5 Detection of resveratrol metabolites in rat plasma by HPLC. 
 An aqueous solution of 2 mg/mL  resveratrol in 10% w/v of hydroxyl propyl-β-
cyclodextrin was prepared and sterilized by filtration. An aliquot of 0.3 mL of this 
solution was injected intravenously into Wistar rats via the tail vein. Blood was 
collected from the tail vein at 10 min, post dose, by vein puncture. The plasma was 
separated by centrifugation at 10,000 RPM using a mini spin, Effendorf centrifuge 
(USA).  The 100 µL of plasma was mixed with 200 µL of acetonitrile to precipitate 
proteins. The supernatant was collected by centrifugation. The obtained supernatant 
was mixed 1:1 with water and analysed by HPLC as described in section 4.2.3. All 
animal experiments were approved by the Animal Ethics Committee of Curtin 
University. 
 
4.3. RESULTS AND DISCUSSION 
4.3.1 Fluroscence and UV analysis 
Analysis of a solution of resveratrol in methanol using fluorescence spectroscopy 
indicated that the maximum excitation and emission wavelengths were 320 nm and 
400 nm respectively. UV absorbance spectra for methanol solutions of both 
resveratrol and the MeO-PEGN-Succ-RSV conjugate mixture indicated absorption 
maxima at 307 nm for both solutions. The UV and fluorescence spectrum is shown 










































Figure 4.1:  A: UV spectrum of resveratrol in methanol. B: fluorescence spectrum of 
resveratrol in methanol. 
In order to evaluate the effect of solvent on the fluorescence intensity, a series of 
fluorescence intensity measurements were recorded for resveratrol and MeO-PEGN-
Succ-RSV with the solutions prepared from mixture of methanol and an aqueous 
buffer. The results indicated an increasing fluorescence intensity of the MeO-PEGN-
Succ-RSV conjugates as the methanol concentration increased (Figure 4.2). The 
highest fluorescence intensity was achieved when the methanol concentration was 





of the solvent mixtures was always higher than that of the equivalent amount of 
resveratrol. The fluorescence intensity of resveratrol itself did not show significant 
change as the solvent polarity changed, this was in stark contrast to the MeO-PEGN-
Succ-RSV conjugate which displayed a drastic increase in fluorescence as the 
methanol concentration increased above 60% (Figure 4.2). To validate these 
findings, further HPLC analyses were performed with isocratic elution comprising of 
75% and 80% methanol with all other parameters unchanged. The analysis was 
performed for MeO-PEGN-Succ-RSV solution 300ng/mL (equivalent to 30ng/mL of 
resveratrol).  Results clearly indicated fluorescence intensity increased with 
methanol concentration in the mobile phase (Figure 4.3). The increase in intensity 
was almost double for every 5% increase in methanol concentration. These results 
are in agreement with the fluorescence measurements performed with varying 
concentration of methanol.  Although isocratic runs looks provide better LOQ due to 
more flat baseline, at this high concentration of methanol, separation cannot be 
achieved between RSV, metabolites and polymer conjugate. These findings lead us 
to design the HPLC mobile phase in such a way that the analytes of interest eluted at 
high methanol concentrations, where the fluorescence intensity would be at a 
maximum.   
The increase in fluorescence intensity of resveratrol after the coupling to PEG could 
be attributed to increased hydrophilicity and dispersing effect of PEG, which in turn 
may prevent intermolecular hydrophobic interactions between resveratrol molecules. 
Our findings are in close agreement with those reported for phthalocyanines by Jian 
et al 7. The group reported that fluorescence of phthalocyanines was rarely observed 
in aqueous media due to aggregation and hydrophobic interactions. Upon 
conjugation with PEG the fluorescence intensity was greatly increased, presumably 
due to reduced hydrophobic interactions and an increased 'monomeric' structure 
which was attributed to the dispersant properties of PEG. The increase in 
fluorescence intensity as a function of methanol concentration, for the MeO-PEGN-
Succ-RSV conjugates can be attributed to the change in the environment of the 
resveratrol. In the low methanol solutions the PEG would interact strongly with 
water and the resveratrol units would presumably aggregate to avoid contact with the 
aqueous phase. This process would lead to significant intermolecular interactions, 
leading to fluorescence quenching 8 . At high methanol concentrations presumably 
the resveratrol interacts more strongly with the solvent and less aggregation occurs. 
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At this point the PEG may prevent intermolecular interactions between resveratrol 
molecules leading to an enhanced fluorescence. Similar findings were reported for 
























Figure 4.2: Effect of solvent composition on fluorescence of A-MeO-PEGN-Succ-
RSV and B-resveratrol, analyses were performed at excitation wavelength of 320 
and emission wavelength of 420 with resveratrol concentration of 1 µg/mL and 













Figure 4.3: Effect of methanol concentration on MeO-PEGN-Succ-RSV (RSV-PEG) 
florescence peak intensity. A: Isocratic chromatogram with 80% methanol; B: 
isocratic chromatogram with 75% methanol. 
 
4.3.2 Chromatographic analysis 
 The increased fluorescence intensity associated with the MeO-PEGN-Succ-RSV 
conjugates permitted development of a sensitive HPLC assay method for analysis of 
resveratrol and the PEG conjugates because the UV detection can be replaced by 
more sensitive fluorescence detection, particularly for analysis of PEG conjugates of 
resveratrol. Representative chromatograms for resveratrol and MeO-PEGN-Succ-
RSV conjugate with both UV and fluorescence detection are shown in Figure 4.4. In 
the absence of fluorescence detection, quantification of MeO-PEGN-Succ-RSV 
conjugates at low concentration would have proved more difficult, demanding either 
alternative techniques or hydrolysis of PEG esters back to resveratrol in order to 
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quantify it accurately. Such an approach is more complex and time consuming. In 
our HPLC assay method, the solvent gradient is such that MeO-PEGN-Succ-RSV 
conjugates elute when the methanol concentration in the mobile phase is 95% and at 
that particular concentration, the fluorescence intensity of the MeO-PEGN-Succ-
RSV conjugates is close to a maximum. This ultimately results in the high sensitivity 
of this method. Such a sensitive method is very useful for physiochemical, metabolic 
and pharmacokinetic profiling of these compounds, where dealing with 
quantification of resveratrol, its PEG conjugates at low concentration is often 
anticipated. Moreover, this HPLC quantification is based on the fluorescence 
properties of resveratrol in resveratrol-PEG conjugate, the method is more specific 
and there would not be any interference from un-cojugated polymer even if co-
eluting. This overcomes limitations of LC-MS method which is based on mass 
number of analytes. The narrow difference between molecular weights of PEG and 
RSV-PEG would complicate specific detection and quantification individual species 
if there is no adequate separation between two. In addition. some LC-MS 
instruments have mass detection limit up to 2000, the polymer conjugates with Mw 
>2000, which do not undergo fragmentation could not be analyzed with such LC-MS 








Figure 4.4: HPLC chromatograms of resveratrol and MeO-PEGN-Succ-RSV. A: 
MeO-PEGN-Succ-RSV ( RSV-PEG ~30ng/mL of resveratrol) chromatogram with 
UV detection (UVD): B: MeO-PEGN-Succ-RSV (~30ng/mL of resveratrol) 
chromatogram with Fluorescence detection (FLD); C: resveratrol 30ng/mL 






4.3.3 Linearity, accuracy, recovery and limit of quantification 
Linearity curves were obtained for resveratrol and the MeO-PEGN-Succ-RSV 
conjugates by plotting mean area of peaks against concentration. Table 4.1 lists the 
linear regression coefficient, linear range, intercept, slope, limit of detection (LOD), 
limit of quantification (LOQ) and Table 2 show the recovery results obtained from 
HPLC analysis of resveratrol and the MeO-PEGN-Succ-RSV conjugate mixture. 
LOD and LOQ were calculated using three and ten times the standard deviation of 
baseline noise and the calibration curve obtained using peak height against 
concentration. LOQ was found to be 5 ng/mL for resveratrol and 300 ng/mL for its 
PEG conjugate (≈30 ng/mL of resveratrol). The slight increase in LOQ value for 
MeO-PEGN-Succ-RSV is due to the baseline shift and subsequent noise at the 
retention time due to the change of gradient.  In the absence of this, the LOQ may be 
improved. However, any move to reduce the methanol concentration to achieve a 
flatter base line at the time of MeO-PEGN-Succ-RSV elution would risk the 
sensitivity as was observed in fluorescence and HPLC analysis with lower methanol 
concentration. On the other hand, increasing the methanol concentration earlier than 
this may lead to poor separation between resveratrol, metabolites and PEG 
conjugate.  The full validation results for resveratrol and MeO-PEGN-Succ-RSV 
analyses  are given in Table 4.3 and 4.4. The HPLC data for other polymer 
conjugates such as MeO-PEGN-Succ-RSV 20 kDa, MeO-PEGO-Succ-RSV 2 kDa. 
MeO-PEG-PLAO-Succ-RSV, 2 kDa and 6.6 kDa are presented in Table 4.5-4.6. 
Only limited data such as linearity, LOD and LOQ were obtained for other polymer 
conjugates in this project   whereas a full set of method validation data  was obtained 
for MeO-PEGN-Succ-RSV, 2 kDa conjugate to demonstrate the feasibility and 
application of the assay method.The representative chromatograms of polymer 
conjugates are shown in Figure 4.5-4.8.  
  
Plasma recovery data were all within acceptable limits for bioanalytical method 
validation 10. The average recovery of resveratrol in plasma was 92-102% ( SD 0.1-
5.3%), suggesting high reproducibility and extraction efficiency of the method. The 
recovery of MeO-PEGN-Succ-RSV in plasma was not done because it broke down 
very quickly in the plasma.. For the same reason, plasma recoveries for MeO-PEGN-
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Succ-RSV 20 kDa and other ester conjugates were not performed because they 
hydrolyzed very quickly back to resveratrol in the plasma. The MeO-PEG-CH2CH2
 
-
O-RSV ether conjugates were stable in plasma and recovery data was presented in 
chapter 3. For all samples, a simple protein precipitation method using acetonitrile 
was used to extract analytes from plasma because of the sensitivity of the analytes to 
light and heat. 
 
Table 4.1:  HPLC calibration parameters for resveratrol and MeO-PEGN-Succ-RSV 
2 kDa. 
Sample Slope Intercept R
Linear Range











0.044 1.1534 0.9999 300-1000* 
 
 




      *The value is equivalent to 30-1000 ng/mL of resveratrol 
        1 
 
Concentration range for the  caliberation curve. 
 
Table 4.2: Recovery of HPLC analysis of resveratrol (RSV) and MeO-PEGN-Succ-
RSV  2 kDa conjugates (RSV-PEG) in a mixture. 
Concentration (µg/mL) 
(RSV)      (RSV-PEG)* 
    
Recovery (%) 
RSV-PEG RSV 
0.1                  1 107.0(±3.2) 100.0(±5.2) 
0.5                  5 108.5(±2.4) 103.0(±1.9) 
1                    10 109.0(±0.7) 107.0(±3.6) 













































































Figure 4.6: MeO-PEGO-Succ-RSV 2 kDa, 10 µg/mL 
 
 
UV Chromatogram  


































































































          























System  precision 
1000 
 
1000.4 (2.02) 0.20 
Method  precision 1000 1005.0(13.00) 
1.30 
 
Interday 50 50.2(0.58) 1.16 
 
100 101.4(0.54) 0.53 
 
1000 1000.4(2.02) 0.20 
 
Intraday 
50 49.5(0.61) 1.24 
 
100 101.0(0.64) 0.63 
 










100 101.0(0.64) 0.63 
 
1000 100.5(1.31) 1.30 
 
Stability at room 
 temperature, 3 days 
50 48.2(1.25) 1.25 
 
100 102.0(1.13) 1.10 
 
1000 1032.1(11.38) 1.10 
 
Stability at 2-8 0
 






100 103.3(0.53) 0.51 
 




        






System precision 6 
 
6.0(0.00) 0.11 
Method precision 6 
 
6.0(0.12) 2.14 
Interday 2 1.9(0.00) 0.18 




Intraday 2 1.9(0.01) 1.02 
 4 3.9(0.03) 1.00 









 4 101.5(1.48) 1.46 
 6 100.1(0.11) 0.11 
 
Stability at 2-8 0
 





 4 3.8(0.03) 1.00 
 6 5.8(0.02) 0.50 
        
 





















































80 76.3(0.63) 0.83 
Interday 40 38.9(0.89) 2.29 




Intraday 40 38.4(0.60) 1.56 
 60 57.1(0.23) 0.41 













Stability at 2-8 0 40 C, 24 hrs 37.3(0.86) 2.30 
 60 57.3(0.37) 0.64 









Table 4.6: Linearity, LOQ and LOD data for various resveratrol-polymer conjugates 
 
a-  100 µg/mL of conjugate is eqvivalent to 1 µg/mL of RSV 
*Concentration range used for the caliberation curve. 
b-  10 µg/mL conjugate is eqvivalent to 1 µg/mL of RSV 
c-  33 µg/mL conjugate is eqvivalent to 1 µg/mL of RSV 
d-  10 µg/mL conjugate is eqvivalent to 1 µg/mL of RSV 
e-  10 µg/mL conjugate is eqvivalent to 1 µg/mL of RSV 
 
4.3.4 Analysis of MeO-PEGN-Succ-RSV and resveratrol by LC-MS 
 The elution of resveratrol and MeO-PEGN-Succ-RSV conjugate observed in LC-
MS analysis was very similar to that achieved in HPLC, with resveratrol eluting at 
17.8 minutes and MeO-PEGN-Succ-RSV at 22 minutes.  LC-MS chromatogram of 
resveratrol showed a peak at the retention time of 17.5 minutes with m/z 227 (Mw of 






MeO-PEGN-Succ-RSV, 20 K 0.0021 a 0.79 0.9994  5-100  8.0 2.3 
 
MeO-PEGO-Succ-RSV, 2 K 0.0300 b 1.94 0.9985  0.5-10 0.9 0.3 
 
MeO-PEG-PLAO-Succ-RSVc 2.2101 , 
6.6K 







43.95 0.9979  5-100 3.2 2.2 
 
 
RSV-O-PEG Ether, 2K 6.4803 e 2.46 0.9996  5-200 5.0 0.7 
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resveratrol is 228) as shown in Figure 4.9B. Similarly there is a peak at retention 
time of 22 minutes with corresponding mass spectrum showing a series of intense 
mass peaks in the range of m/z 550-900 (Figure 4.9A). These mass spectrum peaks 
are believed to be characteristic fragmented peaks of PEG 11. 
 
 The HPLC peak with 
retention time of 22 minutes, suspected to be MeO-PEGN-Succ-RSV, did not show 
resveratrol ion in mass spectrum, but its PDA spectrum did in fact reveal a spectrum 
almost matching that of resveratrol, indicating the formation of MeO-PEGN-Succ-
RSV structure (Figure 7.14-7.15 in Appendix). These data suggest that the new peak 
observed at 22 minutes is of MeO-PEGN-Succ-RSV. The findings of this 
experiment together with HPLC results obtained suggest that the developed HPLC 
and LC-MS methodology can separate, identify and accurately quantify resveratrol 




Figure 4.9:  LC-MS chromatogram of A: MeO-PEGN-Succ-RSV 2000 in scan mode 
(insert: Mass spectrum of MeO-PEGN-Succ-RSV which corresponds to the peak at 
retention time of 22.5 minutes) and  B-:resveratrol (insert: mass spectrum of 
resveratrol from the peak at 17.8 minutes) 
 
4.3.5 Detection of resveratrol metabolites by HPLC 
 The present HPLC method with fluorescence detection was found to be very 
sensitive for metabolite detection (Figure 4.10). Peak intensities of metabolites were 
higher using fluorescence detection than UV detection. The five additional peaks 
observed in the HPLC chromatograms and are believed to be of metabolites with UV 
spectra matching with that of resveratrol. The LC-MS/MS monitoring of metabolites 
with multiple ion monitoring (MRM) at 307/227 and 403/227 revealed the presence 
of two monosulfates peak 1 and 4 and two monoglucuronides 2 and 3 as shown in 
Figure 4.10. These observations are in close agreement with those reported in 
literature 6. There was a fifth peak observed in HPLC and LC-MS/MS with MRM 
307/227, which could be due to di or tri sulphate conjugate of resveratrol and could 
have appeared in MS chromatogram after loss of one or more of the sulphate 
moieties.  All these findings need further confirmatory studies like isolation or 
synthesis of resveratrol metabolites and subsequent NMR analysis to confirm exact 
structures. However, changing the solvent gradient in the method to maximize the 
intensity of MeO-PEGN-Succ-RSV did increase the likelihood of detection of   of 
metabolites while still offered a good separation of metabolites from resveratrol and 






Figure 4.10 HPLC chromatograms of resveratrol and resveratrol metabolites in rat 
plasma. A: Chromatogram with UV detection. B: Chromatogram with fluorescence 
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5.1 INTRODUCTION  
Monitoring the conjugation process, level of reaction intermediates and 
characterizing the polymeric conjugates is a vital part of the process that requires 
suitable analytical techniques that permit monitoring each step of the process in 
order to develop effective synthetic methodologies. Analytical techniques such as 
HPLC, IR, NMR and mass spectroscopy are currently used for this purpose with 
limited success 1,8. All these techniques have some limitations for instance, HPLC, 
although capable of separating different compounds, cannot directly identify the 
polymeric compound unless there is a standard or UV spectrum of the compound 
available; thus the structural attributes and degree of substitution cannot be obtained 
from this technique. H
 
NMR can give useful information for structural identification 
and quantification of simple structures and mixtures, however, in certain cases, 
overlapping signals can make obtaining quantitative information difficult. The 
determination of end group modification of a polymer, using NMR, can also be a 
difficult prospect. Hence the quantification becomes complex and may need other 
complimentary techniques for quantification. The development of an effective 
analytical methodology in addition to NMR, which can overcome some of these 
limitations, will be invaluable for understanding and controlling conjugate synthesis, 
and for characterisation of the synthesised polymeric conjugates or conjugates.   
The qualitative structure elucidation, molecular weight determination and quality 
checks by LC-MS have reported for PEGylated proteins 3. The PEG is known to 
undergo fragmentation in mass detector to small Mw daughter ions. However post 
column addition of amines such dimethyl and triethyl amines prevented 
fragmentation thereby allowing characterization of PeGylated proteins for their 
structure and molecular weight ( Mw). The molecular weight determination by LC-
MS was accurate with <0.01% variation 3. The modifications of Pegylated proteins 
by oxidation and maleamide ring opening were also detected by LC-MS. 
Furthermore, the LC-MS was utilized to determine chemical composition of block 
copolymers such as polyethylene glycol-polycaprolactone (PEG-PCL) and 
polyethylene glycol-polycaprolactone-linoleic acid (PEG-PCL-:LA) 4 . The various 
ionization techniques such as atmospheric pressure chemical ionization and 
electrospray ionization were utilized for mass analysis. Combination of both  
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techniques was helpful in understanding the chemical composition of block 
copolymers. Such a method was proved to be useful in reaction monitoring. This was 
confirmed by a separate  study, in which LC-MS was successfully used for 
monitoring the conversion of PEG to mPEG  5
 
. 
5.1.1 objectives of the study 
Objectives of the current study  were to develop a suitable LC-MS method to 
characterize various stages of PEGylation process of resveratrol, which included. to 
detect, characterize and quantify PEGylated resveratrol and reaction intermediates. It 
is essential that the various stages in pegylation such as modification of MeO-PEG-
OH to MeO-PEGO-SuccOH, conjugation of MeO-PEG-SuccOH to resveratrol were 
monitored qualitatively and quantitatively in order to monitor the progress of the 
reaction and optimise the synthesis.  In this study,  The extent of PEG conversion to 
succinyl ester and extent PEG acid conjugation to resveratrol were monitored and  
determined by LC-MS. Finally LC-MS was also used to estimate the Mw of various 
PEG derivatives and conjugates.  
 
5.2. MATERIALS AND METHODS 
5.2.1 Materials 
Trans-Resveratrol was purchased from DND Pharma-Tech Co. Inc, Shanghai, 
China, with 99% purity. MeO-PEG-OH was purchased from Sigma-Aldrich, 
Australia. MeO-PEGO-SuccOH 2 kDa, MeO-PEGO-Succ-RSV 2 kDa and MeO-
PEGN-Succ-RSV, 2 kDa were prepared as per description  in section 2.2.3, 2.2.4 of 
chapter 2. 
 
5.2.2 LC-MS analysis of resveratrol, resveratrol PEG conjugates and reaction 
intermediates 
The LC-MS analysis was carried out using a Shimadzu (Tokyo, Japan) LC-MS 
single quadrupole mass spectrometer (LC-MS, 2020) equipped with a binary pump 
20AD, thermostated auto sampler SIL 20ACHT, thermostated column compartment 
CTO 20A, PDA detector SPD M 20A and mass analyser MS2020 with both electro 
spray ionization (ESI) and atomic pressure chemical ionization (APCI) systems. 
Data were acquired, processed and analysed by LABSOLUTIONS® 




LC-MS analysis was performed using a linear gradient system consisting of solvent 
A: water and solvent B: acetonitrile. The 10 min linear gradient was programmed as 
follows, 0 min 40%B, 1 min 40%B, 4 min 95%B, 8 min 40%B. Flow rate was 
maintained at 0.4 mL/minute. Elution was performed using a Zorbax SBC-18, 150 x 
4.6 mm, 3.5 µm column maintained at 30ºC and the injection volume was 5 µL. The 
optimised ESI conditions employed included a DL temperature at 3000C, interface 
temperature at 3500C and heat block temperature was maintained at 2200
 
C. The 
drying gas, nitrogen flow was maintained at 10L/minute. The abundance of ions 
corresponding to resveratrol; free MeO-PEG-OH, MeO-PEG acids and PEG-
resveratrol conjugates were recorded using simultaneous negative and positive ion 
detection mode. The scanning mass range was fixed at 50-2000 mass units.  The 
selected ion monitoring system (SIM) including a series of ions with m/z of 700, 
720, 730, 900, 1000 corresponding to PEG and 227 corresponding to resveratrol was 
used for quantitative analysis. 
5.2.3 LC-MS qualitative analysis of resveratrol and PEG derivatives 
Solutions of 10 µg/mL  resveratrol, MeO-PEG-OH, MeO-PEGO-SuccOH, MeO-
PEGN-SuccOH, and MeO-PEG-Resveratrol conjugates, prepared in chapter-2, were 
injected separately into LC-MS and analysed in scan mode to assess the selectivity 
of the LC-MS method and to determine the molecular masses of corresponding 
peaks.  
 
5.2.4 Determination of extent of MeO-PEG-OH conversion to MeO-PEGO-SuccOH 
The extent of functionalization of PEG (eg. MeO-PEG-OH) to acid (MeO-PEGO-
SuccOH) was determined by analysis of the level of MeO-PEG-OH in the 
synthesised MeO-PEGO-SuccOH. Solutions of MeO-PEGO-SuccOH and a standard 
solution of MeO-PEG-OH, 1000 ng/mL prepared in acetonitrile/water mixture 
(50:50), was analysed in SIM mode by the LC-MS system in chromatographic 
conditions similar to those used for the MeO-PEGN-SuccOH and MeO-PEGO-
SuccOH analysis as described above. The extent of functionalization of PEG was 
calculated following the determination of the concentration of MeO-PEG-OH in 




5.2.5 Determination of extent of PEG conjugation to resveratrol by LC-MS  
A series of standard solutions of PEG acids (MeO-PEGN-SuccOH and MeO-PEGO-
SuccOH) in the concentration range of 100 to 1000 ng/mL was prepared in 
acetonitrile/water mixture (50:50) and injected onto the LC-MS system. The analysis 
was performed in SIM mode to quantify concentrations of PEG acids. A standard 
calibration curve was then constructed by plotting area under the curve of PEG acid 
peak against concentration. A solution of resveratrol-PEG conjugate (1000 ng/mL) 
was also analysed in a similar fashion. The extent of conjugation of resveratrol to 
PEG was determined based on the concentration of free carboxylic acid terminated 
PEG detected in the conjugate mixture.  
 
5.2.6 Determination of extent of PEG conjugation to resveratrol  by UV-vis 
spectrophotometery 
The resveratrol standard solutions with a concentration range of 1-10 µg/mL were 
prepared in acetonitrile. The absorbance of solutions was measured at 307 nm using 
a UV-VIS spectrophotometer (Waldbrann, Germany). Similarly 50 and 100 µg/mL 
solutions of resveratrol-PEG conjugates (equivalent to 5 and 10 µg/mL of 
resveratrol) were prepared and the absorbance recorded at 307 nm. The total 
resveratrol content in polymer was determined from the calibration curve of 
resveratrol. The average extent of PEG conjugation to resveratrol (%) was calculated 
based on the resveratrol content obtained experimentally against the theoretical 
value, assuming product is monosubstituted resveratrol.  
 
5.2.7 Molecular weight determination of PEG derivatives and MeO-PEG-resveratrol 
conjugates 
Molecular weight determination of PEG derivatives and resveratrol conjugates was 
performed by LC-MS analysis with an Applied Biosystems 4000 QTRAP LC-
MS/MS system (Toronto, Canada). The analysis was performed by directly injecting 
analyte solutions via a T- junction with mobile phase consisting of 0.5% v/v triethyl 
amine in water. The analyte entered the mass detector without passing through any 
column. Ionization was induced with APCI ionization mode and positive ions were 
monitored with a Q1 MS scan.  Heated nebulizer with gas flow of 20 L/min and with 
current of 3.0 µA was maintained, while source temperature was set at 600 °C and 
declustering potential 80 V.  1 mg/mLanalyte solutions of MeO-PEG-resveratrol, 
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MeO-PEG-OH, MeO-PEGO-SuccOH, and MeO-PEGN-SuccOH were infused 
separately at 20 µL/min with the mobile phase pumped at 0.5 mL/min. The average 
molecular weight of the polymeric compound was calculated using the following 
equation 3
                                                       
    
Where M is mass number of individual peak with intensity I. 
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Structure of PEG-resveratrol conjugates and intermediates 
Synthesis of resveratrol PEG conjugates was discussed in Chapter 2, section 2.3.2. 
The structures of polymers polymer conjugates and intermediates which were 




Figure 5.1: (A & B) Structures of Resveratrol-PEG conjugates and intermediates. (C) 
Structures of O-acylisoureaand N-acylurea.  
 
5.3.2 LC-MS detection of MeO-PEG-resveratrol conjugates and MeO-PEG 
derivatives 
The optimum chromatographic conditions for achieving the satisfactory separation 
of MeO-PEG acids, MeO-PEG-resveratrol conjugates, and MeO-PEG-OH with short 
retention times and good peak shape were obtained after studying the effects of 
column type and column temperature. Under these optimum conditions, resveratrol 
and its PEG conjugates were eluted at 5.4 and 6.6 min respectively (Figure 5.2); 
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whereas MeO-PEG acids and unmodified MeO-PEG-OH eluted at 2.9 and 4.6 min 
respectively as shown in Figure 5.3. Irrespective of the type of acidic linker in the 
structure, both MeO-PEG- resveratrol conjugates eluted at 6.6 min and the same was 
observed with the PEG acids, MeO-PEGN-SuccOH and MeO-PEGO-SuccOH, 
which were all eluted at 2.9 min. A representative chromatogram of a mixture of 
resveratrol-PEG, PEG acids and MeO-PEG-OH is shown in Figure 5.4. The mass 
spectra of peaks corresponding to MeO-PEG-OH, MeO-PEG acids and MeO-PEG-
resveratrol showed a series of intense peaks within the 650-1000 (m/z) range in 
positive ion scan mode, which are characteristic fragmented peaks observed for PEG 
as shown in the Figure 5.4. The fragmentation of high molecular weight PEGs to low 
mass number in the mass detector at neutral or acidic pH conditions is a common 
observation and similar results were reported by Huang et al. for the PEG with Mw 
of 40 KDa 3
 
.  
LC-MS chromatograms of resveratrol and MeO-PEG-resveratrol with inserts of 
mass and UV spectra are shown in Figure 5.2. The mass spectrum of resveratrol 
showed a single intense peak of m/z 227 in negative mode, which correlates to the 
molecular weight of resveratrol. Little distinction could be made between the mass 
spectrum of MeO-PEGN-SuccOH, MeO-PEGO-SuccOH and MeO-PEG-resveratrol 
due to fragmentation, and there was no ion observed for resveratrol in either the 
positive or negative ion scan for MeO-PEG-resveratrol. However a simultaneously 
recorded UV spectrum of the MeO-PEG-resveratrol did in fact show a spectrum 
similar to that of resveratrol. Such a spectrum was not observed with either MeO-
PEGN-SuccOH or MeO-PEGO-SuccOH samples. This unequivocally confirms that 
the peak eluted at 6.6 min belongs to MeO-PEG-resveratrol, demonstrating that the 
developed methodology can detect the formation of MeO-PEG-resveratrol structure 





 Figure 5.2. LC-MS chromatograms (Scan mode) of A: MeO-PEGN-Succ-RSV; B: 






Figure 5.3. LC-MS chromatogram of the mixture of resveratrol derivatives (SIM 







Figure 5.4. LC-MS chromatogram of A: MeO-PEG-OH; B: MeO-PEGO-SuccOH C: 
MeO-PEGO-Succ-resveratrol with small quantity of free MeO-PEGO-SuccOH at 





5.3.3 Determination of extent of functionalization of MeO-PEG-OH to MeO-PEGO-
SuccOH  
In the present study, the LC-MS analysis was found to be an effective tool for 
determining the extent of MeO-PEG-OH conversion to the functionalized acid 
derivative MeO-PEGO-SuccOH. The complete separation of MeO-PEG-OH and 
MeO-PEGO-SuccOH permitted the accurate quantification of free MeO-PEG-OH 
(Figure 5.3 & 5.4). The separation achieved in the present study was better than that 
reported for MeO-PEG-OH and HO-PEG-OH, which could be due to polarity 
differences 5. In the present study, there was no free MeO-PEG-OH detected in 
MeO-PEGO-SuccOH solutions prepared at various concentrations, indicating 
complete conversion of MeO-PEG-OH to the acid. Various studies have reported the 
use of NMR for analysing the level of conversion or functionalization of MeO-PEG-
OH to acid derivatives by calculating ratio of area of specific ethylene protons to that 
of the MeO end group of polymers 8
 
.  Employing the same technique, conversion of 
MeO-PEG-OH to MeO-PEGO-SuccOH was calculated from NMR and it was found 
to be complete, supporting our LC-MS determination.  
5.3.4 Determination of extent of PEG conjugation  to resveratrol  
LC-MS analysis in SIM mode with multiple ions being monitored was found to be a 
very sensitive methodology for detection of MeO-PEG acids despite the noise 
created by multiple ion monitoring. The method is very sensitive, such that the 
lowest concentration,100 ng/mL, with 5µl injection volume, produced a signal that 
was multiple times higher than the noise and well above the signal to noise ratio of 
10 for quantification. The free MeO-PEGN-SuccOH was not detected in the 
conjugation product (i.e MeO-PEGN-Succ- resveratrol solution) therefore the degree 
of substitution was considered to be 100%. However in the case of resveratrol 
coupled to MeO-PEGO-SuccOH, a significant amount of free MeO-PEGO-SuccOH 
was detected in the conjugate solution (27%). Accordingly the degree of substitution 
was found to be 73%. In the absence of such a method, the degree of substitution 
could only be determined by hydrolysing the conjugate back to the parent drug 
resveratrol, the actual free resveratrol generated has to be quantified and compared 
against theoretical value 6 However, the accurate determination of resveratrol after 
hydrolysis could be difficult as resveratrol is highly light, carbonate and alkali 
sensitive 7. The use of NMR has been suggested for determination of polymer 
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conjugation to drugs 8
 
. The ratio of the area for specific signals for protons of the 
drug molecule to that of signals for protons from the MeO end group of the polymer 
can be calculated and compared against the theoretical value. However in certain 
drug molecules where there are multiple sites for polymer conjugation, the resulting 
product could be a mixture of multiple conjugated species. In such a complex 
situation calculating total conjugated drug to polymer ratio would become difficult. 
The similar findings were observed for resveratrol where two major monosubstituted 
species are formed. Given these findings, the present LC-MS method is proven to be 
simple and reliable for determining the extent of resveratrol conjugation to PEG.  
The NMR analysis showed that non-conjugated PEG  in the product was a mixture 
of an N-acylurea by-product and free MeO-PEGO-SuccOH. There was no separate 
peak observed for the N-acylurea derivative in the LC-MS, indicating it presumably 
eluted at the same time as that of MeO-PEGO-SuccOH. Hence, the LC-MS 
quantification performed is a total of two species. Moreover under neutral pH mobile 
phase conditions PEG derivatives undergo fragmentation in the mass detector to 
produce smaller daughter ions and only major ions, which are common in all PEG 
derviates, were selected in selected ion monitoring (SIM) method for quantification.  
As such the presence of different species of non-conjugated PEG, whether it is in the 
form of free MeO-PEGO-SuccOH or the N-acylurea does not affect actual 
quantification of total non-conjugated PEG. 














Table 5.1. Comparison of various methods for determining the extent of PEG 
conjugation to  resveratrol (RSV) 
 Extent of PEG conjugation to RSV % 





















1Based on resveratrol content in the final product. 
2Based on free PEG acid in the final product. 
3
 
 Value could not be obtained from NMR because of complex nature of sample due 
overlapping signals from mixture of species. 
5.3.5 Determination of extent of PEG conjugation to resveratrol by UV spectroscopy 
The extent of PEG conjugation to resveratrol determined by UV spectrophotometer 
measurements are substantially different from those obtained by LC-MS and NMR 
experiments (Table 5.1). It should point out that both LC-MS and NMR analyses the 
free PEG in the samples, whereas the UV spectroscopy method determines the 
resveratrol content. The UV spectroscopy analysis showed that the extent of 
conjugation of MeO-PEGN-Succ-resveratrol was 74%, compared to 100% by LC-
MS and NMR. This result was obtained based on assumption that the conjugate 
contained a monosubstituted resveratrol. As a some fraction of disubstitued 
resveratrol conjugate was in fact present in the mixture (5-10%, by NMR), thus it is 
expected that the conjugation of PEG to resveratrol detected by UV analysis should 
be less than 100%. This underestimation of PEG conjugation by UV analysis may be 
caused by  a change in UV extinction coefficient of resveratrol after coupling to 
PEG.  
 
5.3.6 Molecular weight determination of MeO-PEG, MeO-PEG acids and MeO-
PEG- resveratrol conjugates 
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The average molecular weights of MeO-PEG-OH, MeO-PEG acids and MeO-PEG-
resveratrol conjugates were determined by the mass spectral analysis of PEG 
derivatives with 0.5% v/v triethylamine as mobile phase, which prevented 
fragmentation of PEG to ions with lower m/z values (Figure 5.5) and thus the 
observed mass spectrum consisted of ions of mass number closely correlating to 
actual PEG molecular weight. This observation is in close agreement with Huang 
et.al 3. There was clearly a gradual increase in molecular weights observed for MeO-
PEG-OH, MeO-PEGO-SuccOH and MeO-PEGO-Succ-resveratrol as shown in 
Figure 5. Similar observations were found with MeO-PEGN-SuccOH and MeO-
PEG-COO-resveratrol conjugates (data not shown). The average molecular weight of 
MeO-PEG, MeO-PEGO-SuccOH and MeO-PEGO-Succ-resveratrol determined by 
the developed method was 2108, 2321 and 2423 respectively (Table 2). These 
correlate with the theoretical value for MeO-PEG-OH and  MeO-PEGO-SuccOH 
and MeO-PEGO-Succ-resveratrol The differences in average molecular weights of 
MeO-PEGO-SuccOH and MeO-PEGO-Succ-resveratrol (determined versus 
theoretical)  are slightly more than expected (10.5%), possibly due to the presence of 
free PEG acid in the sample and the possibility of overestimation of PEG acids 
(Table 2). The differences between the determined and the theoretical values with 
consideration of the level of PEG substitution suggest that this method provides 
reasonably accurate molecular weight estimation.  The average molecular weight 
calculated by this approach matches closely with those obtained by spectral 
deconvulation and summation using the ABI software system 3. However in the 
absence of such software, manual calculation performed as reported in this study was 
found to be satisfactory and matched well to the reported values generated by other 
analytical techniques such as gel permeation chromatography (values from raw 
material suppliers). The average molecular weight calculations of MeO-PEG-
resveratrol conjugates were based on the assumption that the majority of substitution 
is mono substitution either at 4’ or 3 hydroxyl groups of resveratrol. The 
disubstituted resveratrol species could not be detected due to limitations of the Mass 
Analyser (<2800 Da). However comparison of the intensity of major ions in PEG 
acids and their respective conjugates revealed that intensities were similar, which 





Figure 5.5. Mass spectra of PEG derivatives with 0.5% v/v triethylamine as mobile 






Table  5.2. Comparision of average molecular weights calculated based on chemical 
structure and that determined by mass spectra, for resveratrol, MeO-PEG-OH, MeO-
PEGO-SuccOH and MeO-PEGO-Succ-RSV 
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(100% PEG substitution) 













1 Average molecular weight provided by manufacturer. 
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6.1 GENERAL DISCUSSION 
Despite numerous data available on the beneficial properties of resveratrol, many 
studies confirmed that resveratrol is rapidly absorbed and highly metabolized by 
conversion to sulfo- and glucuro-conjugates with biological half life of 0.13 hours in 
rats and similar trend was observed in human 1,2.  Although it has been suggested that 
conjugated metabolites may contribute to resveratrol activity, but their potency is 
weaker than that of resveratrol 3.  Hence it is logical to take the approach to 
investigate the effect of extending the resveratrol  residence time in the body with the 
aim  to produce the desired pharmacological effects which were shown in vitro but 
not in vivo due to the  high metabolic rate of resveratrol 4 The objective of this PhD 
project was to develop novel formulation strategies to address poor pharmacokinetic 
profile of resveratrol. Review of literatures in this area suggests that polymer 
conjugation is one of the most feasible approaches to mask the molecule against 
metabolism and extend the circulation time of drugs 5
 
. Accordingly a strategy was 
designed to develop polymer conjugates of resveratrol using permanent and 
cleavable linker chemistry. The various polymer conjugates investigated in this 
project and results of those studies carried out are tabulated in Table 6.1 for easy 
reference. 
6.1.1 Synthesis of resveratrol polymer ester conjugates 
Generally ester conjugates are developed to address problems associated with 
solubility or stability of drugs. Upon reaching systemic circulation, such ester 
conjugates are anticipated to hydrolyze rapidly to produce parent drug molecules. 
The polymeric ester conjugates, in addition to have potential in improving solubility, 
can provide protection against potential metabolism. Based on polymer architect and 
linker chemistry, these polymer conjugates can provide extended circulation time 
and gradually release drug over an extended period of time. With appropriate ligand 
molecule and polymer , it can also provide targeting potential to tissues such as 
tumour.  
 
In this study, simple ester based polymer conjugates were developed for resveratrol  
against metabolism. Soluble polymers such as PEG and micelle forming diblock 
polymer such as PLA-PEG were selected and investigated  for this purpose. Initially 
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resveratrol conjugates with PEG were prepared by employing simple carbodiimide 
coupling chemistry..The carbodiimide coupling involves creation of a covalent link 
between the hydroxyl (OH) group and carboxyl (COOH) group of polymer. It is 
usually brought about by employing a base and a carbodiimide such as DIC, EDC. 
The carbodiimide coupling agent, activates COOH group of polymer by forming an 
reactive intermediate O-acylisourea
 
  which in turn facilitates the formation of ester 
bond while producing urea as a by-product. The carbodiimide coupling agents are 
also referred to as a zero length spacer since they don’t introduce any additional 
atoms during the conjugation process.  
 Initial reactions for conjugation of PEG to resveratrol were carried out using DIC-
DMAP in THF/dichloromethane solvent system. However, in order to achieve the 
ease of separation of product from reactants, reaction conditions were optimized to 
include pyridine as base and carbodiimide DIC as the coupling agent. A simple 
precipitation process using diethyl ether was adopted for purification of resveratrol-
PEG conjugates. The urea by-product N,N'-diisopropylurea, excess of pyridine, DIC, 
were found to be either soluble or miscible with diethyl ether, whereas the 
conjugates were not, making purification process easier. The resveratrol was not 
freely soluble in ether, so multiple washing of product with  ether/ethyl acetate 
mixture  was required to purify the product in order to remove trace amount of 
resveratrol. This was done to prevent interference of resveratrol in NMR spectral 
interpretations. The purification by dialysis using benzyolated (MWCO 2000 Da) 
and regenerated cellulose (MWCO 1000 Da) tubing’s was not successful because 
resveratrol did not diffuse, possibly bound to membrane.  
 
The resveratrol-PEG conjugation was performed with different linker group and 
PEG of different Mw. The extent of PEG conjugation to resveratrol varied. The 
100% conjugation was achieved for MeO-PEGN-SuccOH 2 kDa; 70% for MeO-
PEGO-SuccOH, 2 kDa and  50% for  MeO-PEGN-SuccOH 20 kDa. These results 
clearly indicated that the rate of reaction was dependent on Mw of polymer and 
chemistry of carboxyl end group in polymers. Similarly resveratrol was conjugated 
to MeO-PEG-PLAO-SuccOH using the same conjugation chemistry and achieved 
success as indicated by HPLC analysis . With respect to linker chemistry, DIC failed 
to produce  consistent results in conjugation.  Hence EDC was used instead of DIC, 
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for conjugation of resveratrol to MeO-PEG-PLAO-SuccOH. The MeO-PEG-PLAO-
Succ-RSV conjugates were purified by extraction using DCM/0.1M HCl. All 
resveratrol polymer ester conjugates were characterized by NMR, HPLC and 
selected conjugates by LC-MS. All the techniques indicated formation of conjugates.  
The yield was ranged between 60-65% for all conjugates before washing/purification 
and 30-40% after purification. The NMR indicated that the polymer conjugates were 
mixture of species with 4’-PEG-RSV (or 4’-PEG-PLA-RSV) as a major product 
(50%), followed by 3-PEG-RSV (40%) and a minor 3,4’-di(PEG)-RSV.  
 
6.1.2 Synthesis of Resveratrol-PEG ether conjugates 
The permanent non cleavable PEGylation of resveratrol was achieved via ether bond.  
The resveratrol-PEG ethers were prepared to have stable conjugates as an alternative 
strategy as esters are too prone to hydrolysis in plasma by plasma esterases. The 
permanent PEGylation was achieved by simple etherfication using MeO-PEG-Br 
and potassium carbonate.  The reaction was reported for preparation of resveratrol 
small chain ethers7, 8
 
. However, the reaction conditions as reported did not yield 
desired results with PEG conjugation and hence considerable efforts were made to 
optimize reaction conditions to achieve maximum conjugation of PEG with 
resveratrol. During these experiments it was found that the amount of potassium 
carbonate was very critical in reaction and it determined the extent of PEGylation. 
The higher the concentration of potassium carbonate, the greater the PEGylation. 
The final product can easily purified by a simple extraction procedure using 
DCM/HCl. The NMR again indicated that product is mixture of species, this time 4’-
PEG-RSV slightly more (60%). 
6.1.3  In vitro evaluation of resveratrol polymer conjugates 
Resveratrol polymer conjugates were tested for solubility, stability in buffers, plasma 
and in rat liver microsomes.  Resveratrol-PEG conjugates, irrespective of polymer 
chain length and linker chemistry were all soluble in water, pH 4.5 and 7.4.  The 
resveratrol conjugates with PLA-PEG were insoluble in water and hence they were 
dissolved in acetonitrile and then dispersed in water to form solid micelles or 
nanoparticles in aqueous medium after solvent vaporization. Such conjugate 
dispersion was used for all in vitro and in vivo studies. The CMC values of micelle 
forming polymer conjugates were determined by dye solubilization method using 
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water insoluble dimethyl yellow. The CMC value was  found to be 4 Mg/L for  
MeO-PEG-PLAO-Succ-RSV, 2 kDa, 8 Mg/L for MeO-PEG-PLAO-Succ-RSV, 6.5 
kDa and 500 Mg/L for MeO-PEGO-Succ-RSV 2 kDa.  The average micelle diameter 
for MeO-PEG-PLAO-Succ-RSV, 2 kDa micelles was found to be 170-250 nm (0.05 
to 0.2%),  147 to 165 nm (0.05% to 0.2%) for MeO-PEG-PLAO-Succ-RSV, 6.5 kDa 
and  for MeO-PEGO-Succ-RSV 116 to 181 nm (0.1 to 0.5%). These findings 
suggest that, at lower concentration polymer conjugates aggregate as micelles and at 
higher concentration would form nanoparticles.  
 
In terms of chemical stability, all of resveratrol polymer conjugates were stable in 
buffer pH 4.5.  But in buffer pH 7.4, MeO-PEGN-Succ-RSV 2kDa and 20 kDa were 
found to be unstable, whereas MeO-PEGO-Succ-RSV 2 kDa was stable. It was 
speculated that the self aggregation and possible formation of micelles by MeO-
PEGO-Succ-RSV 2kDa was the reason for the results.. A similar trend was observed 
for MeO-PEG-PLAO-Succ-RSV 2 kDa which was also stable in both pH 4.5 and pH 
7.4.  Plasma stability study indicated that resveratrol-PEG esters underwent instant 
hydrolysis in rat plasma, no intact polymer conjugates were detected immediately 
after its exposure to the plasma (near 0 minute). It is possible that the conjugates 
could be hydrolyzed during the lag time of sampling and dilution with acetonitrile. 
However the micelle forming conjugate, MeO-PEG-PLAO-Succ-RSV 2 kDa, was 
stable in rat plasma with t1/2 of 3 hours. In contrast,  MeO-PEG-PLAO-Succ-RSV 
6.5 kDa was much less stable, with t1/2 of only 5 minutes. From these results, it is 
evident that the micelle forming resveratrol ester conjugates were relatively more 
stable in rat plasma and the length of hydrophobic chain can have an impact on the 
plasma stability of the conjugate. This is not unexpected as it had been reported that 
an optimum hydrophobic core with relatively strong PEG corona on micelle surface 
offered greater plasma stability to conjugate 9, 10
 
.   
AFM and FESEM images revealed that the conjugate of MeO-PEG-PLAO-Succ-
RSV 2 kDa formed solid nanoparticle like structure which resisted structural 
deformation during the process of drying. Whereas micelles of MeO-PEGO-Succ-
RSV 2 kD, and MeO-PEG-PLAO-Succ-RSV 6.5 kDa polymer conjugates appeared 
to be fused during drying process. A consistent phenomena was observed with AFM 
images, with conjugates of MeO-PEG-PLAO-Succ-RSV, 2 kDa showing individual 
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particles and conjugates of MeO-PEG-PLAO-Succ-RSV, 6.5 kDa and MeO-PEGO-
Succ-RSV, 2 kDa displaying fused patches. The formation of compact nanoparticle 
like structure in the case of MeO-PEG-PLAO-Succ-RSV 2 kDa would also explain 
for observed stability of conjugate in plasma.  
 
Resveratrol-PEG ethers with non-cleavable ether link, as anticipated, did not 
hydrolyze in buffers and plasma. Further investigations are necessary to design PEG-
resveratrol ester conjugates which can release the drug slowly in the plasma. Various 
linkers such as acid liable spacers cis-aconityl/hydrazone linker need to be evaluated 
as an alternative to produce better plasma stability of resveratrol-PEG ester 
conjugates 11, 12.  Although peptide spacers (eg. amide bonds) between drug and PEG  
were found to stabilize conjugate in the plasma, feasibility of inclusion such linkers 
for resveratrol, a molecule with hydroxyl groups only, with an appropriate polymer  
is yet to be assessed 13
 
.  
In vitro preliminary metabolism studies of resveratrol and its polymer conjugates 
were performed in rat liver microsomes. Rat liver microsomes were supplemented 
with uridine diphosphoglucuronic acid (UDPA) in order to bring about phase II 
metabolism, glucuronidation. The results revealed that polymer conjugates were 
stable in microsomal incubations containing UDPA, with more than 80% conjugates 
remaining after 60 minutes.  In contrast, resveratrol on its own metabolized rapidly 
with almost none resveratrol left and only metabolites were detected after 10 
minutes. The MeO-PEGN-Succ-RSV, 2 kDa was found to hydrolyze in microsomal 
reaction mixture and free resveratrol generated was metabolized. From these studies, 
it is evident that polymer conjugates must be intact in order to prevent the 
metabolism of resveratrol. The physical mixture of resveratrol and polymer would 
not help in slowing down metabolism or improving pharmacokinetic profile of 
resveratrol.  
 
In vitro antioxidant assay of resveratrol and its polymer conjugates was performed 
using DPPH inhibition assay. The free radical scavenging ability of resveratrol-
polymer conjugates, MeO-PEGN-Succ-RSV, 2 kDa, MeO-PEG-PLAO-Succ-RSV 2 
kDa and RSV-PEG ether 2 kDa decreased slightly against resveratrol. The IC 50 
value of resveratrol was found to be 65 µM, whereas for polymer conjugates it was 
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about 219 µM (resveratrol equivalent) , nearly 4 fold decrease in activity. Although 
the direct free radical scavenging activity of resveratrol was decreased after polymer 
conjugation, resveratrol can also act as in vivo antioxidant by inducing enzymes such 
as dismutase. Such activities of conjugates need to be evaluated. How the improved 
plasma levels and prolonged circulation of polymer conjugates would affect in vivo 
antioxidant activity of resveratrol is yet to be investigated.  
 
6.1.4 Single dose preliminary pharmacokinetic studies of resveratrol and its polymer 
conjugates in a rat model 
Single dose preliminary pharmacokinetic studies of resveratrol and selected polymer 
conjugates (those showed stability in rat plasma) were performed in Wistar rats to 
evaluate effectiveness of polymer conjugation in improving plasma concentration  
profile of resveratrol. As expected, resveratrol exhibited rapidly declining plasma 
profile, reaching almost non-detectable level within 2 hours, due to rapid metabolism 
of resveratrol. Peak areas of metabolites were always higher than resveratrol since 
the initial sampling time at 5 minutes post injection. The pharmacokinetic profile of 
MeO-PEG-PLAO-Succ-RSV showed different profile from resveratrol and other 
PEG ether conjugates. The MeO-PEG-PLAO-Succ-RSV 2kDa showed highest 
plasma concentration (three times of resveratrol concentration) at 5 minutes and 
rapidly declined thereafter.  Interestingly, the sharp decline in conjugate levels in 
plasma may not be actually due to hydrolysis and subsequent metabolism but 
possibly due to its uptake by mononuclear phagocyte systems (MPS)  14. The fact 
that a relatively high level of resveratrol compared to metabolites was detected in 
polymer conjugates also supports this reasoning. In addition, the larger size of 
micelles/nanoparticles produced by  the presence of hydrophobic of polymer made 
the conjugate  susceptible for MPS uptake 14.  On the other hand, resveratrol PEG 
ether 2 kDa produced another distinct profile which was different from resveratrol 
and MeO-PEG-PLAO-Succ-RSV, 2 kDa.  The profile was characterized with higher 
plasma concentration than that of native resveratrol and PEG-PLA conjugate. 
Although there was sharp decline in plasma concentration after 5 minutes, the levels 
were still much higher and almost stagnated after 30 minutes until 4 hours. Despite 
the dose of conjugate (5kDa, ether conjugate) was equivalent to 1/5 of resveratrol, its 
plasma concentration was still more than 10 folds higher than that of resveratrol.  
The resveratrol-PEG ether conjugates were stable in plasma and did not hydrolyze to 
172 
 
native resveratrolas there was neither free resveratrol nor metabolites detected in 
plasma in any of time point. Since PEG ether conjugate was soluble, it was expected 
to be extensively excreted via the kidney. As the 2 kDa molecule was not big enough 
to reach threshold volume to overcome kidney filtration 15
  
, it was thought that the 
stagnant levels after 1 hour could possibly  due to the presence of disubstituted  
resveratrol (3, 4’ di (PEG)-resveratrol) with Mw of 4 kDa. The pharmacokinetic 
profile of resveratrol-PEG ether 5 kDa  indeed showed marginally slower 
elimination after 5 minutes, suggesting size of conjugate only has limited impact on 
the elimination of conjugates.  The rapid elimination, in first 30 minutes, of RSV-
PEG ether 5 kDa could be due to increased polarity. The slower terminal elimination 
of RSV-PEG ether may be attributed to the intrinsic distribution and elimination 
properties of molecules or conformational arrangement of di (PEG)-RSV which 
gives more volume to molecule leading to slower elimination. However all these 
findings need further confirmation with suitable analytical techniques. The AUC tot, 
MRT for RSV-PEG ether 2 kDa were found to be 15.66 µ*h/mL and 6.7 h 
respectively (11.51 µ*h/mL, 6.2 h respectively for RSV-PEG ether 5 kDa). To 
achieve further improvement in pharmacokinetic profile of resveratrol-PEG ethers, 
synthesis of conjugates with polymer of Mw > 20 kDa or polymer conjugate capable 
of forming stable micelles or nanoparticles is recommended. This strategy may 
overcome rapid conjugateexcretion through kidneys and potentially prolong the 
plasma residence with relatively higher plasma concentrations.   However, the ratio 
of PEG to hydrophobic polymer is important to minimise the uptake of conjugates  
by MPS  when high molecule weight polymers are to be used. 
6.1.5 Development of  HPLC and LC-MS  for monitoring and analysing the 
resveratrol-polymer conjugates and detection of reaction intermediates and 
resveratrol metabolites.  
 
A reliable, reproducible, sensitive HPLC method with fluorescence detection was 
developed. The method allowed detection and quantification of resveratrol and 
MeO-PEGN-Succ-RSV conjugates at 5 and 30 ng/mL (resveratrol equivalent) 
respectively. This study revealed that the PEG conjugation enhanced the 
fluorescence properties of resveratrol, and this enhancement could be modulated by 
methanol concentration. These findings were subsequently applied to the 
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development of a simple but sensitive HPLC method for simultaneously analysis of 
resveratrol and it polymer conjugates in plasma samples.  
 
An LC-MS methodology was developed for the separation, characterization and 
quantification of resveratrol-PEG conjugates and reaction intermediates. The 
purpose LC-MS method development was to monitor and optimize reactions 
conditions for small Mw PEG and adopt same reaction conditions for other polymer 
conjugates. The LC-MS method was able provide to information on extent of MeO-
PEG-OH conversion to MeO-PEGO-SuccOH, extent of PEG conjugation to 
resveratrol and Mw of polymer conjugates. Overall LC-MS method was helpful in 
understanding conjugation process. However due to Mw limitations of mass detector 
of  LC-MS instruments, all polymer conjugates could not be analyzed by present 
LC-MS method and analysis using LC-MS with greater mass detection limits can be 
considered for future work. 
 
6.2 Conclusion 
In this study various polymer conjugates of resveratrol were prepared and evaluated 
for their impact on plasma concentration profile of resveratrol. The polymer 
conjugates were investigated for their surface properties and tested for stability in 
buffers, rat plasma and microsomes, the preliminary pharmacokinetic profile of 
selected polymers were evaluated in Wistar rats.  
Resveratrol polymer esters were successfully prepared using carbodiimide coupling 
reactions.  The NMR analysis revealed that conjugates were mixture of mono and 
disubstitued resveratrol with 4’-PEG-RSV as major component (ca 50%) , followed 
by 3’-PEG-RSV (35%). And minor amount of 3, 4’-di (PEG)-RSV. The substitution 
pattern was almost same for all polymer conjugates. LC-MS analysis of some of 
resveratrol polymer conjugates and polymers showed that reaction adopted for 
synthesis did not cause any degradation of polymer. 
 
The resveratrol PEG esters were unstable in plasma and hydrolyzed very rapidly. 
Micelle forming PEG-PLA conjugates were stable in plasma, rate of hydrolysis was 
found to be dependent on PLA/PEG content in polymer, colloidal stability of 
micelles/nanoparticles. Based on AFM and SEM images, MeO-PEG-PLAO-Succ-
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RSV 2 kDa was formed nanoparticle like structure at higher concentration and hence 
was stable in plasma. Resveratrol-PEG ethers were stable in both buffers and plasma. 
Free radical scavenging activity was reduced 4 folds after conjugation of polymers 
however improved plasma levels may compensate for reduced activity and improve 
overall pharmacological activity in vivo. 
 
.Finding that the resveratrol-PEG conjugates exhibits enhanced fluorescence 
properties compared to that of resveratrol, and this enhancement could be modulated 
by methanol concentration has lead to the development of a simple, yet reproducible 
and sensitive HPLC method with fluorescence detection for  simultaneous detection 
and quantification of  resveratrol and  resveratrol polymer conjugates, as well as 
detection of  resveratrol metabolites in vitro and in vivo. 
 
The LC-MS methodology developed has enabled the separation, characterization and 
quantification of resveratrol-PEG conjugates and reaction intermediates, which 
provided us with a better understanding of conjugation process. This made the 
optimisation of conjugation process easier.Pharmacokinetic studies revealed that 
MeO-PEG-PLAO-Succ-RSV did not offer the same level of advantage as 
resveratrol-PEG ether, in terms of extending the circulation time as it was rapidly 
cleared from circulation.  On the other hand resveratrol-PEG ether 2 kDa displayed 
significantly better profile than resveratrol and other polymer conjugates. Plasma 
concentration and duration were improved. The improved pharmacokinetic profile 
with resveratrol-PEG ethers demonstrated that they are good candidates for further 
biological studies such as efficacy and toxicity studies in animal models. Findings of 
this study revealed that polymer conjugation is suitable approach to improve 
pharmacokinetic profile of resveratrol. The selection of polymer and linker 
chemistry was found to be more stable than  those reported by Biasutto et.all 16.. 
Overall,  this present study provided insight into conjugation chemistry for the stable 
polymer conjugates and reported the development of novel formulation strategy, 
stable polymer conjugates, which  improved pharmacokinetic profile (plasma 
concentration–time profile) of resveratrol.
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Table 6.1  Summary of resveratrol-polymer conjugates synthesized and evaluated in this Ph.D project.   
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6.3 SCOPE FOR FUTURE WORK 
Although significant amount of work was done in this project,  still there is a wide 
scope of research can be undertaken to further understand the properties of 
conjugates and their correlation with improving pharmacokinetic profile and  
biological activities of resveratrol. The synthetic procedure adopted in this study has 
some limitations such as extent of  conjugation was not 100% with certain polymers, 
multiple conjugated species were formed in the reaction and moderate yield of final 
product, The resveratrol-polymer ester conjugates did not show desired stability in 
rat plasma. Some of the polymer conjugates such as MeO-PEG-PLAO-Succ-RSV 
were insoluble in water and needed to be converted into micelles. Based on these 
limitations, future work should focus on following issues: 
• The PEG conjugation to resveratrol via hydrolysable ester link was attempted in this 
study but the plasma stability was limiting, therefore, reasonably stable PEG esters 
could not be obtained. In this regards screening various spacer moieties such as cis 
aconityl, hydrazone, carbamate and peptides could be beneficial and should be 
considered in the future studies.  If sustained hydrolysis of PEG ester is controlled, it 
will be very useful for pharmacokinetic and biological evaluation.  
• The resveratrol conjugates with PLA-PEG needs to be further optimized for 
PLA/PEG content, Mw and micelle diameter. The micelles with right amount of 
PLA/PEG and smaller diameter would probably improve plasma residence time of 
conjugate. 
• In the case of resveratrol-PEG ethers, although large improvement in 
pharmacokinetic profile was achieved,  in order to further extend the circulation time 
and improve plasma level, PEG ethers of higher Mw PEGs need to be synthesized  
and evaluated. The resveratrol-PEG ethers tested in this study, can be considered for 
further in vivo pharmacological studies such as xenograft mice model to evaluate the 
translation of improved pharmacokinetic into in vivo biological effects.  
• Resveratrol polymer conjugates with targeting ligands can be considered for tumour 
targeting and improved anticancer activity. 
• More extensive  in vitro metabolism studies should be performed to understand the 
mechanism by which polymers modulate  metabolism of resveratrol. The intact 
polymer conjugate in the microsomal incubation needs to be hydrolysed, after 
reaction is stopped, to see whether resveratrol bound to polymer is metabolite or 
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native resveratrol. A suitable process for hydrolysis of polymer conjugate should be 
developed without causing degradation of resveratrol. 
• Although LC-MS analysis was performed for some of conjugates for Mw 
determination, an LC-MS with greater Mass detection limit should be considered for 
other polymers in order to obtain Mw of all polymer conjugates. 
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Figure 7.1: 1H NMR spectra of the MeO-PEGO-Succ-RSV 2 kDa conjugate mixture in d6
 
-DMSO, recorded at 400 MHz. 
 
 
























Figure 7.2: 1H NMR spectra of the MeO-PEG-PLAO-Succ-RSV 2 kDa conjugate mixture in d6
 









Figure 7.3: 1H NMR spectra of the MeO-PEGN-Succ-RSV 20 kDa conjugate mixture in CD3
 









 Figure 7.4: 1H NMR spectra of the MeO-PEG-PLAO-Succ-RSV 6.5 kDa conjugate mixture in d6
 


































Figure 7.5: 1H NMR spectra of the resveratrol-PEG ether kDa conjugate mixture in d6
 







7.2 Identification of resveratrol metabolites in rat plasma by LC-MS/MS 
 
 
Figure 7.6: LC-MS/MS chromatogram (MRM) of resveratrol, analysis carried out as 












Figure 7.7: LC-MS/MS (MRM) chromatogram of rat plasma sample ( obtained as 













7.3 Data for molecular weight determination of MeO-PEGN-SuccOH and MeO-
PEGN-Succ-RSV. 
 
Figure 7.8: Mass spectrum of MeO-PEGN-SuccOH 2 kDa recorded using 0.5% v/v 

















Figure 7.9: Mass spectrum of MeO-PEGN-SuccOH 2 kDa recorded using 0.5% v/v 





























Figure 7.10: Plot of concentration vs suface tension for the determination of CMC 















Figure 7.11: Plot of concentration vs suface tension for the determination of CMC 







CMC for A=8 mg/L 

































7.6 BD bioscience protocol for in vitro metabolism studies with microsomes 
Mammalian liver is the principal organ for drug and other foreign compound 
(xenobiotic) metabolism. Microsomes are prepared by differential centrifugation 
from a crude tissue (liver) homogenate. Tissue is homogenized in buffer and 
subjected to a 9000 x g centrifugation. The Supernatant from this centrifugation 
(often referred to as “S9”) is recovered and then centrifuged at 100,000 x g. The 
pellet from this high speed centrifugation is referred to as “microsomes” and the 
supernatant is referred to as “cytosol1.” The microsomes from this first 100,000 x g 
centrifugation are resuspended in buffer and centrifuged again at 100,000 x g2. The 
pellet from this final centrifugation is resuspended in 250 mM sucrose and the 
protein concentration adjusted to 20 mg/mL. Microsomes are principally derived 
from the membranes of the endoplasmic reticulum. However, membranes from other 
cellular organelles are typically present in these relatively crude tissue fractions. 
Microsomes provide an enriched source of membrane bound drug metabolizing 
enzymes. Principal among these are the cytochrome P450 (CYP) superfamily of 
oxidative hemoprotein enzymes and uridine glucuronosyl transferase (UGT) 
enzymes but many other enzymes are present.  
Introduction  
Each lot of material is characterized for the level of activity for a series of CYP, 
UGT and other enzymes. Use of these products to study metabolism requires 
fortification with the appropriate cofactors for the enzyme class to be studied. In the 
case of CYPs, fortification with NADPH is recommended. In the case of UGTs, 
fortification with uridine diphosphate glucuronic acid (UDPGA) is recommended. 
UGTs demonstrate the property of “latency” in microsomes. Latency is believed to 
be due to restricted access of the substrate and/or cofactors to the UGT active site3. 
Pore forming agents such as alamethicin are used to mitigate the latency of UGT 
enzymes4.  
This Guidelines for Use document provides information intended to aid in 
experimental design. It contains three parts: (1) a discussion of the major 
components of the assay and the potential influence on assay results, (2) a suggested 
general assay procedures and (3) further considerations for specific applications.  




Enzyme: Consult the product insert (batch data sheet) for important product 
information including CYP content (expressed as pmole enzyme per mg of 
product protein), protein content (typically 20 mg/mL using the method of 
Lowry), level of various enzyme activities. All mammalian liver microsomes 
should be stored at -80oC and thawed rapidly in a 37oC water bath and then 
stored on wet ice prior to use. BD recommends that if all the material is not 
to be used at once, that aliquots be prepared to minimize freeze thaw cycles 
and any potential variability associated with freeze thaw.  
Protein concentration is an experimental variable and will vary depending on 
the application and the susceptibility of the substrate to metabolism. In the 
absence of any other information, an enzyme concentration of 0.5 mg/mL is a 
good starting point.  
Buffer: CYPs and UGTs are active in a range of buffers of different 
concentrations. The product insert contains the buffer composition for the QC 
assay. This is a buffer which BD has found to function well with the specific 
cytochrome P450 product. Generally, 50 mM to 100 mM Tris HCl (pH 7.5) 
or potassium phosphate (pH 7.4) work well and these can be prepared by 
diluting BD Biosciences Cat. Nos. 451202 (0.5M Tris Buffer) or 451201 (0.5 
M phosphate buffer). The activity of CYPs and UGTs can vary with buffer 
and its ionic strength. UGTs have generally been found to be more active in 
Tris buffers relative to phosphate buffers. A recommended UGT buffer, 
containing alamethicin is available from BD Biosciences (Cat. No. 451320, 
5x concentrate). When evaluating new buffers it may be advisable to test new 
compositions relative to the buffer used for the QC assay.  
NADPH: NADPH cofactor (or some other source of reducing equivalents) 
must be supplied for CYP activity. We recommend the use of an NADPH 
generating system which can be prepared from a 1:20  
 
1 The material in BD Biosciences cytosol products are subjected to a second 100,000 
x g centrifugation and the supernatant from this second centrifugation is isolated, 
assayed and packaged. The purpose of this second centrifugation is to reduce any 
potential contamination with microsomal materials.  
2 The purpose of this second 100,000 x g centrifugation of the microsomes is to 




3 The active site of UGTs is generally present in the luminal side of the endoplasmic 
reticulum which becomes the interior of the microsomes upon homogenization. In 
contrast, CYPs are present on the opposite side of the ER and have freer access to 
substrate and cofactors.  
4 Fisher, M.B. et al., Drug Metab. and Disp. 28 (2000) 560-
566. http://dmd.aspetjournals.org/content/28/5/560.abstract
dilution of BD Biosciences Cat. No. 451220 (Solution A) and a 1:100 
dilution of BD Biosciences Cat. No. 451200 (Solution B). An NADPH 
solution can also be added directly. Typically a concentration around 1 mM 
is used to mitigate depletion of this cofactor during longer incubations.  
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UDPGA: UPDGA cofactor must be supplied for UGT activity. We 
recommend use of an UDPGA cofactor system which can be prepared from a 
1:12.5 dilution of BD Biosciences Cat. No. 451300 (Solution A, 25 mM 
UDPGA) to result in a final UDPGA concentration of 2 mM. UDPGA 
concentration can be an experimental variable. Different UGT enzymes have 
differing affinities for UDPGA.  
Vessel: A variety of vessels and materials can be used with polypropylene 
and glass being most commonly used (we recommend polypropylene). 
Polystyrene plates are commonly used for some assay applications. You 
should check for compatibility with any organic solvents (e.g. stop solutions).  
Solvent: CYPs and UGTs are well known to be inhibited by a variety of 
organic solvents and the impact of this inhibition will vary depending on the 
application. For CYP reactions DMSO solvent concentration should not 
exceed 0.2%. Acetonitrile and methanol are less inhibitory towards CYPs 
and can have final concntrations of 2% and 1%, respectively. DMSO and 
methanol are least inhibitory towards UGT isoforms and can be used at final 
concentration of up to 2% with little impact on activity. If acetonitrile is to be 
used, a solvent concentration of 1% or less is recommended for UGT 
reactions.  
Substrate Concentration: The tested substrate concentration will vary 
depending on the application. If metabolic stability is being measured, it is 
customary to use a low substrate concentration (e.g. 1 uM) based on an 




approximates the Intrinsic Clearance5. If inhibition of the cytochrome P450 
is being measured, it is customary to use a substrate concentration which is 
near the apparent Km value as this allows easier estimation of the apparent 
Ki from an IC50. If metabolite formation is being measured for reaction 
phenotyping or kinetic parameters are being determined, a range of substrate 
concentrations (above and below the apparent Km value) may be needed.  
Assay Linearity: The degree of linearity will vary among substrates and 
should be determined experimentally for new substrates.  
Order of Addition of Assay Components: The combination of substrate, 
enzyme and cofactors (NADPH and UDPGA) will cause metabolism to 
begin. We recommend that to initiate metabolism by pre-warming the 
substrate, buffer and cofactors to 37oC and then adding cold liver 
microsomes in a small volume of buffer. An alternative approach is to pre-
warm the enzyme, substrate and buffer and initiate metabolism by the 
addition of cofactors. You may wish to compare these two approaches to 
determine which works best for your specific assay.  
Agitation: After an initial mixing (e.g. by pipetting, inverting a sealed tube 
or vortexing) no further agitation is typically needed.  
Stop Solutions: An example stop solution is provided in the batch data sheet 
QC assay. The stop solution serves two purposes: to inactivate the enzymes 
and to precipitate the protein so it does not interfere with metabolite analysis. 
A 0.5x to 2x volume of acetonitrile is commonly used as a stop solution. 
Acidification of the stop solution with acetic acid (or some other acid) may 
be needed to control the ionization state of the substrate and metabolite (e.g. 
for chromatography or mass spectrometry). Protein is typically removed by 
centrifugation (e.g. 10,000 x g for 3 minutes in microcentrifuge tubes or 4000 
x g for 20 minutes in multiwell plates).  
Metabolite Analyses: A basic method for metabolite analysis by HPLC 
separation, fluorometric or spectrophotometric detection is provided in the 
batch data sheet. The analytical method should be adapted based on the 
metabolite(s) to be detected.  
 
5 Intrinsic Clearance is the ability of the liver to remove a drug absent other, 




(2) Suggested General Assay Procedures  
Cytochrome P450 and other NADPH Dependent Enzymes  
I. Thaw liver microsomes (20 mg protein per mL), NADPH Regenerating System 
Solutions A & B and keep on wet ice.  
II. Prepare 5 mM Substrate in DMSO. Store appropriately based on substrate 
stability.  
III. Also needed, 0.5 M potassium phosphate pH 7.4 (BD Biosciences Cat. No. 
451201), acetonitrile, 1.7 mL microcentrifuge tubes, pipettors and 37oC water bath.  
IV. Combine the following  
i. 713 uL purified water  
ii. 200 uL 0.5 M Potassium phosphate pH 7.4 (BD Biosciences Cat. No. 451201, 100 
mM final concentration)  
iii. 50 uL NADPH Regenerating System Solution A (BD Biosciences Cat. No. 
451220)  
iv. 10 uL NADPH Regenerating System Solution B (BD Biosciences Cat. No. 
451200)  
v. 2 uL Substrate in DMSO (10 uM final concentration)  
V. Warm to 37oC for 5 minutes in a water bath.  





VI. Initiate by the addition of 25 uL (0.5 mg) liver microsomes. Mix by inverting the 
capped tube twice. Return to the 37oC water bath.  
VII. After 0, 5, 10, 20, 30, 40, 50 and 60 minutes, withdraw 100 uL from the 
incubation and add to 100 uL acetonitrile. Mix and place on wet ice.  
VIII. Centrifuge 10,000 x g (or higher) for 3 minutes.  
IX. Withdraw the supernatant from the protein pellet.  
X. Analyze according to your analytical method.  
 
UGT Enzymes  
I. Thaw liver microsomes (20 mg protein per mL), UGT Reaction Mix Solutions A 
& B and keep on wet ice.  
II. Prepare 5 mM Substrate in DMSO. Store appropriately based on substrate 
stability.  
III. Also needed acetonitrile, 1.7 mL microcentrifuge tubes, pipettors and 37oC 
water bath.  
IV. Combine the following  
i. 693 uL purified water  
ii. 200 uL UGT Reaction Mix Solution B (BD Biosciences Cat. No. 451320)  
iii. 80 uL UGT Reaction Mix Solution A (BD Biosciences Cat. No. 451300)  
iv. 2 uL Substrate in DMSO (10 uM final concentration)  
V. Warm to 37oC for 5 minutes in a water bath.  
VI. Initiate by the addition of 25 uL (0.5 mg) liver microsomes. Mix by inverting the 
capped tube twice. Return to the 37oC water bath.  
VII. After 0, 5, 10, 20, 30, 40, 50 and 60 minutes, withdrawn 100 uL from the 
incubation and add to 100 uL acetonitrile. Mix and place on wet ice.  
VIII. Centrifuge 10,000 x g (or higher) for 3 minutes.  
IX. Withdraw the supernatant from the protein pellet.  
















Figure 7.13 Degradation profile various resverarol PEG ethers in microsomal 
incubations A: RSV-PEG ether 2 kDa with UDPA B: RSV-PEG ether 2 kDa with 







7.7 Pharmacokinetic studies of resveratrol and conjugates in Wistar rats 
 
Table 7.1: Pharmacokinetic data for resveratrol and its polymer conjugates in Wistar 
Rats (Intravenous dosing) 
 
 





















Figure 7.14: HPLC chromatogram with peak purity and spectrum for MeO-PEGN-





























































Table 7.2 :Plasma recovery of resveratrol 













Table 7.3: Plasma recovery of RSV-PEG ether, 2 kDa      
































50 103.9 2.19 
100 103.98 2.88 
500 90.62 1.35 
1000 99.8 1.49 
Concentration 
spiked (µg/mL) 
% Recovery against 
Spiked concentration SD 
5 116.33 2.47 
10 105.48 1.77 
25 96.80 0.023 




7.10: Source of polymers used with catalogue numbers 
 
Table 7.4 List some important chemicals used and their codes, suppliers 
 
 
Chemical Name Purity Code Company 
mPEG COOH 2 kDa >99% PEG1158 Irish biotech, GMBH, 
Germany. 
mPEG COOH 20 kDa >99% PEG1159 Irish biotech, GMBH, 
Germany. 
mPEG Br 2 kDa >99% PEG1132 Irish biotech, GMBH, 
Germany. 
mPEG Br 5 kDa >99% PEG1134 Irish biotech, GMBH, 
Germany. 
mPEG-PLA 2 kDa >99% 659657 Sigma, Australia. 
 
mPEG-PLA 5 kDa 
 
>99% AK04 Akina Inc, USA. 














*molar absorption coefficients are interms of resveratrol content. 
Molar extinction coeffiecient was calculated using formula 
A=abc (a is  molar extinction coefficient, b is path length, i.e constant 1 cm, c is 






















RSV-PEG ether 2 kDa 
 
150.7* 



































Figure 7.16: FE-SEM images of A: MeO-PEG-PLAO-Succ-RSV 2 kDa micelle 






















Figure 7.17: AFM images of MeO-PEG-PLAO-Succ-RSV 2 kDa micelles dried 
















Figure 7.18: AFM images of MeO-PEG-PLAO-Succ-RSV 6.6 kDa micelles dried 
under vaccum on mica surface. 
5×4.9 µm  




















Figure 7.19: AFM images of MeO-PEGO-Succ-RSV 2 kDa micelles dried under 
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